var title_f4_9_4240="BL diagnostic algorithm";
var content_f4_9_4240=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F62874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F62874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Diagnostic algorithm for Burkitt lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 523px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BL: Burkitt lymphoma; FISH: fluorescence in situ hybridization; DLBCL: diffuse large B-cell lymphoma.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gascoyne RD, Magrath IT, Sehn L. Burkitt lymphoma. In: Non-Hodgkin Lymphomas, 2nd ed, Armitage JO, Mauch PM, Harris NL, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_9_4240=[""].join("\n");
var outline_f4_9_4240=null;
var title_f4_9_4241="Prulifloxacin: International drug information";
var content_f4_9_4241=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"22\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Prulifloxacin: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F3123375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Quinolone",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F2677766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of complicated and uncomplicated urinary tract infections; chronic bronchitis",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F2677768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chronic bronchitis: 600 mg daily up to 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Urinary Tract Infection:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Complicated: 600 mg daily up to 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Uncomplicated: 600 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2677769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 600 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10499 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-DEDEA7E9BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_9_4241=[""].join("\n");
var outline_f4_9_4241=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3123375\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677766\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677768\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821144\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677769\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10499\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10499|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_9_4242="Human papillomavirus bivalent (types 16, 18) recombinant vaccine: Patient drug information";
var content_f4_9_4242=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Human papillomavirus bivalent (types 16, 18) recombinant vaccine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/46/40677?source=see_link\">",
"     see \"Human papillomavirus bivalent (types 16, 18) recombinant vaccine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/1/29717?source=see_link\">",
"     see \"Human papillomavirus bivalent (types 16, 18) recombinant vaccine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9514407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cervarix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10135562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cervarix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt adi-os drugH1Div\" id=\"F10026008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     CDC Information",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaccine Information Statements (VIS) are made by the staff of the Centers for Disease Control and Prevention (CDC). Each VIS gives information to properly inform the adult receiving the vaccine or, in the case of a minor, the child's parent or legal representative about the risks and benefits of each vaccine. Before a doctor vaccinates a child or an adult, the provider is required by the National Childhood Vaccine Injury Act to give a copy of the VIS. You can also get foreign language versions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2730419",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_hpv_cervarix.asp\" target=\"_blank\">",
"        Vaccine Information Statements (VIS)",
"       </a>",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12279 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E570A510C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_9_4242=[""].join("\n");
var outline_f4_9_4242=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9514407\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10135562\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026008\">",
"      CDC Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/46/40677?source=related_link\">",
"      Human papillomavirus bivalent (types 16, 18) recombinant vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/1/29717?source=related_link\">",
"      Human papillomavirus bivalent (types 16, 18) recombinant vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_9_4243="Hypospadias 2 stage repair 2";
var content_f4_9_4243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Stage two of two-stage hypospadias repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 647px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Second-stage urethroplasty is done 6 months after the first-stage surgery. H) Preoperative view. I) Initial incision on the ventrum outlining the new urethra. J) Urethroplasty. K) Completed urethroplasty with second layer of supporting tissue to prevent fistula. L) Completed repair.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Figure modified from TTMed (Timely Topics in Medicine)-Urology USA. Copyright &copy; 2009 Prous Science S.A.U. or its licensors. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_9_4243=[""].join("\n");
var outline_f4_9_4243=null;
var title_f4_9_4244="Mucinous neoplasm panc Gross I";
var content_f4_9_4244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreatic mucinous cystic neoplasm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Surgical specimen of a mucinous cystic neoplasm consisting of multiple cystic spaces.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_9_4244=[""].join("\n");
var outline_f4_9_4244=null;
var title_f4_9_4245="Syncope (fainting)";
var content_f4_9_4245=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Syncope (fainting) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?4/9/4245/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/9/4245/contributors\" id=\"au5282\">",
"       Brian Olshansky, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?4/9/4245/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/9/4245/contributors\" id=\"se4322\">",
"       Leonard I Ganz, MD, FHRS, FACC",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?4/9/4245/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/9/4245/contributors\" id=\"de1804\">",
"       Susan B Yeon, MD, JD, FACC",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?4/9/4245?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      SYNCOPE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Syncope, commonly known as fainting, refers to a sudden loss of consciousness, followed by a rapid and complete recovery. If you have symptoms of dizziness or lightheadedness, without loss of consciousness, this is called presyncope.",
"    </p>",
"    <p>",
"     Syncope should not be confused with sudden cardiac arrest. A person with sudden cardiac arrest also loses consciousness suddenly but will die without immediate medical attention. A person with syncope recovers quickly, almost always without treatment. However, injuries can occur during a syncopal episode and recurrent episodes can be frightening. Moreover, in patients with heart problems, syncope may be a warning sign that sudden cardiac arrest is about to occur.",
"    </p>",
"    <p>",
"     There are other reasons that a person may pass out, such as low blood sugar, hyperventilation, or seizures. It is important to determine the cause of syncope so that it can be prevented or treated in the future.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2\">",
"     <span class=\"h2\">",
"      Frequency",
"     </span>",
"     &nbsp;&mdash;&nbsp;Syncope is surprisingly common. About one-third of people have a syncopal episode at some point in their life. In most cases, syncope is not a sign of a life-threatening problem, although some people with syncope have a serious underlying medical condition. In non-elderly people, over 75 percent of cases of syncope are not associated with an underlying medical problem.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Risks",
"     </span>",
"     &nbsp;&mdash;&nbsp;A person who suddenly and unexpectedly loses consciousness can be injured. Up to 35 percent of people who have syncope injure themselves; elderly people are more likely to be injured during a syncopal attack. (See",
"     <a class=\"local\" href=\"#H32\">",
"      'Safety issues'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     Because of the risk of injury and the potential for serious underlying disease, any person who has a syncopal episode should seek medical attention.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      SYNCOPE CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     To remain conscious, a supply of oxygen-rich blood must be pumped to the brain without interruption. If the brain is deprived of this blood supply, even for a brief period, loss of consciousness (passing out) will occur.",
"    </p>",
"    <p>",
"     A number of medical conditions can cause syncope. Some of the most common are listed here.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Vasovagal syncope",
"     </span>",
"     &nbsp;&mdash;&nbsp;One of the most common types of syncope is called vasovagal syncope or neurocardiogenic syncope. A variety of conditions can trigger vasovagal syncope, including physical or psychological stress, dehydration, bleeding, or pain. The heart rate slows dramatically and the blood vessels in the body expand, causing blood to pool in the legs, resulting in low blood pressure (hypotension). This causes a decrease in blood flow to the brain.",
"    </p>",
"    <p>",
"     In some cases, vasovagal syncope is triggered by an emotional response to a stimulus, such as fear of injury, heat exposure, the sight of blood, or extreme pain. In other cases, it is caused by abnormal nervous system responses to activities such as urinating, having a bowel movement, coughing, or swallowing. In still other cases, no trigger can be identified.",
"    </p>",
"    <p>",
"     In most cases of vasovagal syncope, you have some warning that you are near fainting. These signs include dizziness, nausea, pale skin, \"tunnel-like\" vision, and profuse sweating. After the episode, symptoms may continue because of continued low blood pressure. Some people feel extremely tired.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Heart rhythm problems",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of disturbances in the rate",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     rhythm of the heart can cause syncope. These disturbances are called arrhythmias.",
"    </p>",
"    <p>",
"     The heart includes an area of specialized cells in the upper right chamber of the heart (right atrium) called the sinus node (",
"     <a class=\"graphic graphic_figure graphicRef71235 \" href=\"UTD.htm?4/20/4420\">",
"      figure 1",
"     </a>",
"     ). These cells send a series of regular electrical impulses to the atria that regulate the heart's rhythm and pace. These impulses travel in an organized way along conduction tissues within the heart muscle and then spread along smaller fibers that go to each muscle cell of the heart. The impulses cause the heart muscle cells to contract in an organized and regular way, generating an effective pumping of blood to all areas of the body.",
"    </p>",
"    <p>",
"     Syncope can occur because of problems at several places in this system. The problems may be due to primary heart rhythm problems, underlying heart disease, or use of a medication. The following are common rhythm problems that cause syncope.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Sinus bradycardia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bradycardia means a slow heart rate. In sinus bradycardia, the heart rate is slower than normal. A dramatically slowed heart rate can decrease the blood supply to the brain.",
"    </p>",
"    <p>",
"     Sometimes, sinus bradycardia occurs because of an abnormality in the sinus node itself. This is called sick sinus syndrome. In other cases, the slowed firing of the sinus node is due to medications. In still others, problems with the nerves that lead to the heart muscle and regulate the sinus node rate are to blame. For syncope to occur due to this problem, the heart usually stops for several seconds. This is known as asystole.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Heart block",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sometimes, part of the conduction system between the sinus node and the rest of the heart becomes blocked, preventing the normal flow of electrical impulses. If the electrical signal from the sinus node fails to get through the entire conduction pathway, the heartbeat can be interrupted. If the interruption is significant and the heart rate is too slow, it can impair blood flow to the brain.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Ventricular tachycardia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Tachycardia is a fast heart rate. The ventricles are the heart's main pumping chambers (",
"     <a class=\"graphic graphic_figure graphicRef77576 \" href=\"UTD.htm?11/14/11495\">",
"      figure 2",
"     </a>",
"     ). Ventricular tachycardia (VT) occurs when muscle in the ventricles send out their own rapid electrical impulses, taking over the rhythm normally controlled by the sinus node. The heartbeat that results from these abnormal impulses is also abnormal, and often fails to pump blood in an adequate way. The heart is racing but does not pump effectively, so blood flow to the brain may be decreased.",
"    </p>",
"    <p>",
"     Most people with syncope due to VT have underlying heart disease, most commonly coronary heart disease. Treatment of people with syncope caused by VT usually includes an implantable cardioverter-defibrillator. (See",
"     <a class=\"local\" href=\"#H30\">",
"      'Implantable cardioverter-defibrillator'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Supraventricular tachycardia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Rapid heartbeats can originate above the ventricles (supraventricular tachyarrhythmias, or SVT). This is not commonly associated with syncope, unless the heart rate is very rapid.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Blockage of blood flow from the heart",
"     </span>",
"     &nbsp;&mdash;&nbsp;Any problem with the structure of the heart that interferes with the flow of blood can cause syncope. The two most common causes of outflow obstruction are hypertrophic cardiomyopathy and aortic stenosis.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Hypertrophic cardiomyopathy &mdash; Hypertrophic cardiomyopathy is an inherited condition in which the areas of the left ventricular muscle walls are thickened. In some cases, the condition can interfere with blood flow out from the left ventricle and can cause syncope. More information about hypertrophic cardiomyopathy, including treatment recommendations, is available separately. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=see_link\">",
"        \"Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Aortic stenosis &mdash; The left ventricle normally pumps blood through the aortic valve into the body's largest artery, the aorta, to supply blood to the body (",
"       <a class=\"graphic graphic_figure graphicRef77576 \" href=\"UTD.htm?11/14/11495\">",
"        figure 2",
"       </a>",
"       ). The aortic valve closes while the left ventricle fills with blood and opens when the ventricle contracts and pumps blood into the aorta.",
"       <br/>",
"       <br/>",
"       When severe, aortic stenosis can reduce blood flow through the valve, and to the brain and the rest of the body. Treatment of syncope caused by aortic stenosis often includes aortic valve replacement surgery. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link\">",
"        \"Indications for valve replacement in aortic stenosis in adults\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Orthostatic hypotension",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hypotension means low blood pressure. Orthostatic hypotension refers to low blood pressure that occurs when a person stands or sits up. This causes an inadequate amount of blood to the brain, leading to syncope.",
"    </p>",
"    <p>",
"     Causes of orthostatic hypotension include the following.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Blood or fluid loss &mdash; Sometimes there is not enough blood in the body to ensure adequate flow to the brain when sitting or standing up. Low blood volume can be caused by blood loss or severe dehydration.",
"      </li>",
"      <li>",
"       Medications &mdash; Certain medications can interfere with the normal mechanisms that maintain blood pressure. Examples include some antidepressants, certain blood pressure or heart medicines, or medicines containing opiates, such as morphine.",
"      </li>",
"      <li>",
"       Illnesses that affect the nervous system &mdash; A number of illnesses can affect the specialized branch of the nervous system that helps maintain blood pressure (the autonomic nervous system). Examples are Parkinson disease, diabetes mellitus, the Shy-Drager syndrome, and amyloidosis.",
"      </li>",
"      <li>",
"       Alcohol &mdash; Drinking alcohol can cause blood vessels to expand, causing blood pressure to fall and syncope to occur.",
"      </li>",
"      <li>",
"       Carotid sinus hypersensitivity &mdash; Carotid sinus hypersensitivity is a condition in which reflexes lead to a slow heart rate",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       enlargement of blood vessels. This may be triggered by pressure on the carotid arteries (the main artery in the neck), and can lead to low blood pressure and syncope.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Other causes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Less common causes of syncope include a heart attack, cardiac tumor, or blood clot in the arteries supplying the lungs.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      SYNCOPE DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     There are three main ways to identify the causes of syncope: the medical history, the physical examination, and cardiac testing. A medical history and physical examination are recommended for anyone who has had syncope. Some people will also require cardiac testing.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Medical history",
"     </span>",
"     &nbsp;&mdash;&nbsp;Gathering as much information as possible about events that occurred before, during, and after a syncopal episode can be helpful in determining the possible cause of syncope.",
"    </p>",
"    <p>",
"     As an example, vasovagal syncope is suspected in a person who has warning signs of nausea or sweating. In contrast, a sudden loss of consciousness with no warning is more likely to be due to a heart rhythm problem. A person who has syncope during exertion is more likely to have an obstruction to blood flow (aortic stenosis or hypertrophic cardiomyopathy) or ventricular tachycardia as a cause.",
"    </p>",
"    <p>",
"     Information about current medications and preexisting medical conditions such as diabetes, heart disease, or psychiatric illness can help pinpoint the cause of syncope. If the person has abnormal body movements while unconscious and requires a long time to recover consciousness, the person may have had a seizure and not a true syncopal episode.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Physical examination",
"     </span>",
"     &nbsp;&mdash;&nbsp;The clinician will measure your heart rate and blood pressure to help determine if a rhythm disturbance or low blood pressure caused the syncope. You may be asked to sit or stand while the blood pressure is measured to test for orthostatic hypotension. The clinician will listen to your heart for abnormal sounds that can be present in conditions such as aortic stenosis. You may have a test for blood in the stool to evaluate for blood loss, which could result in syncopal episodes.",
"    </p>",
"    <p>",
"     If the cause of the syncope is not readily apparent, the clinician may perform special maneuvers to test your response. As an example, you may be asked to bear down as if having a bowel movement; abnormal heart sounds that occur in response to this maneuver can point to hypertrophic cardiomyopathy. The clinician may firmly massage your carotid artery (located in the neck) while your heart rate is closely monitored with an electrocardiogram. The heart's response to this maneuver can give clues to a possible diagnosis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of medical tests are available to help determine the cause of the syncope. However, testing is not always required.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Electrocardiogram",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most patients who have had an episode of syncope will have an electrocardiogram (ECG or EKG). An ECG can be performed in a clinician's office and takes only a few minutes. Sticky pads are placed on your chest, abdomen, arm, and leg, and are connected to a recording device with long, thin cables. This is not painful and there is no risk of electric shock with an ECG.",
"    </p>",
"    <p>",
"     The ECG provides a picture of the electrical activity passing through the heart muscle. A normal ECG does not necessarily mean that syncope is not caused by a heart rhythm problem. Heart rhythm problems are often brief, come and go, and may not be present at the moment when the ECG is performed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Rhythm monitoring",
"     </span>",
"     &nbsp;&mdash;&nbsp;Heart rhythm monitoring may be recommended to diagnose rhythm problems that come and go and have not been detected with a routine ECG. This monitoring may be done at home or in the hospital.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Holter monitor &mdash; You may be asked to wear a monitoring device, called a Holter monitor, for 24 or 48 hours while performing normal daily activities at home. The device is connected to several long thin cables that are attached to your chest with sticky pads (similar to an ECG). The cables connect to a small, portable machine that can be attached to a belt or strap that is carried over the shoulder (",
"       <a class=\"graphic graphic_figure graphicRef76605 \" href=\"UTD.htm?38/7/39039\">",
"        figure 3",
"       </a>",
"       ).",
"       <br/>",
"       <br/>",
"       However, this type of monitoring has limited use and provides a diagnosis in only about 2 to 3 percent of people with syncope. If you do not experience a syncopal episode while wearing the Holter monitor, the test may need to be repeated, or an alternate form of long-term monitoring may be recommended.",
"      </li>",
"      <li>",
"       Event recorder &mdash; An event recorder may be recommended to capture rhythm problems associated with a syncopal episode. The advantages of an event recorder compared to a Holter monitor are its small size and the ability to monitor for abnormal rhythms for longer periods of time (usually one to two months).",
"       <br/>",
"       <br/>",
"       Some devices require you to activate the recorder when you feel symptoms of a syncopal episode. However, if you lose consciousness and another person is not available to assist with the recording, the opportunity to \"capture\" the event on the monitor may be lost (",
"       <a class=\"graphic graphic_figure graphicRef75670 \" href=\"UTD.htm?18/22/18799\">",
"        figure 4",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Intermittent loop recorders &mdash; Intermittent loop recorders were developed to capture rhythm problems that occur before the device is activated. When you activate the monitoring device after regaining consciousness, the ECG recordings from the previous few minutes are retrieved and stored for analysis at a later time.",
"       <br/>",
"       <br/>",
"       An implantable loop recorder (ILR) provides a way to monitor rhythms over an extended period of time (eg, 18 to 24 months). The ILR is implanted under the skin on the upper left chest area. It stores events automatically according to programmed criteria, or can be activated by the patient. The ILR may be most useful if your symptoms are infrequent and an arrhythmia is suspected, but other forms of testing are negative or inconclusive.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h3\">",
"      Echocardiogram",
"     </span>",
"     &nbsp;&mdash;&nbsp;An echocardiogram is useful for identifying underlying structural heart disease such as hypertrophic cardiomyopathy or significant aortic stenosis. These findings alone do not conclusively establish the specific cause for syncope.",
"    </p>",
"    <p>",
"     An echocardiogram uses ultrasound (sound waves) to obtain detailed pictures of your heart as it beats. A technician presses a transducer (wand) against your chest and abdomen. The transducer is attached to a recording device and monitor. You are awake during the procedure. An echocardiogram does not use radiation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h3\">",
"      Upright tilt table test",
"     </span>",
"     &nbsp;&mdash;&nbsp;This test is often done in healthy patients who have syncope. You lie on a flat table and are tilted at various angles while your heart rate and blood pressure are monitored closely (",
"     <a class=\"graphic graphic_figure graphicRef57312 \" href=\"UTD.htm?13/49/14097\">",
"      figure 5",
"     </a>",
"     ). Your response to the change in position can sometimes give clues about the cause of syncope.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h3\">",
"      Electrophysiology study",
"     </span>",
"     &nbsp;&mdash;&nbsp;An electrophysiology study (EPS) may be performed if you have heart disease or if a rhythm problem is suspected.",
"    </p>",
"    <p>",
"     Most people undergo EPS in a hospital setting. You will be given a sedative before the procedure but may be awake during testing. The physician uses a local anesthetic to numb a small area over blood vessel, usually in the groin, and then threads small wires through the blood vessels into the heart using x-ray (fluoroscopic) guidance. Once in the heart, precise measurements of the heart's electrical function can be obtained.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h3\">",
"      Exercise testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some people, especially those with a history of syncope during exertion, an exercise test is useful. Your blood pressure, heart rate, and rhythm are monitored while exercising on a treadmill or bicycle.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h3\">",
"      Electroencephalogram",
"     </span>",
"     &nbsp;&mdash;&nbsp;EEG involves the measurement of electrical activity in the brain. It can be performed in a provider's office or in a hospital, and generally takes about one hour. Multiple electrodes (small, flat metal discs) will be attached to your head and face with a sticky paste. The electrodes are connected to a recording device with long, thin wires. You must lie still and avoid speaking during the test.",
"    </p>",
"    <p>",
"     An electroencephalogram (EEG) is frequently obtained in people with syncope, but is rarely useful. It can be helpful if you have syncope and seizure-like activity.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25\">",
"     <span class=\"h1\">",
"      SYNCOPE TREATMENTS",
"     </span>",
"    </p>",
"    <p>",
"     Treatment of syncope is based upon the underlying cause. The goal of treatment is to prevent recurrences or more serious problems.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h2\">",
"      Vasovagal syncope treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Vasovagal syncope can usually be treated by learning to take precautions to avoid potential triggers and minimize the potential risk of harm. For example, if you faint while blood is being drawn, you may be instructed to lie down during the procedure. If you have a feeling that you will pass out during any activity, you should immediately lie down and elevate your legs.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h3\">",
"      Counter-pressure maneuvers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Counter-pressure maneuvers such as tensing your arms with clenched fists, leg pumping, and leg-crossing may stop a vasovagal syncopal episode, or at least delay it long enough that you can lie down with the feet elevated. Such maneuvers include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Leg crossing while tensing the leg, abdominal, and buttock muscles.",
"      </li>",
"      <li>",
"       Handgripping, which involves gripping a rubber ball or similar object as hard as possible.",
"      </li>",
"      <li>",
"       Arm tensing, which involves gripping one hand with the other while simultaneously moving both arms away from the body.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28\">",
"     <span class=\"h2\">",
"      Medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with a heart rhythm problem may be started on medication to control the rhythm.",
"    </p>",
"    <p>",
"     People with orthostatic hypotension may benefit from increasing the amount of blood fluid volume. Fludrocortisone (Florinef&reg;) is one medicine that is used to increase blood volume. Midodrine is a medication that constricts blood vessels that may be used in combination with fludrocortisone.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29\">",
"     <span class=\"h2\">",
"      Pacemakers",
"     </span>",
"     &nbsp;&mdash;&nbsp;A pacemaker is a small device that is implanted under your skin. Wires from the device are threaded to the heart where they emit impulses that help regulate the heartbeat. Pacemakers are often recommended if you have syncope caused by sinus bradycardia, carotid sinus hypersensitivity, or heart block. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/16/20741?source=see_link\">",
"      \"Patient information: Pacemakers (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H30\">",
"     <span class=\"h2\">",
"      Implantable cardioverter-defibrillator",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some people with serious, life-threatening ventricular arrhythmias (such as ventricular tachycardia) that cause syncope, a device called an implantable cardioverter-defibrillator (ICD) is used. The device is surgically implanted under the skin in your chest, similar to a pacemaker. It can sense when a life-threatening ventricular arrhythmia is occurring and administer an electric shock to correct the problem and potentially prevent the person from dying. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=see_link\">",
"      \"Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H31\">",
"     <span class=\"h2\">",
"      Orthostatic training",
"     </span>",
"     &nbsp;&mdash;&nbsp;In people with orthostatic hypotension and certain types of vasovagal syncope, orthostatic training may be useful to prevent syncope. Techniques are designed to decrease pooling of blood in the extremities, which can allow the blood pressure to drop when you stand. Methods to decrease this problem include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Use of elastic compression stockings, which are worn on the feet and lower legs",
"      </li>",
"      <li>",
"       Contraction of the leg muscles before and while standing",
"      </li>",
"      <li>",
"       Rising to stand slowly and in stages",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H32\">",
"     <span class=\"h1\">",
"      SAFETY ISSUES",
"     </span>",
"    </p>",
"    <p>",
"     Passing out while driving or other activities can potentially harm both the patient and those around",
"     <span class=\"nowrap\">",
"      him/her.",
"     </span>",
"     As a result, driving restrictions are sometimes recommended for certain people with syncope. This generally includes people who have a history of syncope that occurs without warning or known cause. Driving restrictions are governed by state or local laws.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H33\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7377147\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7377154\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"     <br/>",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/5/36946?source=see_link\">",
"      Patient information: Syncope (fainting) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/49/6931?source=see_link\">",
"      Patient information: Pacemakers (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/25/6546?source=see_link\">",
"      Patient information: Orthostatic hypotension (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/46/8931?source=see_link\">",
"      Patient information: Bradycardia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/40/19075?source=see_link\">",
"      Patient information: Sick sinus syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/16/8451?source=see_link\">",
"      Patient information: Atrial flutter (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/38/30307?source=see_link\">",
"      Patient information: Aortic dissection (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/24/1411?source=see_link\">",
"      Patient information: Time to stop driving? (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/17/33042?source=see_link\">",
"      Patient information: Vagal maneuvers and their responses (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/25/19859?source=see_link\">",
"      Patient information: Long QT syndrome (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7377198\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=see_link\">",
"      Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/16/20741?source=see_link\">",
"      Patient information: Pacemakers (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=see_link\">",
"      Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7377213\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"     <br/>",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9034?source=see_link\">",
"      Approach to the adult patient with syncope in the emergency department",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10598?source=see_link\">",
"      Carotid sinus hypersensitivity",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=see_link\">",
"      Evaluation of syncope in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28855?source=see_link\">",
"      Management of the patient with syncope",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link\">",
"      Reflex syncope",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=see_link\">",
"      Nonepileptic paroxysmal disorders in adolescents and adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5272?source=see_link\">",
"      Pathogenesis and etiology of syncope",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27399?source=see_link\">",
"      Upright tilt table testing in the evaluation of syncope",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link\">",
"      Indications for valve replacement in aortic stenosis in adults",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/\">",
"      www.nhlbi.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.americanheart.org/\">",
"      www.americanheart.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?4/9/4245/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 27, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?4/9/4245?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     Grubb BP. The fainting phenomenon: understanding why people faint and what to do about it, Second Edition, Blackwell Publishing Inc., Malden 2007.",
"    </li>",
"    <li>",
"     Syncope: mechanisms and management, 2nd ed., Grubb B, Olshansky B.  (Eds), Blackwell Publishing Inc., Malden 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4245/abstract/3\">",
"      Task Force for the Diagnosis and Management of Syncope, European Society of Cardiology (ESC), European Heart Rhythm Association (EHRA), et al. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J 2009; 30:2631.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f4_9_4245=[""].join("\n");
var outline_f4_9_4245=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           SYNCOPE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           SYNCOPE CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           SYNCOPE DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25\">",
"           SYNCOPE TREATMENTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H32\">",
"           SAFETY ISSUES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H33\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/20/4420\" title=\"figure 1\">",
"           Heart conduction system PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/14/11495\" title=\"figure 2\">",
"           Cardiac anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/7/39039\" title=\"figure 3\">",
"           Holter monitor PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/22/18799\" title=\"figure 4\">",
"           Event recorder PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/49/14097\" title=\"figure 5\">",
"           Tilt table test PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f4_9_4246="Infected eczema ear";
var content_f4_9_4246=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Staphylococcus aureus infection in atopic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEgAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDlJrkqoBkkY5+bnpUZMLFXYSFTxy3X3pZvNivGh8sMCSN2M/nTUQsGDLu2nC4H5147fQ+rS6lqzRZpmUzCFCCMjk4qSR0e0MMJPlqxwx6sPc+tZ0cbyMNo5YY544HerlosUmFkVhIM8qep7UrjcUtSeCZ12r5zEZ6elTyTSwBY3B/fD7wJBFQ3JaKBVZMNnODx/wDr705cS/Z5rgxoFXKsQSWx7dzSb6EpX1LcIcxMIfNZOEZgD8xA7GnWolWdQ8qgx4OGbPI7Uz7W6QjaSELZxu65PJI68VAJEUyMjRtMz7dz9l9qlspRYeexeQu5X0A7/WklmSO3VhKTOWKkZzxUayQbkEqNjJ3Mh5PPYduKpXYxdZXeUzwW61nOTSOqnC71LsWovbyNs8uQlSgYg9+4rZ0gtf6hYx3chMcjhflHU+nHTtWLNDFBaWyiMGWQCVnJyV6/KACRjoeQDWvpnm2UORMwlZN3lovYnHX178VEHLqKqo2vHc3dUs4oJ1W3JJlz8o7EH9O1ZEnmpvSRm3KcZLZ/CpbueeWSNmkZ9ihd5PJPc1LbRRtbuWZd4I6/XrWphC8UrlN1kwVMhAzyM1ZhkQINrybiCGG0nHpippERmAHPrt7mpZXdkUtsiCYRQq4x9aVi3O4v2jzon8xt8zj78h+4B6f14qstzLbDaZFdWIJ78ZpxxDIcqJR+n19aqXOM4gBwBk+2e3NJjjFPQ2IbyI3MDW3kxTE8IBuXnsR3/HNSRKRLLFLKIptpUmN8e/zc+tYMJtwRmOVsDnkdfT2FSi5Uu5tYI4jj7inoOnfrU83cHT7G1JLZ2axmJpt4TPls28Bj+mO9W7Y2T4tp3nhnI+XzVAXB9SOvtXP2MyxqxmgEysCADwF96dcM8w3vIwVQcBvu49jQpol076XL8wlhnePemV+VSp3AjPr1/wA4qxHe3dtIjmYkKNqNuLAn8e3tWbb3Wy2j/dxF1J3SyJ8xU98+2K0XsLZrQT282x8gbGOOcZPJOCKL32G7LSRqWVzBNuW5WZ7pm3Kn3VOfX86dF5UquiPGsm8/IXwfwzwfrVFbyR033JSVkUeW4XDMO657EVp209s1kZbmCIoBlHfjJ7DjqeKa1OaacdS3BP5UASMZd2H7xcEA1ceZZLQi6jS3cE4mB+Vvf0/OsmCNX2/ZWh8zGSqsATzxj1pHktUAEnnN83+rjXaF9QfX6072MJRTZYtrksiwec8rJ8pAG1WB7/X3qwboPLcQwfLCZMr5rFePr2qhYrFNOXRkW3WNv3bsSR/9fvSsrNETdo+CfLRk5YN7/hSu7A4q5r2Atwm2USROzYQMM885bPfrV2SSKPcHl22qAK5cfKx7j1+prlIG84PBLKFblVJBK4Pfj0rSuVYabFb2ctvKqqN0rgEHseOo4zQpaGc6eurNaXjfcacxcQrnavCScdgOtOS++0LGQx+0n5l38Fem7HpWMyX9rG82lBhbyQ7VKrwHzgkL2GM4p9rcR30Er6vBOvkAI8gTl26DP19KpS1szNw0vv8AmM1vTJLuYwpqPl3DMHYO2TgZGF9uaw9VhnRLctNudUKyMwwc54bPauzlPkWcbCy8yFBtJBy0foee1c54ltDeW8Vzbwqxl2hSHyzZ47e3ftiiUb6l0qjuk9jibuPylkDSAyRHZ8j7lY5qratI0buzMcnCkk8+1WLiMFZIySZCSzpt6AZ/U1RiEjKMlhECNwBOAD3qD1IbGjFMCSFTcxAPJJC+tXoZZQ21iCrkZc9Prn0qmoMszJzK6/KMADIHQ/561btriSK6jeZckEbkb7pHTp9Kd7EtXLCs6Nhg+wHIy3Wp4HYE7WP0Peo5NrSAJ90cAjuBVi3AKgDsalkdCfz5Noy/GMYFOSVkIB5HrS+UWQD+Ee3rUrQYwobdjj6VDuRdCoxEu5cHd0GakaTacr17qaI0bYiYXCknPeh0O4PwAT9aLsWg1pCyDnAbjio2WQAhWOzHU1OYmlLLEhO3nis65fnaCVPcVL0NI67Dbi7cKU3EY96y7i9OCrISeoYHpRfueuTj1FUZYJ2hL/wYyWBpXbOmMYpXZFPffO5ml+YA7Pc+9GjWM13bXV2zvhBubgkH6/n+FY0cBuLtiWIyeDj0rs9Kso44FiUTbpSMBAeB0LcdR7VpDUKrUVoQpBJ5YWQkAckZ4pWbZKpWRmBbbjOOPWr8kDbmOBgLzgcD2quISXVcCNWwQSPmbB/SrZlFpnFTmFo5kSMIHOWbdkkj+lUoYfKKh3WNRyZD2HsKSFjNJNhXZUJYhTwOadJcmUFBmRuqE4wD3rpdmZRi1oKH2HeJFdhkLtX5cfSls5BBIJJFDoCGKYxu9s1C6FSiqWLEZK4wQT2q3FbmVne43QZxsTB+cn3PQccmpbsjSyS1Jri9E/nF4FEiAMg6gD/61ZSu3msRI+CT7ZqDd+9d25AJGc5BI96kgBk3IEUu+MHHK/SuedTmNIwUEaUc8VxIlvaxtluPmwB71YtY7NpSLqR2Xp+6jztPse9Z1svkygbxuUnBC9Tjgn2rTsLQMj+Y6PIYyzHBwoz1+v8AjWibaCVktGJqVisEirEkgLYKhiCR9cd6tPbLLAqyxMseBtKsOvfPvTtRELTRtbmaS2VQiFxyx74/nVdFdGVWWUEklQffuKbQo3cVqEMKkKvl4XkKVPJ56n19K3dOhicPDLdSRRom/O7gY6iqdtHJIwjBRWVSECpnOP6k1pW7T/JbpbhTKQrM4xgjvVKKIqSvoQXqwRzlIjM4PG4gZzj0qW1jWNWMjhh2G0Z/PtU18sMMRjtLpI1kHznbjaM9M/UniqhlCx7DKgT67s+5oJXvIZKUBxxweDu6fWr+mxJI7tLqEMMSrkyHDj6Y7mqYidNrKYyucKWHCMR0YH+tSGOCSSN/3oKsAXQA7T+HvUlPVWH6hGVf9xKs0agfvHXZn2AP1qC8iWKNV2bpDhi452+2asQWiy3DRF3ZpDkSE4J9zn+dWXt/skTM0qZVimA53ZGOSDwRjB6UWBT5bIzJIwmmrGpj8xn8xm3AHbjH8+1Vgxjgifb5sLEgMy4we/I61oSwm8ihS2hE0w58xDkYH3sKB1xTb7z109bON1ayZhLEshBZPXGOhPpXNVTWqGp9B7+XchNqFPMwqvjhe2PQ1PqWnNbpeRooLW5VWyNpIP8AFj8vzqHSDcvpFwsls81rE2QwHCP6Z/I1rWepQixtl1eNZncgIzgs21R8vT61NN825m5SjLTUyoWKWsUDYcIrFomTge/vV9Y4/ssNsuxnLYQOcZ/HsO1X454rfUWe+tnMUe4eXgbyrHoPzrmmkae+l2RFkbIWPptXt+VapcpULzd9upfiUxTL5qsx37QVO5UAPOB36VtzTQyIiA5jVfljjAIj56++axre38gRSxPOvzYYlAPLIH+c1dFmt6qNYwFpYgASZMF+O3bt0rRJk1LN3bJPs5mkAtwrI2BtGAR9M9DxUi2k1xytq7bQQCvyc++RVbSnimSSK4VzLn+/ggjnb61piTyUjRr5EXyz+7dy/wB4nHTpQkjKTadipbypaXUfnoVlTnrw/HTmtnUZ5JsNb4MoAIwm4k47+n1rDuIZPLz5a3KbjgZJOe/I6/nQ935dnA5kfdIN4dD8ysOx9qlO10KUOZpiRTql2rXtuu3BBAbv0zxWjdXdg0xWC1MUcaeYwCDDkDHT8ayZLmR43a7XJkw5I/vcgZ/CrkMQNsF3FbqFgqyycHB6DHoKm4Tit2aWg3N9e+a0hRLeM7Uj3YZff0x2rREuZFk06Tz3kYo3O6MY9fyrMt4jYy3Ez3srRwssYSOPeJjjk49Kdd36WNpPKtuscEuwrDbLtOCMjI9eCT9KqL5Uc0o80vdNOe+a0k8m4ZFgmBImQnA/2SO1UdXRHgnazfMwgyfJJI46YHbOTUGn3o1OebTAkf2cgM7NgtuOOmPT1qBll0jWbWyjeJ9P27ZCSRg8k89qtSuiVCz8zi9QgePUVKfIoO0K3JwcZ+tQus0U9zsaN8pg4XAI69PXtXUa9Ym8uDIFBmRj8hPXpxnvkdKwJ7qdpSJbaIMGyDsweOxH4daze9md9OfMkQw/uDKHRllc4A9Pw9sVYZJmKNKuCV3bm/iqKeZpZS6uSq/Om7uD3B+tWJJPNhWSRtrF+oXKkn+VDNbvRlqENna2Aw5/Sr9vGqgnjIOD61StWDpuY98EirkQJJwcA/kaREi4vQe1TIc4yAMVXX1B59qmBwQvJOOh4xSZix4bYXAAAJyCKR/mHXpQzDZknnpVeSQYIzmouUkMkkdCSrbSRjIrMu2JJbPNW5JQQc4J6c1l3kvyuCxAHp3pbnRBWKsswYtEQWLkDNO1SWKKwGmxyyC7cq0m8dBj7ue1S2ccIt570K7/AGcbgDwWPYLWdZRy315JPIfMcfOT1yP8a1imhyak/T8zR0nSo44Y55MuAwJCkDjPPvW6JliVUhDeUuW28E+uD7VE7LHp0EKLljySR0HpVdyyxE5K54IBq/h2M9Zu7D7UId4KqQ3U9vyqG1cG6U43MHB571TllLPksCew9KZG3mThS6DucdPpWad2bciSOXZY0WZWbbAWJYgYwM9KitYpG864tFZ0h4ZioCjvn2qK6OF8os4G4sysvA9ye9JYXBkP9nxK7xTuD+7Hztjtn0rpk7OyMVG0bmpo2+6vkcwrIoJdmPHzdu3aqnim+nuZUjQhkjUIQoO3PfHtV7RJHkvPLh3G4jJi8uTILAnjHqegq1e6bbyXkttGWhlQkShlzxnkBR7+9TNNolSSqXZyUEcSW0hmSRiD8pBxn1qSxMqFmiyOOcdatNpM/myrGCyxhmwWyVUdzj1rV0iH7Lb3M4bZIIwvlN95gTyOnUg5HQVzcsm7HRKStpqLBZRfZoJgssm1CbhnA2KwJICEHkY25zjmrqxNbteW8ZiWQxhGXORz15HTHFNtL4f2Ld2ktuZZGZfs7lv9QpOWAXpyepoiuNiXDsoAkZWY56kHODnqPauqEeVGVpPctJ9lihsxdrIwQf6sMATnGT0NUi0JhRURldMku7Zz6D8K0Ltb+9UX1xL5jsNxyecdB04+n0qFrdYtgaN1fIJx0P0P9aGONi7bKFtke0BimBImaTquRgcnHJz9azHD3cyI0uOMLjooA/SrbWRvfNmwojRlyoJLPnrj/GrcyRMXmcFVdgqKFA2n69MYo3EpJPzKsls8NqcNKU4V/m4I61GkEbQklihzk5PbHFPjmhEqLEHkUHcdx/1hHT2xUl4+QkhAUuWy0sg3H1/+tSKuyu4lcbySkXHL/Kp+p9auafc2sNqs07m4c5DW6qVz6EEcVlQxy3DrbxRlmcgrk9B7ZraB8ixaCyvFHkDzCrZDHrkA4/lxSvYVTRWKVzJK05FupIkjA2k5C98H8RQk1xdziQ5eZQMMCBgj9Kg02S/g84WpfYV3Sqpwdo7/AF5rQh1hRMjyQjceDuHHp2waz9om9SndaJXJtG1l9Lnm8qNpDJGfNkYgFSf7uPelLwqBPEB13ogT+DuPqOa6DQ7eG8jjluJ7eJZXKBVUbSQe5/KofEVp5E0dvfx7Y5WYREAZzwBxVuOhzc8XO1tRmmRQvaXUjXCJJKTNsEg5x0Xb75rFu3t5LhDEkjGBSWV+Aoz0rWWfS7G2LPY+dOq7VEpOH/2uOn0NMjFn9nbUVjWKR8xS28hGVDd1HcfhUqFtBw91uVmVbkzzQrIB50spJ8zOWBUAZJzgVAInSESSOUbeVWSToW7jPWrxuLARQoz+cEXaCDtDDn5Tzwfesa+ukdvLg8z7CrExRytnYDzg4HX3qpWWpvC70SNX7YZCIBLgOoEhkOQ5+p54xTRb3Ef+k2D4RecxqVwMd8HP4VWSW1vLR/Mt1haJdwiiAQE9mYkknjjgCqmm6lNp10JQ4BPDLn5WHvUuaTVxcj15TUWT7e7fZpglzcELgnC4x3PXOe9NezuLHU0e42DbiQuHBH/1+lR6hfi6Nuba28knqzNn8Kov5yM0r8+YpHOCCPp2rKpNREr7bG3pUt0LjyoklklZmPl7cjnq4xxnFPheJbie3uXWOI427eoOPT9KbpV1PNbssU7rc468gMo4OCOhxiqwuRHdsrpEGDct/Mc1aaaTIabbRcS8hjQ4iO8jG/8AgUdsDvSXc8iXUMkczIAgIZ15wB1x71UedlcvbnG5TEy4wWU8gn356+1Ts/22OJZwiSRLsVlH3x/d+tK4uW2ppG+lSdTGQ8LIrNIgwQfT6mrGoxWU/kyzzyQFiS5X7zrjgdfl4rP1GSG2FoTMJo5FKeTGCGh24ALeufSnXUELgveSCNZVGNx+YgdCAPy5oWxhZaPY1rRIbBY5rEo0UgZpJGOXIPTn1zVtbW1LgIrhsFmHA4PQnHB9MVknfHPEYZElj8xFQowAYYwSfyrUs9Xgnu2tvs0gZI3BdgMcHpx0z+daR0VjCae6MjV49trI8cbN9lkWN5ugCY649s/ka52+i82RI7hg07udjE9U6/mP85rptSuv7O1F5Z7dnsbnbGTtJCPtHOT/AJ4rE8RNbx6gssCrOrQh45M9W/x61Mjei2mjERQVCw+ZKkbbgSOMdD9M1diZEgaMOvzfNg/dB9MVW8xOkR2KD820/d+op5b5ipaPBwS3fJ7ihbHXuW7MKwxuww9e1aUBIgGBuA9etZSxY+ZJNwA5I9K0I8uhw24AY64pEyJg5ySuQDzzT95GMnOePpVcmNSAXI4yx/wp6TRiP5jlhyCKlsViTzioIIB9M96rzysG5zz2p8k+8cHkdh3qvKxYlmOT6mpaLiiCd32HoM8+4qlMUDbCreWq7mY9cfSpJJRkbBkg9/Sq7RyyZiUlVAJZjxjHOKcVc1bsjHa7up0VIpttsWJKqenOMGuh0dRHCEULwVbeOBgkZBrIhiVY7mYgqu8JGoH4nNatmfLTbI4wOAO2cVqtGTLVGzdNH5ZYSY3D5VUdPfism8ulGQowB+ZqOa7ZVYhiCRtPPUelZnn72IJ9ef6UpMKcLasfJcsrAKAXI4zVnT42+0R4VSwIJ3dKoQxSFsk7mA/yK1IYCFV05AwSff0pRRrJo5EWv2iUIrt5rbjL7Hrx68Vd0LT4U/0gSASAZSPdg5HU/wD1qhaB40beoZ5HJwpxgZ61qrbpbktHOFlCbnUr8vXnHt0roaTepzSelrjNNjijk3m4mLqxk2j5S3pz9eaInklnO75GDCYyF8Nx6fn09qaG+1tH5ilJgDtK9COagkkeSR5D/rB0KjoB1/CnYOW7LlzeNJb3VsUjQ7w7yquGcZACgdAMnNZ2x8hnRljLldzHsO+PX9KW3V5kf5WOAcAHhe/fucUpiuvtPmmTzxjIx90cdKhmsYqOiJbUlYojNjy/MKvtOGI45IrSutOeJI2dMrk/OOj/AP18Vn2Shpsysck4+X3PeugafepgdP8ARcDYjHB49PrTWpM209CotyzJyCB0AHAHrgf1pI8u8ZZRzjBJx9KSe24DhcIylgF/h7AfnUdvHEGVmfGwZZSuQSO3rTY0la6LcqxxwqWnEk7A/JEcqvXqe5q1qM3mtb4Z5I0jQBQRgELzVK5uTPO7eREgfkIF/rVq4hW3s7Z8xMZACjxtkY9COxzRcnl2vuVY1855WiDworAs5XKrzwM1n3qqt483zsjKCGY8Meh5rU+0hMRPGCPMBZQ3Gc9x3q3rc63JlhZHjXYqKpUEHoc8Dp14FQ1ccZOMtjnrW8EckTxqJWUldrnA5HUnNatk86J5qw7pI1KIQAwVcYOQfr1qKHSCtlJKuyQAMXUn5cgj7p9a1PtXl6S85ljsWZPKU4Z/NGNw59yB+VYSv1CrKLfumbGt1YMYJYzD5+yQSNyQmeCMdRn09KSdobl5JGRpXZNzFRtMblj27jp+dZEVzCJglysmx2XzJFOXRe+0cDPpmtjQEgY3hN5FFviIijnba0p3DA6Yz9axjK7sOUeVcz3ILK+mtnNvKcwM3KOoIDdM89KkN89hJZs7wXcJTf5TvvxgkAMP4enT0xWPd+Zb3IaeNnB3DnPX6+oq3BazyxSTvatcKx8hJYmAVZMZGeOeP/11pGTZvyR3fU7CLW/D7WtzdyWU0MyBUgtfM3q+cknkAbc8Z5PPSsEXNs6I6rK8u/bsDEliR2HQDP41Te7voprl5FiRpgUkTylA2nGQFx8vQcjFRhZZrtZov3AL5QxA4Q9sHrx61rzNkQpRjd3/ABN/R5Ha9hB0yznCyvG8E0m2NWxgHOfWs67ke6hicphkxE0caFVUAY3M3TknGP8AGrOl262MN2ziOTcu7a4ySO2atT3Uj6YqDzFh2NuQNgAEgsMd+QOvpUTb5bmTlaV0QWcLadDBeLJalZHMbMQHHA6FepHvVae6h1Gd99siFYyF8pQuW7fWrMV1HLYeVJACy5VW2YMfqPeso/J86E9ewPHvmueVRpKxMXdtvc2NIljDwpdONi5Ub225B6irkn2JXLiHCE4yOUXOcY9KzpZp1sPJkihZJlDRuVBJx/db+Yq9fB7fQLX7QjEswkJyMAEc4x/Wri+ZGclzNPuWJljtdRleymTa8fnCPqeew+h5+lUmtmuTJKEYSkbmVF3fNUNlNCssayMLhcK6sRtaP2HrWqr/AGWBC4ASKbEmSVbnnP6V0JXQNOHqZsD7XDSIrkEZZfT0xV5o1eUtZxIoJz5iNkYA5yvXvS3FtFJcSISYpWAKhWG1+f0OK0LbTLVTtW523PVNuCQff2pKJMprcoSWqm8tJJFkK5AkkIIVsev4YqO6u45XnijZ9jENuUcMM/3fqM1sW1xc2FiokSOeEynLF8H6nNPQWVteSSxwJ8h3Fzt2g46deTVcvYy5+6uU7ewg+wLcRn5gwl8snai+nJ7+1XoYNP2ykTMJZVOMN95uOB+feqFrNYNZ3IWOZPP2sUlUbCB6frUpvNBllSOOdUlBySQdpzxj0o91WbIkpNvcetnf6rAba6ZTawp8lzwW46Y/XmsLUdNS3t40gnSYpxIrH7+TngdiK7CZ45B5cbeRhSGYONhb1JHb6VzN1BNatNbnzJSjDEyLuLen1Hb8KqyYoSd+3kZV/YizuA7RMgaNR+7ZSGOecmqEc8EkMOGCgn5uOVPf6j+VdDNbRXULyQqwdSQVzjB7jB/hNc/d6eYHcMvzMdyMByPUEf1qZRtsdVKaeki1FuiJCHcB1x/FUwkfbt25UDcPpWdayvJBHEzJHJECQemeeRz3q9Gr+WqzAB+itnP4VG5q/MmFwuN4wc8bSM4qMTEcq3IqrOZIyjbEdExuUnP45qBr5JHckrEfQnGalxZSNmCQvhgBnryQM0Tsu0jhm6deh9KyTcwlBskUeu719KjjvMMRGXZTw23gH600ugOPUvOpVcyjy4yep6gewqEL5ts9y0higQhUjwd0zHufaozcQiXcIo5Jm+/ydie5J7+1Na5Evyl/miJG932jHrz0q0kLViXDo0MaxqFVT8x67m7mknv0WMInVVwOAPqRWQ+rSTFFgCiJSSBjhcntUK27SzM7MW5+XJ6CmzZQ7lmS4lmOzJ2ZycnrVqwtmlLYU5ALnnHA61UVVXAHLdzVq2nYkLkkscEetZ3NXF20L0SHPHc49K0reYK6BCnBxkjjPeq8MwtYy21DJjCsxBK9jgevvVdJt0qomCpI5/u1SdjFrmMaWDbOsi3jeS2WAcnqv8J/GpXaKJLOa2kD3DgtKrcryTxz26VDdQwpcSvDKxjWQHYw6g88f1qe4Xa0MscRgVcHBHY4wT/jXQZdiOW4uLwOzsN5JyowAfZQKIllmlMVtGI/N4IHXjr+HtSgCEllVstyp7qc9aRVkMkLh9jRHcj5wQfXFNstJW0JI7dms2uUuY8hvLEZ4dvfB7VDbER7zLO6QoudsfVzz0/HvUOQgPAckEYbvU9qmArq4I27SsnSpZpayIbdh8wVcZ9TkitqOTFsCrLuA9csal020sfOtw8RuQufN2PsOTnbz0xnHJpl3cJLfNMYlQE4IjwFOOmOOn86FdENqbskThXhtPKdwwkYMyIeUGOpP49Oe9RpZxR2xZHlN00mxYiQBjGSxx9amf8AeOzMqfKM/Kv3snPFU5FW5dGfKRKcMV/hXvn3psmOpt6eq7njuydzISfm4Cgcn3NUoy807CDJZzhUVAVIHT9KhtQz6d5IaJkViQp6gZ5bI/GtHS4oPMUvLJFGvOY4txIHcE+9JMmXu3ZmPpzecJZGOw85Zfkz6HGelbR02602KJ1BklZd3mRncoB7cDpVnULi5Dq5SOK1JEiPMR+8z0O0fStq4m1i4tIXtWhjZnxICAPOHHKr19qqy3MJ1pO17HE6jcyS6R5U52h5CUMYCjPB5/Gubu9QmMPkSZYE4BPbHFdRrIcaHNutHEEkmyGZWAUOpyVIPPc4rjZvnYnuvp61w4rRnZQipK4Ii4Oc053cj5WU8547VLpNot/fRW8l1DarIcedcNtRT/tHtUGqpHY3k8UM6XEcZKiVPutjqR7e9cSvujfmjezNLSrY3kflvcxlskrbyEqdv94MRtHNdCx1HRLMaapW3gu4wzOoH74Z4y/XHbAx71v+FdQ0rWPDFlDrQls9V+zLaIHQASwZJQjIwAQRz1PY1HqekTz2o0oQFJLSRvJaZsMUwDx2I9K9CnDlV0efPFc07SWn9anN31jqWjXiK7jzJFDnA3FfQHPQ8ZxVO3FxaXEVzlXcHcAvIxjv2q59gvDJtkMsIOf3shIU444PenQWNubqD/TlaJztd0UhUOe4OPc8VSZuqitr+Q238yaUJM5Jfnj7xz2Hsf6V0EVwttPpzzQA2iXHmFVUlUQHoSep9hSappNkJok02SO6XZiX5wWDjPOf6D0qHRNOa+SC5aSNrezfDwSE7JMcjj3JqpLoYTqRnHmexpeLjFP4i0/U440ktL6QMtuGHz4YBt2OMnNctqlpY21rcJdm707V7VxEtqVLpMM9Se3HpxWzrlnY3FpZ22nN5dwtwzS+axGM9No6bf1rO1W8u9Sth9uknubbS1EfmqisuG4Hzdcn3rnqRu2+4qCsopP+un3lezs7u6sY7h8izjztLHH1I/IfjWjO8TmSxCsgchYgX4YdeT0HIq34ZAmglhluW8tEUi3boCRyQeAMHsaoarbrLeTSwOdkbkKTwBgk8fiD+lXTp8sblJ3m4voVbdUs9Q/0hS6xnDL0yR/St2FY5ZJEihJjmBSNWfOcj5ePbt6U2W0F/FFLC0Lszlt54MjdMf8A1qfZvFZXEdsy8sSruwG5SOmD6VslYmc+ZXW5lqmYhDL8rqx+ZjwPb8+9ST5jeJo2BTHBHQ+tWEuWkvGkkhD5BXp9wnofSr0CPBO1i9rGFkizhiWGSOmex56VKQSlbcSEx3GlPht628Z5OQCc+n4VSsYjPasI7fdMCGyTkkDOeKuWen3LTGKxCIsqH+IMrbTyBn+tQhprGaQ4Er7NqfOMRtnk47etV6mV1qkytck2SxCaJ5FbIwx4AJ7eh/pUE0mj3DIzb2xiNUUAevXpmpikU1mFaQPcpNlgzZ78kDp+XbFOu9P0/wA1rqMSuNmVijXAPqc+lZyTZaaW97kimS2vVt1mtbvaTKI5s7QMYx78duoPNW47bVHihitLhboMTtWUYdMYONx655/Ko7vT44IlkguolU7droRggr69znP5VVvXeO3WSRZZyGG4EjbjPHTOO3Wri+XRmVubVEq3Njt23EM/mh8sN+Ch9f8AOaW+e3u4RLboohGcqxKuOO59KWORYbaSRwVaWUjGN+zjI+tZ0s81ydzyorj5iD8oGPbpV8w1G7uZF9bf6TGtuzkHqF56VDJdIquudsinI3AhjWhcljKzABGTBGzsay7h3lZ2mAkkb7xJ61FkdEW+pMLwyLjaWkyWZiRlh9O9UpLrdu+QD1G0VA1o88rm2VlKjdy/YVVa2nJwJOalxbN4uKLBun+6qbQo4bOaQSfIXlnjVFGTlsE/Qd6qtHMSFUjIHJQYz9fWoTahiN2WI9aVkaproWrjUI2wsEbbcjgMf85qFTNMrLM52HqKtRWT7iDzjrjkCrUduo+XGXJwMCqDQqQQ/MFAx7AdK0ViEanJH41ZtbJmdVX5cnBJ7VaW3hjnm82TfBGcbiD8/OP5c0tROSMGTcSccc56dKljC4B5U43HPc+31q6QhiULEGfGdx7deg/rUITy5E3J8uQSD0+lRymyndWJopd0TxOox/AT1HqCajhcCbCkcMOPWpYYoyWeZ/3YGVUDBJ6dR0qMWzow2FCnBJ74zSle2hF1qUXhDRPJndyd2T0PY/5/pVlBujSLLFOCAT3xj+f8qozRtNNFG0kYKSZBYkD6Ht2qd51dnKgn5toYD72a7L9zDluWPPlmW3R3JkT5FJ7elJMrCP7PGpebdjCKW3ZqESM0okZdpxg+/wCFOkkmjAKt75Xj/wDVR0Go2ZH5ZM7b4wJCcbSCOc9KsEoYykUaoq4BzjJOT3qItlcY+c8kj0+lTi2Y2bTsyhN4RRxuJ9MenvSsX2uQfvcF4sYHHy+lC3G1mj3FlJHU/eA7Z7f/AFqkjt1EiCQ7ULAMc9s81f1rTE0yG1nKRstyheIA9Rzgn8xUTulcHOKaj3E07UoYWCRmSFjITkAOMduvpU2tP5t2ZYGmltQwTfIBhjxuJx71Dotrp0nntLKIjCg2bc5kY9SR2A/X2p19JbzSKttu3bsBQMA/5NEW3HUiy57pHQR6S1lBHcSyxujrvZdoChM9cjrnNTabYQeTLfSSR21sImCSOhKS4IIXA5IJrJnttQUWyRG5uHcrsUDgL6e/vUuuaw4kFuvmRpYhVRQwVVOOnHfOapySOVxlLRPc0pNVitI7i5vIxLcQqJjEYWJB4GOfur071i6X4lvdR1qKa5wnnN5abSR5Y74rEuJnu5pJtQmkkU4ZlaQ7nPqKvaDpHmn7Xbys0KEkKFIb/P0rF1JSeho6VOnFuW4klqby+vkDoqMx3LM/PXqPf6Vi6lZizkdIGLpGwUtj+IdR612ujaHYanq7wOBGQcbHYqzAgnAHU9KxvF1xYWkkmnafAVZTiV2BBb8/Ws6kLxuy6VVufLG5zalG3bAea6DTPDUk+lf2oJY2Eci/uvKLqT2DHpknAx71PoNstxp0sNpZm6u8JLGoGXYqclVH0zVqHxteSaVaabdwxtDDK0gRfkw24sBtA7ZI9M49Kwp0ox1kx1Kk5aU1s9fQ9O07SP7UtUN/E0MysJPsoG3yjnqpI+7joB24q9rtrpU2nXjyNmXTE3NNIGOQQflB7qeRgdK4ew8fXwV7mJY5X37jHOSH24wcEcen51ra7qula1oRGjXUcOqMBvgcrGzqOSp3Y3AkY4PevRU4OOh47oVFNc2i8uhp3Oq6Nr3g+5MEKRLAPnhZ9siMo4xkdeD9a8nvfPur62+2pPaWzgqjyRsTgc46cnkdPUV3NtqCxx+JU8RWMNkbi2+1rbjLOAqhQ4bpgnv6g1y2jeI72SCD7NNuj83DSkgx4+UKChGM5H45rGtLnSudmGg6fNyrT17ruVba4hW5ZfMkRVXB4xz2HH410Hhrz7Wy1aSxaMX8oG6KRMkof4gexHWuf8UpImpSXU0qyPKfnYAINwHTA6dKcsz3S2rSsSDlt6KM/dAwR+ArnUuV2OiVNTjfuS6lfS3HyXB3TSYi4UDA/CqmmW8kFwY7ASXFxgny1TIKhc556EDPSkitJ59VX7QjhWfBZQTit+40h7bUMxSNKHOTt4kweoBqqd5lOUaa5e4y4az1TSI5wxhu4STJCY9oYnPzA9+OtZ128aW8FtG8rSSYMoB3c+g711q6bawsfLjlzJ0zNtLDGPKYDjGefrXF3ipNr6YCwLv2gryB75781tNuO5FCUZN22WpJBMIvMi27lQfLhsEN6/Wr1w6XdlbCJVE+355Mn5uxGP1/GqkoWyv5Ga3Cx+YMqDkAg8474zUkuoGG7aa2iCEHOE4AHqPQdqd11NGrtNGpHLBPozKxWCWFSdv3wwx95fxqjpusyQRtHI5kYkKo2/MP+BfpVnRJLJLpG5Z352jO0Kex6+lZMynT78uE3R7jgEdvT8qTlazMowi24NGtb6ncabcGK7KBWySpUjGe/TNWm+yXrPI0kMM331aLLZPTHSqGrG2a2t5UZgspJ2lcsGB5Ynp07CqWn3YWcMsrRKuApAx36/nRz20ZHs+Zcy0ZoC3hl05JGZ7edsfd6Hn061atLaTTnuIrv97BNGVLKRhDkckdOc1ZvptLGoyRzQSTvKoZATsB44IPpxVS6jt721Fws6Rxk7RArcqc8ZPrjnn0qrLoZcze+zKM5ETwJcOSyDzGCDaDjoDj2qRVEVuJhDImSCMkc/VabBO1o8Yt0Wadj5QZyduP/wBfrWlaWkZaG4vWfy5IypiZtzbj1x/OlG17FSfLuZE1u1xKNkMqEtktnKA49hSy2iNZIIyvyudkjEAyeq7far+qTLp9tFCjuh5L4wWPpg1zj6kGuxIAyGNsqDyRRJqLsy4KU1dF+68tN0cWZEI+Ybv4v8KzLuJSgC7Q55IA/mfWpI9sgL5Pqcn73sKQk5GDknquKXNc0UbFE25yMEEnnNKkO2b72ExySMg/5NXS6hcYcNnnK98diKSTDdewouWipc2safNnhueOMf8A1qZCqLGQMEN7c1duUUxxqyCM44PXI9SajS2xuyUK/wCy2T0od7mkWrakflfMNvEZH0qSZQqo2RvHHFKuSp4HTmqt1JLvUYC+meM0m7IqKuyYtgEhuB2zwaWS5EkOx8lEBIwcfN0yf5VTxtzvdjGSRvVMgkDoD+VPxG8MexPKODvBPBqeZl8qI453RiyOy/jQwdlU7Q2D0HWoMF2B6D2q1ITEmIg6uy4yeM/QfSo5nsaPR6FyZpvke5iSJZYwI41GAAO+B9D1pkk8EklqkIII+8T1J/qKWRbdYS3zu559gMfzpLKSYpJBBGojlkTLlctxnAB7Dn+Va+Rl0uZUzZaTIDMSfm75zmlRWiXejgnPDZxz7VNJFJHE5Ns4jd9qynOMjtVZTsOWyRk9RnNdRK1ROHw28sC5GWBOf1q2u25JREykalxtXkf48msxnEe5pBz02A4Of6Un2spEUPl8qUGMhh3P1/Gpc0twdNvYvGB4uuN+R05A/GrKNbhJI7lUjlUkAoOM98//AFqpwXMOxlitTgjB+cn379ajcoswcEtuDbw6Z5IqebsNQctyzGDK5jQckgAngda1TK93bW9ldxyypGNkMgQ7lJbkD1+lZaWzR2gk8xY1ZwgRjgnjJyfbj86kW/ntZAtrNJhTv3Dore1O91qEoc2xpTSQRN/oPmNJGMFjHsGB/eX371Ui06e5j8+13O/mhWYdASOAB+f5URNd3kjuAZBndKFPXPrjr0rd8NWFj/ambqULCYmLGN8+WT0APc9P1pOPMZyl7OL7i288h0eTT7CdBOHV3uGlIKrnlQTwO5J+lcTfTEyuqO7puJQv97HYn3rY8RasXu7i104hLJD5K/Ku5wDncSO5NYDghfc85rnrPSyNaFPlXM+pr6LbtcsFjhkuZCQfLQenqa1oru70Wd2ghLwshViV3eXuH+c1zlhdPBeQBtvkMdrL6/lXWqp0ixvb026rJIhWJWYtjJ5OO4HvmopvQxqrWz1uVfD999ttZYX1H7Pc2Tm6Qs3zNnhtrdiBjqe/tXEXUu+eQlzlmzvbqfc1oXZhkkaRQsfHz7Pu574o0i3tL7UIUuGzahwZSDgherY/AUpScrI6IRVO8j0LwTpOpaZax6hZ21yJ5I1ltZgoZQTxhweoYenrU8lvY6tqdxc66IdNu5shV27SXzyuTx05z7+orK8TN4d0nT4E0HULq4keQsYXmdxHjBUkcAfl3rGk1jV720tw063PlDyoUkVXfBwNo4yeelaNqC5P+CeeqU6j9otL/J/qdfqngs6dZPcGRlSPJLsOMdvrVO08KpeQhhqFlPJsaN4Wc5jcnClWzjnP4VysnivWtLtZtLnmlhjU+XcWs4zyGJwQeV69BWNr+qJe26zWtkloXAEsUBJRv9oAnIqeaF9EawoVvtS+Z0+uy6utjNYG8t5LbTXWGRVx1DHauf4hnNVNJsbOC/SXU3UQkiTbECqbyckbR0/CoPCni1tL0K+0u+06C+troBVVvkaMrnDAjr1+vA5rOuZI7ss1lFKkgZ5Njtu8tQBgK3Unrnipk1o1qdEactYPRd11O61SFr0RPDEr21xuZVZxkYP5/jVu0ithbtaTK1veAb9+Rh1A+4Owzz1rlNK1GV4LeAyJFLHKJQ7nnJ4wQew5/OuguLGKG/um1PylliVS8cEmfML8qyeox1FNcrfMkck4cvusWJrm+Nvb2UJt/Kd5vmbfIoAyAeMY6YqpYXl1bXvnXVyZSr8ozEFWPr7VI6T2V7HO7M5dvMV1OFZccjHqDx+FaFjqGmtfG5ujtu1j+6PuyHBI6dxgDmnRd32B6LRXVjTurhNUhFuksZizubP3kA7g/WqV5Z2gunSGYxz8DDAFDgcEEDJ57VDpV2bi0ksnCLFuJAVMkseSGPYcVcvNPuIrKUtPM0IjLpGqDgcYIPXpmumVmtTJL2b5b2MlxJJHi/tpjMWCmR/l2n1CjrmsqKPztsFvIIpBkhpBuDfl2GK0dSvLm5t4ZXhEMIiB3MSd3P3vxNZqWF5LYyyRb5SmDGqxEoVJO4hugwQOvXNc8pW21OqmtNXY3fDrpCGhXyopGHmPO7ECQZ7Adqz7iV57yeKRYEcEN+9IXk/3PUUaTZS3VnPqNwxDwo0TjIX5QDkAd/pWZbTGGdpRK4liXZGoCnKkEHORxxWU5uyZCprmk09TaijW1lmUIJkjUlHbgYPByD+WKyFEdtcKCXaKdOCOAVPUfnU2r3im4SWBMQMApjLbgcjJB96iP7zyFIYxIjMigfiaa1KjFpXfUvJcrMjGZBgR7Ywq4PHCjd61JBdutwVmtVYxZRYCdqq+MEn3/wAKxZLxnWOJ2UIjZVdmP8mr6wxmxRmlxM5yFZMfLjOc1qpEygktTZvbjzjHqVtsjJUpKgbIQhQOg/n3q9oENre2oNpc/wDEynICsSrlRnnenXp0x+dcZaX5hmEcp/0VmCsF+Un8up5oMN5pf2e9haaBmUtFcxMRweOCPap9rrexDoact7djp7rRNYtL2+S+JItk3QyxQiUyOclF2D5lVsHkjg9etYMenyXcgLwTW+xXabhcBhyQo+hX86qR3N0biWRZrhFkXYxaYlmHoT3q7p9p5ckcsLIk6LuLDqB/+qldTehSjKC1epYt9Huvsq3fl7bY85cZbB6cVVa1YHYhJIJ+bbg9fSuiupLma0tYLaQxeUMqS2QT6kfSmNpqi1k2TjzyysQoLFgM85+v86qLe1jJVf5jIMQiLLLuHIAVz+vFMlTa5OY2UE8DuKu3lvEjrJdyHJADMTyCRkHFUru4E/MUaIoG3gbckd8dq0fmbR1GXEsed5ZiQBgYHyge9UZnhRFIPmOSSw5GKkBLKygg8jjHPp+VJBaOZOELbs/p1qJS7G0bR3GWrr9piAuFMbkAkrtCZ9apSTxvOp6OrHkjIPWp5vMRh5TiPJ+XK8896rhFJBwwfPBbkEf0rPmbLVr3LeyQWqReeoi3FxHIyghiANwH0x+VQ291b20yG4RpBwjENuC/Ny4XjPA+6TjmmpF58khLhX24Crj5ucdT/SonsmEhVuWA+7n/ADzRe2qGrbM1bm5017n7RpySzg5WWJ4tmSSSHUAn24zx71Qilf7SqtHuZs7VYj5MdW+vHSmpaqH5YwvjI2nj35qW+kVntDbj/SIVBMjBVDgdDj8+tXa/vE2V7IgvfLiuWVXPlqODjHOPSpdO8+adUilbn3/A/pUMyLcWaSSrhUJAYEfMc88fjVvRpzDK25I33RlQWP3R2x6mqi9Sm7Q8ym26Rzbi4BhRmZCxPJI4wPwxVVkI3AKTwOD2rTtFe1eSWMAkgq2TyOcgiqdzLJM+5lHz9cdTXU0TB66bFa9XyYIF3bi+XbH1xVeWFZsz2qOEQqpJ65I9fWrvkJdksskcbggBWbGfpUbRiCUoqnHU+hrnqK5qn0W5f0q1mnURJEZHAwoUck46VrTaXBDHE8zbcsC8ezLE+gP1qrot2lveQLMCbVnDMwBJUc8e9at1Mt/cTWtqrS7R546KqsCTgegx+vNVTiktzmk5qfZGJc289srA7imQRvPPPcD06VTkUJtDqwVjycYOM9a1pJLs6cZi6O0TfdZtzbevAPUDH61Z0aNbxCo2+Ykbhw2Mc8g89aJPoa+0cFdkEF1BZSyzBTKECjZIvLN3GR279eaq3Wp3+ozzlnCxsrP5QwiAAHGRUd3nJjupbqOUDgFcYYHuO2Kr2sP2qaWGO9SFshwZiVDsPfsaylVexUYR+Jj7u1hs4J3cNIyomxtpTDnBIKnnoT+VVRBcXKZjhYhUMh2rkhfX6Utnp0mo699lExuZCxLOrZ3Y64J61Hd30kd262e4qG8qNQuQ+D/F61DaaL8k7vc6w2Gn+EpLGfxHbxXdxKwY2UVwDJEmPvMBxyMYGev0p/izx1Y67Hb2dppKWVnCw2ucNJjvjsP1rkmsWZ5pLkSTPnbIyjJ34zjPSnjTJYo0ULmWSTYIxz16H6cH8qanJJqKsjn9lTclObu/w+4XUzaNbL5dkY/lOJGkLFvfb0FVrB1hVpJITsaNkXB28469O1bUktpFp94/22KSXaI4lMeSvrtHqeQawrqcySDdjcoAwOFBxUSdtTWnLmTiMjRriUhQzE9cc10Nt4O1O7tLi5jjiSC3j8ySR5gMDGenUmrPhO98OWgjj1K61G3uJInFxNDCrqrbvlCHkjK9TjrXQ6Z9h8Q/EG0tfDqywaVGgJkctum2qSSd3Tnj6DpRCmpWu73Ma1ecW7KyXVo8w8pPtMkspZ5CfmMhySfqeamIc8Rr5m7hQq5r1TxDp8dtqOq6ta2djqKGQQ4kAbkqCSoHcep9K4yCW4smV44nt9QctslicKQGyGBXHocdsUp0+V2bHTxPOrpHM6fpmpapIkFhaTzTMxwIkLMccnir50S9sri8S9aOGW1aMNH5gLl35HQ44HJ54rqoYdWFnavHHcWdrbxvE3lOBJMSQXyVw3OQeavSWHhKzAmitr036wOBaXJEkTOwIG5geMfXPT0q1SugeKd9Pw1OKuriXc9pOLcypLlplG5jgYwGHBXvW/bu1zpHlQ2Idrcb5b1dxZUJPBHTr39qxp7G3VbdYneR40HmM0ezax/hAzyPeun0h9T0S+j1WWzlNoHRZ45IwiOrZ+XafYHBxxXNrzblVZLlVt/uIhrl0mnWtjdBZLeKYzeZj5pDjAyfQU/SPLgmuLm7XzotrIdnRdwwB9eevasmcpJc3Agi2RSSEwhjuMaknC5+hA/CtHR3t/ImLp5ciAKXf5kI/pW9Cbb94ylFKN0txtjMYbqeG1uHFzgLGR0Y55GfYdPWtS58Q31xaLZ3QY7/AJBtAUyY6bj+P5Vi61bzWd4sxaLYfmjdVIVuAeB6c1mXF3dosU/MakFEYpwfXBxz/wDXrSdS2jNPZRqWkdP4o1MXMtrawKqwLGiqkI2L5hxnPPPPepNBvI7p5LK/uYo1CMiW20thwSAuMc568etcRc3ocoqlFYrhhjgfnVjTr37K4ngLLOh+WUc4zxnHtWXtLyuN4a1PlOitkaMzRzryACyMvU4wDg/XNLotzMsgsLtVKxufs8bIoBkchTvbrgDn8K6nU7KHVZ7a6hjeWKc+WrgBS8iqMkZ5DHrg9a5+GNYJhe2xZbgjA2qG2tng7T3rSULa9DlVRTTuv+HK2pxQ6QUik2OR5kZTOWZhgbjjsewovtPa11CaOGKQxTRBod2ONwH5dfwp3iWSa7nF3cQxfaI5AXkVAQxwAFKjjHGarR3f2ue2hEXkqQ7CNchQSCMLk5A6d+tKKSdkWr8ql95m6lYGzj8xpo2bO3CNnBB6VFb3paERszfux8pJz1/wHauZ1We7sNdhsmYgnkjjIzzg+9a1sduAx5rOV4v1N4x5o6u5dmRZZGQLvRmwCRgt6cdqtGY20siWqLHGPk8vGR6dDUEAZkeQOFKY2g9WY9AKiMvJ8zO8dfXNZthy3LflokgDEAr94q24c+npW3Y5fB/5ZgY4PGBXNqysB1wD0rotDt50WKWIErvALKMkHPcDqK2ovUyrKy1NuS21IJb3TRIFkQtHtO4kA45/pVW4niWzeaW/HmEAGKMc8+nTjjrWhcXU625kup3ZslYwvoef857VzN0olU7mXbnr7+ldcrLY5Ka5tx13OlwPMQZA7HLN7+5rLdWaN5XnCBSODnLfhVya1mWFZFjKRbgm4NnLHt+lT6jbWgj2ed5rqm4lB8qtnpnvxWE7nVGSjojJsbu2bULVLk/ZIpGQSzAFnUZ5Kj1NMnvkt72eO1jeTEjKpmOSy54LY6HGMj1rPmswecbzzkqeePbFMt7UzXcaNvEbNgiMZwPbP9ax5m9DocYbmrITPC06L8jyKjPj5UOCSDnvgE8VTlMiozwcwmQx+YTwT7fr+dMvmVbgxpAEVwDkvzn39DTL55CmwkRAqq7UA5AGMnHU+/U009RRWxpGydLSK4fY0bHaJFbIz6cd6sRxXEbOxKyPtDyAuCccf4iqz/YWSzgguF+VCJe+GGT+Oex96WwUKBdJtU9VZ+Bkew7VrbWyM3drUl1GKGGCUbCJycrg5UDuCDWXDFPLNLu8r5FD9f4fQVbaUOhBPmSumC2eATyB/wDW9aq20d1ZyJcXNq8WWHlkjaGxVNGkU0vMnW0ZIkBL+YzDy4yD0Pem+S8UijaASQSB2/wq3c3j3Nq7QhpEibcWXjGcdfyqOKUfY/tEM4DLtXCjlux59qdkmJOXUnnEUduysV4bkKTnOOuT0FZsqkFggOMYB9K0L+NNpA+dsnHv15qkjs8CxsM4JPH3jnHP6V0zdhU1oENs1yk0zIcoA25OifWoRG6S5kU/LzhvSr2ks4lnDDKeUxaP+9jFRFWE7iOQsj85I6+nWsGro1V7tGnpIVNUjEKEFmA9VHfPsBWtq5EOtFmhSfylKxNE20Nx3x1Ht1rI0Ass06wM5LxH5Rj5SBnJzToSzqI5A5fkgA4IB54/Gqj7qMJQ967KyIwyY90b9iD0GarbntxhPmEjKz9s46Zx7mtq1l8uUExcxuHAbkN9fxrMnjYSPJGByxDLjpTkro1i7uzHXkU72y3cqu0ZU7pG5H3sH64JrNvIbea6+y2CzzyMy7GxgnjkY+v8quxee1jPbEkxuhdFB4BHP4dKxSske2ZDh88ev4Vx1tC4R13Lk2kX9s0/l208BjUrJmQBsdTx9KbpVhcwXWnXk0LR2E03kRzSdHcYyAOvfmmQardOGhjmch25Gc89M10mptPf6FaIsZS3sJ97T7SVbzGXn0A+X8aUbPVE1HOPuytqXvEuiXPh77LpOfOuLkfIEx5ZLHG4e46c81XvNMOmWX9lPqEM1xckTTfusPAADwW5Ptjv+VanivxGb/xVaX2nwGMRwCGITKPukctzwDk471y+s+Ibq61+4ntpXtZrpRFcOmFYt0bnsK1m4Juxx0o1ZRSfq/Uu6HZWOprJaaVEiSpA0klxet8keOrqB3OQAD0rg9Qm8l5WhWSSMSYBxgkZ64rfvbU2en7FMqmVhtjY4LoeM47gkD8qqRaZcXIjO0qXbaMjr0Ax69ayk9lY6YdWnuUFR44gXVgD0Y8Zrp/C+k6lrkc0Wn+a3kgbnDFVjGD1PvyMdTTdR8P6nZQyIzjyo48vvAGxS2BnPOD/AD4rofDktlaeHYY7GOWWcSmeZt+0SbfUdMDg+vFEIe/7xNateHuaszbKyvLXUnWS6jjNrguyncgYcbQO57VfgtSmrrGsCOXb77kKC3VtpHGK6PxZNoMcNvc29rczwq4WVzCQspwG4Ydeo+lR6bqOive3LMYrKOOIm1jbJZpcdAefbjvW7pJO1zidWUo83KyGeCNJ445nkhST5ZFiOEcehfoTn9DXPa1JHp9/dW92iR2jOjJhgJGXJ4U/UHJIrautYtbrT4bIIbS/u0XzY5cxRRtj5nUkkAHGM+tcDdynUvE1tFql2qwtOsL3BGQibsbvcAZPvU1HoaYaDcnzdDZtr28uRe3tra+ZY2kSpNtAC+Xuyu/GCzZ79ePauu0+bxJrOhSz3V9ssZ7fj7UyKJkUluB1JznkfSuGTUzpt3r9tbXjzm6d4PMjwsTpu5YL2yBxjsavW2pS6j9is5RJcMsQtbdW52L0AUAf/XrKLSdm2bVqTaukjobPQEk0O9vrgkNA8ONpG1Vc8lh1JGRx2zVvxBb6doWnXS2P2gCSOJ43lKsHckkjjoMDoazILIPrEFlPNIC0LSTSwXKk7gpKkseMAgZB5qpYaQmotPcXzyJZKjgToQS8oXKg+2eSRWqslaK1MLXd5y03/r7iK+1o6pFYaddNZRRTKiCSRwBESQuSRzjpxzjFQaxf3d7bwaFFZ7vszSIbeHLsrgjcQR1zjOfc02XSTBZ6ZcJEJ4nMsciswG7B5XJzgkdKtLps+k3tpdaLqckYuAGjkVdpD/8API88tkgc8Gpd2jojyRs1529ThyvmfKRgkEY6Vd0eY2c6y7UbYcAMuQfqDU97HJJqMxuEJmeQsWwFJYnnI7c0kigIS8YLA8Z7VgtGeg5qSsdt4b8QzzRw6ZHaWVvY5aa4dYyXkbB5OTgfQAYxxTbA2/kzr9nmW3nBeCcrwSvoT26/pXL6cPM1G2gSR1WSQIxj5xn19a34i8El1BeXz4hmbbbqpEeTxwOx4reM2edVpxjJ8vUW+vWnaCxtCLaTdmN+mWIwQT7j9adFpd/5LQamgt7q1fJ80jeegCr68nOPesTVt0s/nuiQq/ASP7qn0otrqW5uoobhp5vMAU85Jx06/wA6mM1e7H7NqK5Sp4k0toJ7G6nEbNdRG4SRBjjJXB4HIK1Ba2pf55pFtof775P5AcmtbxJbwQMkKKZH5+dnLKOmAPTvkVhMzkkO25j1JNZzTUrG9G8oInt7ySIFQQoxkEjdg+o9/ei2j+0yDe5GPyY+lP0+zNzdooX5SM4PtW3p1qGdhDCylVMhlAOEA5z9BilGLbFOahsOsrOKGN5BiZSCvmAkYPHI+nvXWWkUkglurO0e1tkURJMDgFsdT7/pWfbQWsumfuiwnDAxbomDEHqT7cZ57H1zUW6Kz1I2urSXLWy4LqCULE44GenXrXZC0UefNudxGaa/jlEDtNcttAA+UkDrnt3rKvZ5ZEnmkRUjZzg7ONwGQgxwPWu0+06VZWU08cZtyQ0MULMZPMYHIG7+565x+tcl4xktIltRHA8croJSqptVCTg8dTwP1om2lcdGV5WsWtGuo57S9SbZDCI9yhSCxYjIGfXOK5yORmkEeW2twRnuK1LQWR0liJGeeSL/AFajlTnrnseR9MVWh0/Za+ZOyKzqZIULDJUdWPfnsO/WsqjukaxtFtlSeSA/LJHMQSD8nX37VXdHs0glSWPyZ0YhA4LDGQQ2OQa0rHTLuT7fmaKL7PB5rmRs8EgBR7knpUd7pOyL/R2RZXQMx3HkHkgjvWKva5fPG/LcoW7284MkpWADPyxrz6hjn8uKjkRLgSlMfKw5bAJz3x1NRwAwJIcBwfkIUdPpnrUtnFseOSXeInUlivLbR6e9NNmuzuiGFTHOI+GDNg8fN/nitTQkVob4q0ieUNwTg71z0474rPS3kuVd5VeC2lPBxkn0H0rRswIv9Dmk/dAkBSMYJXAJ/GuimrNMdR3RlalJapfh7RC9vMdwRm5XtjPtVyVrmYReZN50TDGDghT3HPQ1jzBbWaRJtpQZ+7zyRVnTLuOCERl9scqFZVPrnIIqua7sbyhomtSa1v1tbWWFMODIHZsc8AjGOneorGRt7hBH5MmASwxgk8fQ1mtLIuYZNiE9mXOc9Dn0rRaK5trZbEXSrC7LI6A4DEdM/T0NQmEqaXzOhkVD5gwFGCd2Odw6CqFmqR3Je4JdVB3Y9ParaPvjwq9WwSaQwlWKkcNweeD/AJxXXLU5Y6aMdZGM3Ms204HKhR0H+fWpJovNSRwpdmGQWYAjuTjvTrOIgE5VcAks3TA7VMIhKeEBbbwPQ0ktBOWt0UoLOcFGjVo3kyo5xmnCOUSlhy/oBg56fnWkIxLbERso2DPLDIA/rk1PBBCYlaHeLtCNwBBBXBJNTyg6vcj0+3Y2XzIVfdypXsfU1BJaEu0CKdzEfKQPyzWtboJJzNFuMeSrovQccEfjziq10GSM8OGbkcdR6+1aKOhnzu47w1bWshka5i3lGCK3OMk8Uvibw5DblBaI7zsvzLtwCfXPQE+lVIJBBcRXO5BGSDtfkk55IHtiutN5bRWt5NM4nvbaPP2YclznAAH4kmpcYyVmY1JThPmXU8oa0+x3MctzbeXnDFPu7l6Hn161Hd39zKos7eWRba4YfJn5Tg4UY9sn8667xHZTy6XDdTvDgIZAIl4Uv/B9a5htKvLK0hv5RHCFbEQkzlWB3ZAH+ea4pwcXZHoU6sZq73PQfGQgt9K0Z9bLWa28KQpFENxb7pc5/wBkgfXmvKtRnF1qE76eJCs7thOrbevP4Vuaj4vvNSnuJtXijvJHhKxZ4EGTn5R0+uefcVyts+Jw2AOdxOeB+FFSSk7onD0JUo+9v+BueEoptQ1m3DASxq4J80FkVR6j0rqPGKWOg31oreVdW0h81BDIQmDxx/Qe1c14bl1G4ufs1jNLHN96OKEYLd/6Vr67aa9ewSR6hayLumE5RLcADBIyOw5P6mqik42Mav8AFTb07FvV9d0+7srvTVt7sT3FwGkud2SEXJVAvcHPPPFYF/pc9vcLFDbXRinjEsO6P5pI/wC8AO2a1Ujnk1GKOBlkaOOIxvsUh89iD1I6c+lbXiix1jwzolqcKi3IEQukb5ipGQuewx2FTKDleT6CjNUmoR6+Zw6313bxCAzyeUMgRljgZGDxSNeXFrdWxtjulV12FwNu7PB5rvNK8FNdeErjUTdRJcsCqRSKOR7sehPavO4Z0g1i1XVDKtok6C4CgFlUHnAPGcZ4NLllFK/U0jUhUcuXpua2p+JNTvLI6bqcsMsMDELKYVaVR02hx1H9KpeNNVt9Q+yi3Hl+XbJC6x/dYjJyB269PWr/AIj1DRXv4n8LtcyQbi7C8iTIYA8AAcrj19a5yxghglt5pl8xJAZAG78kH+VVNtaN3KpwVlJRt5Gjql3b6rNaahAuy6e3VbyMRBESVflBTAAwyhTj1zV7wvqlzpOppPayCOUAqku3cY88EgHvjj8agu0WGaQ2D+XHPCvmIpyDk52fUEDpRoVm+p6hFaxyJCGPzO5wEA6msm3z3W5b5XTaex2PjCO1+1w6pbM0k13EZpyo2xHdgbVA6HqTWTY6vcqjWaHzBOd22eXEYcEbWxjGB6Gu81bV9O/sAQLbLJGo+yW0MB3eaR/GCfr/ADriZ79ra4C2dikyxKI5pZYfNeN+oB/hAzxmt5Kzvc4cPJyhZx27nSSzLpnhC30lIZLi3Ci4uZtoQoxJbYQeuDt6duKwrfXGjtmsdOs1mVxl5CmXDEgkof4egHtijXLom68rX9PezlMSG3t4E+aVtuA5bPfgnAosHGk6PqNlc3DWt8oWeJoxuSdWwSmRxnpz2wRSnJ30dkVGC5btXbd/+CU9K05NUeZ5PtLzLhmMeDnJOck96jOlXDN5twFgUnPzJ87c9QneqVpcTRNLPEsg8shnwcYGe9bGj3t9e6jcXsEdxO9vG0xdZwrRRYxjJ7DPasoWaSe5vJTjdp6Et7cXOlyPc2UEL2jKsZP3XUgdVPY9arGysXtY47HUJX1B5DI6yH92ykZHPUMO+aydYN59tlivHcSI+SrOGwTz1H+9TInuYCUjXLt0yuTSlUu7IaptRTT1/M1LdEuP3d7G6sX2segBHck8Zra0/S4H0yVLO9RbmYmFYWzn5mHf8BxXM3N9cXmkJBsCmGYFyv8AFkYH6/zrS8Pz3xK2lhaxyXBXCDdtYmqjJX0RFSEuW6djSttKuZw1lqcUcZtcxopwjqe/QfN+NPufDNnHawtaxvJMmTKXA2npyuevXpitGZJDb2Ml7LLE0se/72EyT83XrjjjjitOK+CQCC6nCSSkpCh6sMYPP+etdLpwkrs5JVZp3izmLS1jsJgI7VixyWY5yB6Ypt5eyvfTmK3jngKGIRgDgY4I9x1rStr+wvdQeG1gEUiqSpPGGHb36VjXL2tteKkytaMC7SSqQSwbkgjqfSk0kvdLV2/eWp0ltqMVxYGW5nzcWtvt8sLsYKThcE9ByCfbOKo6tczkxwz6fGtwH8oyPNvDL24OMDHTPXmqLvHPdObJY0jl5t2jHy7c/dAPOfr0qolvLFDO1yhjUqBu3ffOcBsnv/KgmNNJ3HymSCCbzbu3WYR4RJF3KQDyEJyAeO3WqMkN/quo2iyyNczyoqRA4JI9Pbqa2pobXULJTLMcoo2tuBGT/Dnr26euaq6rJbWtlaQS25MjbgJFb5kHt7896ionbyNYz1slqWNCtdOknS2vr1Uk5Coegz2zVnVtKuItstlHbGGM7WjWTc6uSBx2ORjiudsLWXZI5JjiUHLHiui0q9WWa1tzawW7XDYWQqDtx/ESeccHg+tKlaS5WZzTjLmTuU9XVo5DAY/JhRFdXCbnZyDgYPAHXjtiqsNwr6ddSzKGvYiro3AyCcHjoT9K1pY5Hkmh1Eq8m8hbkfdBx/Efp/OoporJZIBFOscxU/6qItvf+EleoH4VUqVndAmrJWOevLmJbJEhgkilBPmbWyr8gg+2Ky4Bncn7zDjy15+6CeTjv1Nb/wDZ7SxRiJg8hDGVSMLHg88/TmnQWcErjY0SXqSGCSNuEXHfPTt3rGMJM6YzjFaGMlqm5yu5YVfAOc5A6U2YwiQyK+ATtI67hXW2VtZxWd+ZkFxcw/u440YhSeQBxweeRXMXSfaYjJHFsiRSzeSM7T6nP863UOVXLhPmepzt6ZfPMQAHzZH+1nofaoJY/LYfMSu7HTBqS4bEwYbuBgeo+tLCDM6jeDJuBIK54+prJnor3UmXxYyXUEUzQSrKeFfHysB6U62t2S5dhJHI2cMhGSR7e/FNSa8uPIleaVltx5cOT8sa8naB2HJq1ZFUm862lMcj8Nu6c9quLTMG31Nq1UPFIpTbI7Z3dABzyf8APrUixeU+GAbb07g1BB5TS+XcSFYwSN+OQM1CJy7tGSzLkbPnzj/63Wutuxx8rbNm3tg0zZKqNnyjPBHXmpJUYTuV/eCMEF07HsR61nqmLncI5NpTO0HOSPU1LNdybslygRdox3HTBpcxHK76EyQtuKlAXHVlOcijy3WSPOFDjgk8GorK+O4pI2FI2k4z1qzpjNLe7WUNtHAxnv6d+tK6G01e5cTMAlfO1kZQwU4xnjIqrdSTrcCOTfHKowwY4Ppj6c1r3yTNeSrPEq/6MzycYHABByPcCsy/imlfzQci5iEdu0hBO1Rk/wD66tsyg09WQ6faG7xF5cZ2kusgPznaeVHY5rSsILo6u908blnJBk2jJzx8x7elZiyzx2O2MkSxrn5GGcliTnHSn63e3EOnw7rqRSI1KRHKvyeTkeh6Z681HMlqOUZSfL3OgtyLhZYr+NZbcDZ5MCglc4xyepGM5rB8X6jYS6T5MriTUEdSGcGNo1APtyT0wOKg0K/mvb+CMTTyQxW3mTbcK0aI2SVB++f8aj1+x/4SqO91PTA3l2sYOJBglBwM9t2B2rFtyWhMKSp1E56I4+7W2mtop2UxbgQyIfmLc9vQ/pWQiMzqqqAOgBx+tWrqVZ3VwpVggU8Y5FWNDe0i1a0k1Da1skqvIGzhlByQce1cjld2PU1ihmnyzafeQzRyyQTR/Om0kMP/AKxFepXPiu/t9H05khWacwlnLZZTnjkcc4/XFcvqtzZ+KNeEOlWYgt0yI3bhynX5v6egrXvYtceztg1s0KJB5QdFCGWMEZI9eoya3g3Fvleh5tflqOLmtfM5ieRrK5tNTKOsqyh0jPClV6/4Ve1nURrUNxLqOozW8CqZbO0Zmmw3QIvZV5PNLeWBnj1dby8jN3Yxgxwl9xZS3zbSOpGcn6muduGUotlEY5FaVWEoTDDjGM+nXj2qJXV10Z0wjGdn1R6d4M1aaCwWC9iZIUCyI7t8zuBwAD2yRyfSuR0ZdMn8Q63qfiwu1sobcI1YhpXJC5K9OQSPpV3V9VsnnihsLieS3WNRISuWaTgHHoO1VtN8My3Oo6layzARQTxyy7XypGM7RjgsATz9a2V3ZLWxzqMYqUnpcw/ENp/Z+g2qWy295ZTSmVNQVCsoJHMTDJAxjNa/gvSB4oTSrbVNQCWdi724hiKpKqNl8gkYOXOOfWq3jHTLnTNcuor9H+yXEglSZFG0A+w4z61jwXl9plxctpd0yRKR+9iYxlwOhx+PSs5O0rNaHSk507xevRlnWIBbeIPsVxcSi3imEbOVG5RnBPHBPuKZodncfaDaqjHzLkLJc8lIk3YGSOgPc1mGQzoXdiXJ5B9a9Y8EazNomhroF0kcd3cZMKF92WzlQwxgB+g6mppWlJp6IWIvCmnHV/1qL4shhTxJpN/p/mGKWPyoY4kD7Ah28rng5NV9AtvtWsanZQ3a6fZNB515J5f+qSJsui/3jubBJzwDWE+uXmk+IGTbbQyxSsphBOyIkjPzk5znIz2ph1DUpbb+wTPp8qywSSieadVWEFt7nzCerYH+Fb80bnMqU1FRv03/AK7DtV8TQ6v4pXWNVgvJrC0hMX7kFRI4U4BPRdxJzjHHSq168+p3thNPJDHZXCmSNlGIbcKcFQOuBgD37c1kyeKoh4TvvD9jBKrNcreFgSwChcbScc888jAqjZxzlPNRZxE5HIGAcDjisqm2utzqhBLRK1tF6GmtxK98pjmijcFtsmDh8Zxkc9elWrCKM2eXhl8xJ08xsZjVDkYYDnOf5VmySeYQ03mO0ahMtwRxx+GKljuJYoXVGIilG18HhucjP41zSdi7X0Rp6hb2dtLcw20zzFHUI3l4DIRyfbnFL4qVtO1GK1i8pZrX920sWdzNgHcT9cjj0qESyRrJcJHEriTDlGHTGcAenuKg1jU31NvOkiQShSCVGA3JOSPx/SmpJEqLcl1RdYrBIs0Z2QXaKz7ecYxux+INdHY6pFazzf2bIkyQEzop+RpUPBUkcqdpb8D9K4KGeU2QjkfKxy+Z9ARyBW54du1l1iZLeACGUZLMMspHQ/iTW0Ja6EVKXuu/Q6K81ya50qdNOs5JNHtpPOL3KhpYSwHygg4Kg8Dim3GtqsAs3to9kjCQOUO5RgHKHPGfSiCY6fZakjJBHFqo+z+S0pbyV5OVOex6fSs/RY/tV4IHnEjfLFDFGwZAQwyST7ZPseta3bdrnOoRs3bRf1+ZLJbyQs0lpKyO7Eh0fIf0+hB9aivythFFJd2/nGPeF3HO5ic8+oFbzFDYXFszxm7Fz5AbHzOM8nI/D61H4g1O2e2mtfsMSXi4jaVT8oA68evaqnD3dyFUbklY4y4eSRvPlC5PRUXaq/QCm/2hcyholknMmcAFiTjGD/KrjnCBwAwbgjHb2pJrE2LxTtNEUYtsDZD447fp9Qa86UpJto61KOzQ61ie3iAeN/MOQjschc/7Pc/X1q9Z2ZWRLa5KxmEGR/MbJ56Ac9+Knt7y3mslRIVM4clp/MzuXHC7e31rS0fwvJqEMN7cR2yWnngqskjJJIinLlT2XBxn1Aq6U5T0sc9SpZe9oY2p3oEcqxEys7YKqDhe4HoDxzW9rpgYaZNptsI0uLd3ltQ7AQ8ABs8EngknvViQ2WmSz6dDcm70+K483yJZflRt5GVI+8e3P1rN1MAtO0xEcwByrjDfewBg+x4xXVBctzFNNqyK2n6a14rlJSrITlZXJDg8Hr3B/nTEkaGCf7LLay/aG8k31wpYp1yFx3xzms4QtLdSQzQsWIYhSrO2B259Kmu5Ik0LyiUilmmJwgYsFHZ16ccEcVd1Y6eW73OrsL9be2MSXttcQ3Rds+WEwBnIx2GB0NUtI162ecwXqpaO7/u7mOLbHIOvzE8gnsfQ1zdzJayfNKknlRwKilGAUOe+ccg8+9Nso5NcF35t9F9ttLcGJbl8AoqkbM9DgYwMZpKtJuyJWHjZykdhqN7p9zpE/wDYhtVn3CZoREV+ZcFSPXoOlcBeXGoahq63KXEgkSMli0YQKx+8MDORkkc9RRbavNp8iy2wlSQIFSQvkA45wMc9e9U47ib+0J4oJDD9piCyLnAck7iD+NEqnPY6qNB07/r+I6KzthbvNIFVB82ADuc9AAOwNZJspPOZACG6gHg/Suj05YIdSf7YJBIMAQRHbg46k8/p3qrqtwLlUhaMJ5R5Kk7nPqTUuKaOiE5KVjLSWXykiIwiZwq8Envn3rWSArYRyMMeYwHT7oP/AOqs8urpF5ucjGXI7ZretlRbzdPNETGUmVZZNryRjGFUdAcdAfSnCIqjsL5fmtkjjcQrVcEQn1gtEjxQAhiFGMKOtQLDJCZEk/dnG47iCP8A61LDLtjLSyYQvjK/N+QrqaOTV7C3Ez287pHIWUk7SDnap46djgVRMpEu0hhGeWQdj7VNfSLLcM9ruXavUjBOPWnKARDNJEQjgjHqcdfzrCTd7GsbJXZa0NVluwr/ACxZyzhS2PbH5Vux2sTXBmsmVY41GZGbYVKrzjPfg1naG729rLJbKjTRlX2Hksu7nj2qxrLzpqv+lhDbOnmEOAQAT/D79v51cbKN2clVylN2NS+kfVnZIo5YvMQsXPIXIGcn/Oc1RLmKazsJoF8zekXmg7iOein3yKu6n4h8sWttYKCvkhm44fBBC/QYNYUmo2lzfQTQu/m7kYscgD2/Djmqc13FSjJx20N02Ell4rkhZvLZUYszcluCBj8xWD4zgM9xa3KvmGSNQyjqhA/kfWt6zuZpo55ZGea+kG1HBzux0IPrVbUYoobN7ucNM9rtkO48gsACCOhw3anNKUXYUJOM0+uxxlvvW0QJCFhB3vKVw2eQMN+J49q3bdzpOjsjxTSJcKDtIOAD1wOm7HQ9qz7nXmjjnkght9jOpQGIE7hzk1mXWpXmoTJ59xI3JIzIfkJ67fQHNcsJJbnXKEp7qyM7X7YwzpL5gdbjdMjZ/gJ446iqOnQPeXMdvCjySyMFVR3JrW8T2l5ClvPcWkMETwJ5RhACuoGN3XknHNZWiTfZtVtWDuoDA7kzn6cVEo6m6d43R1Eel3WmXU0DTw29/AcJFnJkJ4+Ujgityw8UXNvqul2+vRSQSWUcsIfk+Zu4BYZ7eozXLTRXep6vHay3ccCAP5ckuQq9SFz6Hgc9M11baZNr/wANoNQS6t55tPYq0SJ+8jUn+I/rRFOLagcVWK0c+unpfQteD7iXSL29jPhu6v8AUbaQCKWOFjsRjhlYEdCp71g+JdF1G31uW5ljt45ZwZ2jjZfk3EkkD26fhXcfCTxRc3sN9p+o3itdwQhoGlf53RSSVz/F+J6V10GnW93fXGLK2ksbxFcyupZUwfuAfwg7hjn1rpjTVSCszlnXlh60uaP/AAf67Hz7NLPChii/ds4G7afvrnIH51bs9Rnt7WUwkxmTAljA4cg963vE2jLLr2o2thA7X8czeXBApYPEOpHoRjp71h3Ph/W4rC2v2sJPskw3xyIQ3GCckDkdO9czjOL0PSjOnOKvbUm13xRrE9ta2+pxRhIhtXMeDID/AHs1lXVybuckJHBGOoVOBVa8WOREfeWkx8xZs8+1dL4VurJtLuH1a5mnuLdlezs44dxlk6DJx0AHT3/CleU3Zs0cI0o3jH7jG0eG2+2QvcKfJHDgAk5wcNxjvjvn610muaJANEj1yO9aSdpStxJF88W/AwQwHDE5OD68VratrUMlkuqaJ9kfUJIjBPZNa7nU9S0a46AAjcK56PWL3xNqaw3MjvY3NwjSQRRrHGzgADOMAEjjNackYrl3OfmnN8/wpb/1Y53VprWOOJbfzWcp++aQgkt7UyzWaayt4Le6Mlsha+liEeTC65UHJHIxg8HFN8XAL4n1FUtkto4p3VYUbcqAHoD3plpezmG8UNKjTx+WFiUhTH12n/Z7/hUr3XqdLV4Kx0R8QWOmatbL4NhjtFSERTTzgFrpjgsWJ4AyPatLXLHxJLcKLyzkEkirInlPuQgnaCCCRyR6/pXJ2sFrMnm3LJjzAhReGVTj5hxg12tna4RmvNeltmhia3gDymORYwoaPIBxtOTgfrRzOpuctSMaVmt/O7ZhW8sC3kiatazwqJA0sbn58jgrnrg9Kk16ytk0u0m0+XzZCSGhCkMByfxAwear6zql3q8tw0t1uR2TL4AMjLnBA647/jzTNU16/vL2O9a5lF45KmTOCeCpPHA4JH41Ls73LhTldNaEAdTpzSKsTHd5hBOCAB2P9PepPEGlTaNPbxTOCZ4Vmx3VWAIz+BrNE8tlcI6RqFIKhm5HTn+tR39y9wyu7O8mxU3MxY4UYHXtjA/CocYpa7nQou909ByCedJJLWN3SBTI7DoqggbifxA/GtLQNUaC+UsioApkyMjO0ZxjuDjH40mgCwubHVbC7ZYp7tY/ImIJELK25gFAJJYDAAx70t/aautwl9c6e0CxwrtHlCNNgwM49T3+tNK1miJyUm4SLM+pT3Vy89yJTGxBVD91E9h/nvWhGGnaystPMM9+7FgEISSPaWwQx4wysOAf4eaWTSNZ1yO6uLSykddNtY1nUvgg9cKp5zjqB6eprKsdLk1nSL2VLq0jksIGdLedtjSKMlihxye2PWtEne/cxXJbe1v6X9aHS2NxZ2tgsctzD5lvc4Zo8mYdic+3PTjP50vjDX7TU9aa8W28rcMDHSUL0YjsTxkdvfrXFaTMYbcrM4bJ+6OgGP509ZzNOq4yxXChu3c4qZ1XblRLw6U+Zlq5uU2fIpLZJKluM9aouZxtkkVl3fMpxxjOO/WoS5a52cDnpnr7Vv6tqsdy1mpUoLeBYgAeAB/+usI6q7KtZ2SKtlJC8JjBjSRud2Tkf7J7YJrvotdtr220a0uryGZrZI87LdoZQARuhDg4bhQQccn3rzplcovl5EQ+b5V9v1q9az2U+kXTyebbzxBTCBhhIc4bceoPcYyOKpNx2MqlNVLXO9kudF/szUYxNFc3Kag8zK+SVhLAA7uNx5HuMnird34isLG2hNy637xW2I40QMxEm7crls/MjKDnuDXBP9s8RMk88SJHaQhZZkX95LyTvY9zzjPoBUF1Gtzat9lguQ0AJYqfN+TszY9+OK3jUdtEZLDRbtJnVX+t2b2DJNoqWonKyvOs5d84zlD1AOeRk9aqya5p01lojJYJDLbyuJpZVLpL8g5PPJHpn0rIjeNtIe585DNceXEVaEfuzwMgD0AHb860rzS7JfEmjWukzTT25AiaS5lUDze+B1VQT3684rS8nsWqcI6O/Xv2MyaWzOp28Vot41jvMkoZRtlYZPC9lGehJqpqU0MOnQqIWN3JK537fldSeMd+PT2rZ1LRZNLuLs3hCPbXK20cTuBlG4LKueRjac993fBqjqMMZ1UGzvI9Rt1iSRpZflBYKNy4OOPYVNmr3OmnKLaa2/r/ADM5FDQQLFBidm+dJlwoPsx7H09qs3NoY7H99zeykKwQYVI/c+p/lVuCNrmBhfzPBdQj92rg4wBlQB+NWNdms7fTo7WPE96drtPGw25IzjHsMD8KpRSRTm+ZJf1/wDn5JTHGDalYzwGI6kj3qbT9NvNV+0vEM/Z4jNM7MBhe5APJ+gqOK0ZoZDKC+xwHC8nnniqck9ypaAs7J94DHNZuVtWb2b0juRSTl5mEcbPAw2/OcE+59KWEEXYgnVXjZ1Gc5/Jqns3hL7FAaTBUxtwHB9/WrFtaO8YlKlVU5J/uY4waI3epTklobcVtHqNksjMiyJuGQPmJHOD7elUYItkbSNnAHIxjv61v6Uz2unFb2Zc5JijYkFVY9B+Pb3rP1O8luDHD5YSNQwwRgsfXHWu1rS7PPhKTk4rYo2wS4frsJU4/CtrS7C4ntZLeeNVMgUo7tjyx3OPXHH41RtZtPgjUGKZpQ2dwxxxxgn0PNaV5fQtsEodNsgV93VlI6/X6VmorcKspPRIvWmmf2WBNPsnikj2L5Q3hs84Pf8a5jXr1p7uNWYRABQzHsMd8V0smqI2iTW9itwRBsXLEMCvJ3Z7d8fWuG1xS+G3HeevuPU+9Ks0oWQYaLcm57l20Juba6toYnmu1TzI2VuV2ctj1G3J4qpbyRJbRSQmWSeSRlaJeBtABBB789qxrW5ljJI3B+mVYj659sVv3GrNBcW39nBY4wu9HVSGidlAZcknKjHGfWuWNtzqcXF2R1Wn3l1aFlglYK8YcpIg+U5//AF/lW3rk/wDa+ikLHGLu6QKJpJANx6BR7nHf864KTVp4buy81Ri3QpIy8liTnPvjNb+h6vNqeoPp8NnENNjU8bMj1y3ufSuyMk1Y4KlFq1S22pxer/atKeW1vUa2lOFKkY3Drkeo6c1lwXULwSGNxI+7aoB6e5rd+Il/c6jrzv58c0eVjjOwDgAclf8APSuZtIUle7JcRS7htGwgSHpx6fjXPJWbselTfNBSfUu30shslRJmZNgDIScY3EgY7dc8VnwS+TdQzx5UowI7kYNWmglFu5lOxghYD1Geo/KqB+9x26Vnr1Cy6HofjfShatYXCtLLps6B1mAGcsM7WqT4c6y+mate2SQLcWV/FsaN32/MM4OfxNZWk+LXisobW8CT28SFfKlG5emKJba2863utPDwBkMgDnv7e1W5LmU4nKoPkdKoV5Ptfh3xAJQ0kcsLfehk2kg8EA+4Jr3aXXbeDR9NhsppNRknCRjyHBAUDBO48Zzg/wAq8Q8W31pPdQ/Y2DgRjzGxjDdxWjo+pDTo1k0+Z/LAjUSxfeh5JYlTycH8DTo1HTk0tjPEYf28YyktUVtQ1LUr7x9cto2+3vZZGjTy5eSSMElvU/1q7LLr76XN4aitEtZo4yblWAR5tpBA55Y+gHWs3wtqtraare3d7JKDOkii4iUeZlv4v/1Voav4jvvE2sCfT7d7S4Zl8uYOd/QAfN68UJqzd9WbyptSUVFWS381sc94h0mfRLiG0vwiXnlrJJErBim4ZGcd8dq2tB063/s57u9Z4IIFd8xnLysAMJgHIU5wT71cHh270HxFZ3fifZdw3UirNIZCxhZujSE/jj6H0qv47vLN9fmt9LkL20BMfmA4D9zj0Hb8M96XIoXk/uB1XUtCOul7rY17vxn9q17R9al0wR6TpqtHbWMEmCrFerPjucdug+uebsrZ7nT73UbZjYus4ESRowV5nOdikcAgdB6CnWemyXUZg+1IsIPmOT91SVyBxySeldX4VtE0+3sJTJLOpZne22koGII3BMcsOMHqK0i5Td2ctV06UbRX9av/ADPPNUsmsrr7PNJHJcR7JCBh1JJBKntn1FX7Owu760luLSG7DxGSeBvJCRNCMmXcwx0+XgZ69KseKr2dftdnbBU0uWT7TEgVS7t90sWHIGcnk+tZNpqF9a6ZIq6lcRfZzthtAxaN1blx6A8DtzWdkpWWx0w55wUupuTaXFZaK9/YzRzWjruaPBzGxAJH5ms2C1+33LrqN8Um2AgsC7MQMgewxxWre6p9v8Prbywi0uA0ccrMT8wBPODyBg/pUEOiXl7bi9eKKCw8wwG63AAADLMFyCxC8jnnHc1U43aSMoSaTcnZjrbRrWaOWKO4Rpooy5CscZJHAI6/L71mv5DaLdByxmhG8DHHDDgd+ma77S7sW8byaTBaQW93GIYRGTJnHBkIbHJBJ9fWuC1NpLG/ntYdyiN9rllywx69u3603BRRVCq6jaKt9cQXemskayCO3UGHeQTuY5bOOOxqOxsJ723a6AURqHZnIwmVGSM9jjH5ipIbeSHSHJiXrl2J4+boKrJfzRaTc2KyyLan5/LDHbu45/QVnJJv3jqjs+TuVbW4MV5HsZwpdTx1yCCOK9I8c3OsSLY6ZJHJcQv/AKSggUhgGyNuRzyo6e54PFYHw606C3+IOkWmrECaRfNXYwOx2QsoOehwfwOKTxRdPbeMdXuNNH2RY7wolsHbEn+1jsCPTp9KpRajf5GFRqdZJLZX+/Q7FNZ0vwza6M9tdfbJ0fbfRW0oZb5Dlo5mb1VuMMMjkV5p4j1SG+1SWW3t0itxIzJGowFJOSB7e9dWmlzyWkdxp1ml3NOvmLb2sZ+TJydoHJArkruSO4s7l5LENczyLFHcyTEeTtxkbehGO57VkqyqabJEUYxjK61ZXik8xSyctIQqIOg9/epYk3S7cklM5x61Z0nTJNRnvNKsLS41W+V8xSWTjy9o+UscrkqcjGSoq7qOgX+j6rbaclvLJLeYS0kdNizPgAqM9wzbTnvUyptq6Rvzxvyt6lW/nEscCsIg0aBFKRhD6/NjqeepqtbqztjymcE53bsFQOvtV7WPD9/oE8A1VES7kDO8B5aJQ2AWwMYJBxgnIqOJ1ksLpTjzF2lAR0XP/wBeoUWnZiVmk47E63rWs6GDcEV1lUseVYdwR0q3f3MWqwS3kUEEV2kXlzBAAJQP4yP72O45J5qrHbzXUJa0tJpY0wrSIMheMYb0+tZTxNG5jlzGwO1s5G3HWtNY+hLpxeq0aL1ha6lMBc6bBdSxY27bcFiyjg5C8gc9T61dkvrn7S01kJLOXywGa3+XAPBBx7Vh/wBp3mkTl7GWSMujRv5bYyp9x24qVtauJlR/LjTYMYUYzx39TTeiViXzN6mlYQSS7vsrbCWUMpGNmMbW3Z4759AK1Li60+Gxvv7Xjnk1tjutrmObIZ8j5mHYY475rndJWGVZZHvWiA+YqOvXv7Zrbe6tnhvBrNtPdTMAYJ4n+SNcchlzlgTz1xW0Iu1yXUTlZm1bxap4kgiu9Ya1tYYpUga6ZMOS3AIGcP1zwOmcYrO1PTJdE1G8tDPFfLG3lnyWBKcBiwXkgYrSudStdQtLGF7m4aS0YIxWEfZ4FxwFLNuyPpWvrer6HbaTMk8Yv9VuohGLqL76rgDJOBnp3rVwTVyI1JRaSWj6JHNz6hZSW4urW8m+27fLMAt8L1xndnuMcEetZmvxo1wJoJN0Ui5DYA6e1VdNvRHuSFF3SI6FpRkDPQr6NSanMn2yNULCCBFUlDg8evGKybvE7IQ5Z6Fa4lnUfI7rE55K8AmprIt58IiIWQyY3u+FAPUfTk81Np0M19cmKGB5c/cUDGTVS4VLed4p2KzKcbSuQPWsrdTS6fu9TR8SWVnDqRbRsyQPjOeiv3VT/EPf3q3p129mYknhBRsiQMcg9qmvbG7trSze4VGtbxTPbunUqOMH+7j0rTtJrL+ztrxgSoSVLcq2eNuPXnrV7S7HJKp7iT1ItR1b7PO9vJE32tFz5pYHzOM53dP8MVm2SKt2kzyq5OCrAk5P92su3hjvYWEUEsexSwkZgF3c9z74/WnW4ERhkFwsjKxyV6Ajsa6XNsIU1FWW5dTbhjIcuTyO1RyTrckfLnYAOe9VphLkqVYIOhI7Uls6QtgtgBgc4rNyNeXS5fS5W0tbqMgl5dsZycAKDknHrxisjWbhWIMTHb0xWpqUP2q3SWJ1BI3Mv9a5i6Yu+1s4B5qKu1iqUU/eJ4Y9qByfmY8N6UsS7ZR5jbwTjPp7VR+0Bfk3bsc5q9pjKZC5w3PU9qwNJN2bNqctb6cPtUTeXu+Ts2fY11Phy6srnSAbedbeQEYDZ3emC1YEKQXF0onLbSpxtbvjjrWpo9/Z6NawFrY3FwGbJOAFU/hzW8X5nn1fejZLUz9cu7BZLpZgp1SEKqq4+UqOcjA7+/rWL4Zhsbl2bVrqSKEHEqRriRj179q6DU4NL15RJNFcWlyrBBNHGdu3t35/pWRcQadDdK0MM99KpEZDf6lsjrkcnmkpdzWGseVXRDrOnrb6vObSdmiCBFt5wNzqw6gjjgH9Kw5LFkupIyuAvJHXC+ua6LTYrYiSWa0mYuxjSOKUqGAPIJ6ge49Kku2szBvDuFKlN0mSQRghVPGcZPNJrm1LV4tRWpmaZbrZ3E7urspj2syxl1Ab1Patm28P32r6LNe6ZZz3KWzCJtqHJ4zwPYdfqKpLfy2rwvp9xP5nkeXIzE43EnOB6AcfWuu0jVr7RVeK4ttYgsp442ugI23SEZ+ZTn5QQcY7ipUIN+8Ko5xV47/1c87RfJeOQhW2tnaec4PIxW4NQk8yeGJoYbe6QJcSpArOi5ySPQ/TFRX1hDA1vfSSPPYTSlWKgLKnPIIPQ46VWnjhaSVNPM0vzfKCozt7ZA71CvE6fdnqV3tnuZ0iswzkkrGAuDt9cV6jb+ELXw5ptvcS3si6ksayFHA2ckDIH8QGfWuGsEl0uKK/tbkx3UcgZZVU4BH8I7H37Vpar411O+vpbmW2haSRdi7yXEXGMoCeOmcdMmtabhBXluc1dVKrUab91bkXinVo57C1t543E8TOtzM0mXnfjaSvZQOg96yn02WaazFnbzyNdcRhlxkDv/8AXrOeVXufOmUMd27HZjXSQeKLyOD7PLbiOBYf3GDkxZ5yh6gHjj2qXJT1Zo4ypxSghJNYt7KCyt4oit3ZyPM8kZA3c/Kc/wARB/KoZ77UdekzDczJuHzyu21ge4GOcHd0rmZ4riRobiXgXStLG7LhSd2CM9Cc1vwwy6fZ27x3MzTyMFdQNuHx/Djr6VcW9uhnUowir9TQvdHttG0P/SZpYJrrETxIC5UAn5jg8noQOnNcfM9uszxRzMIY2zhiCzc44A4zj3q1rf295fJjuGMOAzgcEMBjB9v8aw/JdJODk9MY5B9KupZbIVC6Wruy7ETPcRxbTyygYYknn3+tdUkF7p99ZWlzajdMJIo4nClHccAsoJyQGHpzg5rM8Naqnh3VbHVkt1N1YP8APA5IM+7cDk9sDGBj3rS1d7bUvGAgsZVm0x5VdZC27yc/O6JJgZGSeoycCoiklzX1HV5r8ttLbmzeatHocMFuLC6G5fluZeS7DqfrzXJahceatxeM7mSeXge3+f51veO7/wC2y3VxpNjcx29i6xLPIuBGVHMZIH3ske+K5K91D+0bjR4rOFoXto/3/wA2Vlk3E7gMcDGK1kZ4aHKr21e51WmaNJqkF2MJ+7haUY6jjI49a5qzcRzy286sImGZQcL905AyenIrpLPWvs9rcrahzdSLsMrKPoQPXiuavEK2shV5GtWOACc7G6jP5dRWc7K1jSi5XaexuL9n8Pa5p2u6tYrqthdxi5RoZCFSXOQgfGCy4GQfWsLWrqfWX1TX7lrOKSa4BMSS4dXY5yF6kY4Joj1QXFrb2OpG+u7a32i2tknwindl8LgjJBOPesC5KksEVkiMhKq3LBc8An1qrp7FKNnd7/odr4X1270u1MkFwFeMExMrbXXPUA9ce1VXtptS0xmgjdY3keZpGU4OOSQT78VjaD/aV/K1lpCzPcyxtEVjAJZPvHJ9BjOfavYV3ad4D0pb+/igs4WwIY8eZcAvl3yemOg9xUKhFu5nWkqck47s77whYxabpNtb2JSG7htY1eJUVeP4iTg5yckmvL/ipd2J8QC28PXF2JXk3yxIxKLP0BjUdGJPOOp5qo/xE1GDUbuWyaU2wHlospBbZ/tEYGT61j6xot5olloWrySyR3OoI1zgcGM5yNp+hBretVU4csVscmHwsqVXnqPV7efXX0LOteK/EF/pcdpqupfaIpFVXhVFDYQkASEDOcjOCfesGxcs7iBBI8q7PLAyTyOg9fpWvrNrpFp4UtY4I5n1iSTzZJfODKEJbAIHQkbeveug+BJhXxLfXly0axW9mSZHwArM6qDu7d654xcqiTe51ynClRlOMdum1zf8Gae1v4Ka8vA9vHFK7WpR0Vrotx5LAg9XVQARXn/iawfR9WNpcsbmRFG242kLIuOq+oB4z7V6nr3h+0uJNQn0S7totUtQ9zJFHltzFCyzIuepDBd2OoyOaxpdHPiPxR4Qs9QuS9tJo6sGgIJVlU9cZ4zjk9elbVKV0oLc4KNdKTqN6O7/AFPGdRDvIWYDnnjpVOR3W2dRuGBn8a7H4lzWZ8V3KaSI47KIbFjRVAR8kuAR1+Ynn8O1cfOTs3kk/Wue1nynpxfPFSta5WGVCGRzuzuU9wD64/Oulsba9up5LJpUEoCnzt3Gw/0rmZwhuFZMr0zk/wAq6rwy7/aIRIIoRxF5jDIZSepHtkflXVTtc5Zp8rLvhm6tZvFWoWOpQWg8yFljlOSPOQcFSOxxUet373Nw0VquIIsIEU5JPT6mqulFNG8Q6sdSto7+cQvHbsxwqMxwHH0rTtILGa1huNTmis5rrzJbeeKTzPnQ4xIo5QEgY+uRUTlf3Ua0WovmfyMOSecnyiHXZ82w5+Ujvj14rS0aSS9vI5JoppFUHeEGVf0yDwO/PrWfM9zHdm9nPnSKVkDyjcJOnHvXfafq0Av49VWGEm+Ike2gjCKpUY4Xp1yPfFZQV3qzpq1OWOiKd7q8NtPezWWYyI0iX94oeI+qoDwcZz1rltBAuNUje42y5fJEnIb0BrodfsoXlvIbS1jildEkiLn50TlioxwTk4PtiuPsriOAAuGMi9MAjae1FVu4qSTg+Xdnfaoboz2FrvLqSBCoYlYwT0XPQZq3qWkyadqr6fcywjZGHEnQPnnH1qePT7eWz0yRZLhL19jFGUkn5d28H0qxfahdXU6zXqvcGOP5X8vIwD/F+dDjfc87nd0keX2V64dLfOED787sdOcZ9M1uRRxR2yXFtIN7cMgHA46ev41yDnbI3ODuJH51oQXu2E7FAde/4VSn0Z6U6d9UdBPMoi2cMSOTnpWPcymNlZjgDpkc1Hpji5mcPIQ4BZQTgZ96gu0urq0muFV28pgjMOg9yaG+ZAkoaGlp1xI9tMJ5URGYDjklay9VkRpCbXJVRklR/WqkFsYrYtuZmOeKZazXBWWNeIWOCBxk9qTdxqLTuUHWSN3kTLFuMHpV/S7kxzIJhIytySq4A+hNdFYaJDbwwxTysLq5weDkIPT6k1HrmywuTAuLgwrsR2wV55Ix6g/l3qpLTUyU+Z2iX7Fp5biJba3k3uOAF/UVrz2EkhwZPLlTAeN1wfy/Gs3TmuI7hHkuY7+3aIZMT7cR46Y6hgf4cVsDULOG52XV5I7bF2F1y+McAn2rNabmM+ZP3UTxNdaWu+KP91EMs4UrkngD/wDVSajps5043th+9snPmNHGvMTHqD6j+VVdQktDHGIjKwI3sc42j2/nXdW1/p9po0aQBR58AZ0ZvnKkYCgepNVCPM7NnPObp2klqzzmwuYry7t7QgJHKoj3jqvzZLE/n+dZb+UyvGQ8ipK44ztTsP8AGlE7QatewQkp5W6FIyBwvbce5H61m3msyzGO3Z1MSv5pQKFG/oSR3/Ghr3bs9CEPe02Oon0m7uLCKXTI0uYUhDMsA+cY6kr1zWh4B1fUEa/so75YDcxgpNO+BHt7hj0xUHgnT7i02ag081pbbGImzhi2Oigc4zWpd2Hh/S44Zr26MSTI7IQu7zG9AuOKqMdpI5atSOtKWvyOctspc3oS432sm5SzgOH7Fu3HvVjVL25kaWyjs4LeFVRoYLC32mTaDlnb73AJPP5Vi3PiO3lluzbWhhilXZz06AeldLp1n/aiSpZXLl4YSQzHG92Azg/QYqeXojaT5XzSRBrt0H0qC3iKSW7bWUqMBGx836/yrJXyI7di5k8wqceh+n0q0LWVNO8pJ0U2TOzwO2GZupIHXoAKTTJoJbeVL+3kdTiVHEmNvPP144qXq7jilGNkXYNPthAYrS2S4nVvNSdTu3DaPlKnoO/NRaTH9uCaS8kFmrSEq0igmJsZ5PUAkAY96n09r7ThNPpjq0E6smA4LBfp64rPuI1cPdSoxkY8MQNv16fpQtCVd6X/AOHMLUDIqpC7v5ETFo0JP7s5+YenXmtfQTJNpt5dOqSRWQO5HkCthhhWA74rIuUDuyqrMwORj+IVQcvGytCWz3/PpUqdmdjhzQsa0l1bNp5jk86K8LHaxGVlQ+voRjrVICG9lZ5WDzIuTzgH3OPwq02opeWAiuFPnLJ8h2jAB+8PbntUV1py213+7uIZ2kjDps4Byfu/UVuppxszldNqV1oVtR1G4vpRLeRQvMAqKUQJ8qjHQcHjv14rotMFlaaHc3l6rSKqC3ZASAXYEqrdDvCqPu8cdetYsFo99YysoAFuN7nIHXICj8jxVK3tGv8AULSxgfY9xKisWOFBz/Tk1KlZ3NZJSjy7WOi0nwtrv/CL6nf3Rls9K8sXQVt0gkLHAOB04GST6CszwFa2974jFlcw3M8kqtGsdqVVyRz/ABYHOMdRXtOqaTHNoOq6YmoWz2j2RisJ5LgeYQFWQkg9FZlx9K8Z8D2unTaija3di3gdgrkEbwvJyC3y9cZz2PHNbTjytI4aVZ1ISf5L+tTWu7GQalPb2lrfCO2mZSJChAjONoMi5BPJ5HAqfTtFa11G70u/MMmVSTKozZU5JCn17dK6HU/EkcQ0iNruym0kEpCLSIs8Ua8AHOMnkEp1XgVFH4n1YeMje6LfR6jY2cYjhWWPLvFgbtwAyPmY8n9elQ4q+4lOrKOitp/XQ4HVrK0guzNpN9taJw6neA0ZHIII7/Ssm8tHttTs11bfsuAkzlGG5kY8kH1Irufifouh6NpCTNFNa6nPC9xDFa4eHLTcbycHG3djA9PTnDttG1izuIZ9TsIZbW3t4roosizHyG4DrtJOODn0/Kh03A3jWUo3uXfA2iXXm3l3bieN4o2524Ij7nB65Bq3428TpqemWeniztVjgcsLmIEM2Qcgr054P4V0uoXMV54elu9IuVt7dP3mHbDYA6Y688cHP6V5ZftaP5MkEsiKQA6SAMQ3qMdQf0/WobfLZdRU7VJc8lsdz4K8KNL4k0W2vmWNb+3knVnGQChzj05AB/Guw+IOtaJrmmafPBJJcW2nu9vIrOqybSoG9FJyeg5rzfwXrd9b6iYxdLMlva3UdstxKVA3ociPg4YnnHfpnmsu1icaW7+TNIXbymcMcLjnBGO/Pen7RRhypb/8AToSqVVUm9tvnf8AQm1IxSyyragmEtuGU2nGOh5NdF8Mdft9GXWLa6sVvWvYliigYDDvkghj1xgngf8A165SCVmLL0HXnitXQdWuNI1aLULVIpGQ8o4xkdDyOQSO49axhPllc6a1PnpuG51+hane2dyENjHBeRWxgt3idopIhvLAuDkvjgYbqtcZr+u3MmtXN1BMLaWRBE/2QmJMYAKKB0XjpRLfuLiW5TNuSWYhHJ6543Hn2yTWTpek32tXyW2nW5lkkyUVSOfz4qruWiMY01BucimziUk+nUVZOk3TaK+pssS2KSeVuaUBmf0C9T/9Y0t7b21nBbCJp2u2VvPjkTaI23EADnngc571dluJZvD95G2qLshlRo7Rk+ebcPmbPYLtHU//AFxJI1ldrQ5iaMlQT2rR0S4EF2pnV5IcbZAOoXuR6GmywYt/MVCFHUkg596qxzmB98X3ipGR6GtFIjksbsF4n2W4luke4JdYEbcBwMn8+lJ4auLe01uym1I7LaNjv/ciTcOeNvGfTrVCCdpbC4t5L9okDidYDGWE0v3eCOhwT7U8NkRwSvviTlGXsDyRzSe9xxjo0b+vXS6heKqvKbdQFQyhd4Hvt4pLa3e1WOZfLeInap39OvbqprEinCLn5sN93J6itnTAt6yqr/vmIAQ9/p7+g71mnd3ZbahGy2LVzcNHdu15LI9wjKgRsg4xgH+VZot1+07nMaqcklm4/A967/UfhhqDPDFYFpppQWVpNqKygc55yDnAx/hVDRPCa63q8Ok6ndRWf2OUpMpkUMecFVPc5pypzulYxji6SjeMvUybS41DTLi3dPPE8IG1X5HPIA9sfzrTtfEd5EJt1soe5RozjdgbiMbRnHGMCtPxJF4isLG8sRpMbaMtwyKACxhZQMOGzlRgjrxziuXuvEt3c3MduLe3t4XVIynbI43ZPQ0m5Q0uTFe2XNZP5mN/YySwvLHJunBJKBDkDNU7e0aWbZEjO/8AcXkmvTDqlnodncQxRtOWJVhIRlgeG57A1lanrtpLZWkWkWsdpNGCWmUYbnt+FbyppbsqGIqPaOnc5ezt4o7hd6+SQDv8w4O4dBntUN0JpY2QnCOQ+xT8oPTJp2qTB7lMcbh85JzubufxNKj87RjaDjnrWb7HTFNasqwWM4t5LkgFITyzDjPp6VNptxALpHntQqRYZvK4DADnI9TU5lKabNbh9xlYMwz0AzVdvMsIyJUQGdVZR2AIyD+VStweujNi71OCSzgH2XypPM3rIpwVAHYf4/hWrFLo+oFBe2buduWkXIZmwMnOcdawbOFJNPRmkY28TEKyjgtnofwrW0nU7OC4k+1LGsDsQXZGdFHcdzk56jp7da1X945ZxSXu30Oit7GOXw8+m2tmkRlbdE0pCuHDDnefUdce3asO9u9UtBBa6mIJ9r+au5FZznAwW644FT6ze/2he2kF3mGGJ2kWdjlzC2NiMB6Y4/3qpanZSW0BvXkZ0nk2xljhjjocHnA/Kqmk1oZU9Pi6/wBbna6XoenavK0TQyI8y/M0Z4U9ep/L0rk/iBo11p+rRGyDm1jhCKzfw4J4z/jW7oGuLJEZrwvFdIm0TZJJI+6PYcY981euo31i2eKQgCXGwgsZEAHcdGBBx7Yo5IyjoZQlOlUvLY8wa3uZJmnhiH7wH/A1XjtIzfW8t9ENkI2lAdpPPrXX6naPp9oFiuI7hCMK8XGz2PcH2ribxWjvYSZN4JyeelYuLielCXtI6bHqWv6xpkWhx2tgbeRUgDLGo5Azg5PODk4zXN+KtTtruO38xy3lKFyeQowOSR1OTXH/AG2OKYbEVsjacjoev9asCe5mjhaZPkXO7AxkY9O4rRzMaeEVPVGppemCKO6e8uIfNjKyRwuPmfPPH6cV0ehzlBM7TjZA+4oh27s8nj0rBtrsBxcrAXuMgxEsQqcYGKs2F20Ekr3buBKuTkcnsR/Wp57scqbkncsX1qFlW9kjdVlclplbkHr9e9UZbn7SI1iiO9VKPIeki5yMj1qe+u0ukIjMhBG3k8DPt+VQwA29vkRl9p54/wA9qyk+Z2RUU2tdyezkihyJY0SIkbgKhuZ0lXYpZYFIVQnIX1OO9JIYWC+WVZnYL8wyMGrduyRiRbIIGQEt5o3Yx/OlFDStqc7/AKu8aNnbOSFdD096darbyTZumCgnlsZFXL2z+zO8lztDo4UqnTGMgg+9ZbxtvLAbAeduOlRJWOpWktAubdFd1BU47g/yqBLZgjyGQHYcKNwyPwq9GY2lAZMqBzz1NWJYbQQJL5N3jBi3PjZ5gA7jGOMkf1ppPoS9NyxY6e1rpM08+37bc48tCcOqdS5z2ORgCql74Y1K3sre+ntJoYrhsQucfvD1wP8AE1qLrLyyi58xFkGGEsiguCpHyjAxyOnQDmu51VLEAappd7aTaYIwbd2ORaHoQUJyGzzyDXRCCkt9jhnVnSktN/6t/Xmcz4i8NWdj4Ygv/wC3EEDwObfC4lMvBVH5znkj2xXNeFLS41fV49DhimS8ljMa7WCFjgMd+R90AE4+ldX4Ysr7VtRbXdc0dbnw9ZxsqKECC4facyqDjJwCc+3rXNeN7C20TUrHUvDl/NJ9qzdRhpg01sVweSO2COv07V0OCsprYilNuTpt3l36X7adjM1iRtM1y8XZBc2FlcTWsQ3OgaUDBdRnIP3ST34rf+DTwXvjS3tbsI0s1u6wyOMiIrhiSOOdqtj0Jz2rl7bUNPay1ET20f8Aa19Onl3ExZo4I+S7epYnHPNaCjTNK+HDXUWpu2qawxiFjAUbyVjY/M5PzLkZHGMhu4zUxSbTKqJ8jg+un/BOr+IfjSwudNu9C0mxjtStz5kV8k4fcsXyAnAJJO04HGAVqnqup2OnfDbw1eWt6X8Qplraa3VQsSlsSwTLjn73Rh34464ng6TTNO8IvdXOvCK6vZktLqwigDS+QG3ffbpu2jkYxxycYrnJLya6vLt4mlhtp5TK247zgnGWOME+/rzVyk1uRCjBpRjeyfnrp5/8N95saJdfYllW4j8y3ePEig8rngNz254plvbw23nm7VZgARGOCNxHysw9MHj3ArPd5nVbmdJFM+SC33HUcYH8/rW6UFzYRxCIrJlImLEIDk/LnJ64xzXNLRnUZ8VvstJJIZEWaJc5zjeh44+mefauh0fU9I0+52rFJeabLbqkiS/LLFKB8zDBwe4B9D61sW+l6XYaVo01pKRqjTPpt/bRTcuJUYIwyDtBBHOOeRXBwBFs7i3aIR3UByz7sliDgjHYClKLhqRGSq3Wtv6/4dGpcT6a1wzwQzxxFyRGXDYU9BkjrTY5bdGIVGyTxuIyBUvhu+0Ozmln163ubp0UCCKALgNkfM2eDxngg0lw15DaW08UMqWV+0scN3Mq/vhnaQTztI6Hn396xcW1c22fKTaTNaR63ay6hZS3tlGxaS2jAJkABwD7Zxn2ottZvdJvpbzRImskRhhCBJsXOQGOAOcY7ZrLcXC3zWqyW/nxlkZzIFQbc87jgEcfjUcurz/2MdO8mBI5JBK8gT95JjO0Fj2GTjp171UbpWJlBN3epNrt8JdeFzrd2k73BEszWZVsFucDou4dxVWLVPsUUn9k3M4N3btb3cbKoGGPIB7qRg9iOnvVrRdJ0zVdL1v7bctDqkECy2KZAWUg/OvPVsYwPrUutfD7U9F0qDU5NW0i4s5lUo8c53fMCcbSoOeD0z+Fbxhdc3UzdSMWoP0OTv5WZwokbCjbz2HpUULZYEckdc1LrNrHHfTLYXIvIFxsm8sx+Zxydp5HOetVrXzRdKpjYL3z71dly6A3dmlpkjw39tJHcfZXWVWE/P7vn73HpVvUbcW163lz+fExJEqqVRzk8rnnGMHkA89KqW+1G+cZzke1WCWMflYX5W3DI5FYyl0LUep0Phm70qC3vbbWLA3IuAPKuVb5oMA9B7nH60ywmuNOvYNSshDFcRPvjcAEoe3HpzVC18qNI2mydjYdM4yPb1q/b/Zp75AG8mCRuHfnYPX3qVKSQnTi233PSrnx81vpMF4LmS716YMs8b5EUAzwUxwG6dPesLwX4g+w6lLqd/bJeOGPm+aAnU5BU+v4Ummrp2lWsN3cmOcMzKI8I4OP7y9emT9aw7a6hvL6UXVwtrFI/MvZFJ/hHb/61W5ybTb1OWNCnyyio6f1oX/GfivVtfuZHN1NHYTSErbhsKMdAcdcYHWsuTUri/iKNb27SxgAttG7bnk/XNQaraQW2YYriSQ8sjryjDPXnms5bMLNCzsQG5zmsnKXM7s66dOCglFWsdLrc0V3dPJBH5S5x/ve9chPJJb3hAySM9DXda0trPKRZvu2/e+XknHJx9a5a4sGluEMilIycHPBYeuPrXRU1YUZLlsFoILi4t2uBIyM6h1ThiueQPepvIiXUiFjZYi5wp5KjPT34rQg0xImWQSr5KAsSflLY7D1NUb2YOPMxl2bJOetZtWWpSlzPQqXStBOwBIJzg46ioIhJqSQ2sRJkCFUXrzya0bgCedMFS/dT0yaxTIUu9yjaSeO3esi1qjb0jUUayW3kQB4yVKlDlSB970PTv60zTUS4iUEuqq2HAGcMe/0rL1KKRFeW1laLzkIK59eoH6fhTNKv5rS8T91II2G3cpBwexNbt86Rjy8l7HoD2++yC+asrkF0dTyvYg+3TBrHt7S6sn8ySUzwsCFMp8w4OcBc9OalN/NCQJ0aHehZlIwPqQOn0rR0u3wD5wMVvIDPBIy5EhHoMYAqzm1itSbRoEge2FyB8zYZuqsf5DFat45jtS1rKEuVEh/dgk88jJ9ccVJDBJfaRcNaqs025SERfuNx0A4HTNUIr2Kx8+O++0JcbgysGAAbPJPB56078pknzu/XsY9xZXkAjWaGQCQKwDHh6xdc08xqDKr5X+JegPUCux1izme9nt7PM1pEQwmzuLEgYz7/TpUK+GtVvbWCGzUMSCWbqKiavojphXUbOTSPPTG0o3pEzAD5sdc+1dNY2u3R4pLpDvAKxjPJOR2/Gtix8Jnw/pc1xrrMhkzhZByPyrnhqD2RljEkbofn3P1+o9xUpOO5t7RVv4fQd9jCwXNxGxQhhtiIwR2JArPVp7u5Us7tgHJPpTI4ZZzvRvPQcs7HIP0HbrWnbyMkKq4UIuRs7n8azdmbpcq7j9NtxJKUlL+vAwD7ZralgiWOCK3iaSYOfNweCpIHH0rBtdR8pGUxkpn7y9eKkTW5kuluLdBFKrAq2MnPrSi4xM5U5yd0OFndfbriJLZ93OFI96r294I2eRg3nA5Vwc89+O9TalqtzqtyLi8dGkHBITbxk5GB9abd2kIt3khScRHaqsUH3jnP0qL3fumkU7WmVZ5ftTwoud3G5m6VbFld32qfYIcSzZz1749ao28Yjdln3FQDgAgFWHY11/hWHT1FublpR5yt5jbgGWQdMY524/WiKu7MVafs43RgatpxsVhC7llDbZBtwAR2x3rY8P6Fpes6fdGeea3mhBfzUIwQOxU9eO4q54otGVI4bhwIsEpcOPm5Gct69etcgs80VtI8c+0sWjCg/eU8MT6Vs7RephFyrQ912YxraKK7kG5xCoJQ43FsDjp6/pW14U8OS6rqcD5ijt8F5t4BwBznB7e9Y9nM6xxMjEGNw2cA9P89K6Lwxq9tZ3FxFdMDPPB+5diSivu5DgZ4xnt1pQjFvUqv7SMHybiWfii/t7yG1a4F1AoZTbXkhMSyFiq7UGPlxg7eema5PVGmuJrjUtUhmk8ndZhoxtCyFCU39yO+e+Oaf55fxM10phhkjHmAxAFFcDrjHr2961vGXhjU9O0rUfOgjle2hgvLkvIUZlcnHynGQDkHuMV0Qk5KxnywpyT0Tf9fqQeEPDyeL/B0lvIY7a7s5SLWRYlLTsWHyO2flGWHJ6gnrjjm9Y0i0s72+uY5HksoCywHYSZnDlDlhwAD34yMY5zXo37PupaXHpHiPTL23WJ7mJpZ7yVgYUj27VVgTwAWY59+tee634gLWl1pi/YmtFFtCJLWPasnkKVD5Iyd2ST7nNbNJRRhCU3UlF7Kxr+F/Dmta34O13+ztKtbhHeKRbiYETNsOWEJ6dGBbPY9zWP4b1N9NuWSdFZVUxPDcx7l2nnlT7816Z8IPF/iSbSLXTtE06ynsbASCaSeXBO9sooCgsBnIzgjJ5Iql4r8J2b+I9ffxPrbRamBHf+ZHIHUwkNujUPgsV2oi85PBxUyheKaFGs1UlGaVvLV9v8mcP4k1xdV1pXSK2CQqYIlDGOPnIDjkY5OeePXijQpJLmI6XJAA8gOXZSWUjkH8K66Pw1beI9HubXSvC1va6tfWcV1ZTvqB/fMHTzgqE7VbDZ2k5ANc34reeDWfImeIXW4tlMkkHGCzEnOdvHtWdSLtdmlOcW+VaW/r+vMk1vzo9bh1W6VmWOWNLiOJtsiEYJwMnqckHp9Kl8REzXF/qk/lySalKLi2ljAVZI+QTtHR8gbh6g+tQ6fGGn+yX2MyMq+cWBABxx+oNbJ07T9Ot55bsi9voLkw3FltIDoMFJoHxweRlOcjOeKzTurGkvdaaOdtdF1HUrW5vbaGJ4o0eV/wB6i/KiguQCc8Aj86t6BoOq63Y3SWEsX2S1T7VNG1wAqcH5tvc444HcZqK/u/8AX2qXBk0q9cXLNHDtCODjcB3wO2R1FN0WcwX9tZXVyYrF/MAZ1ysTSJt3kdcfdJ+ntU8qTszXmnytozbWcxeYY1BZkKEkA4U8E4/rUV+r27stwjhwASrAhsEZBx9DXoPgvQfD03jLWLe6vJho8Ee+F3I3OBj7wA9yeKt+K7I6lojXBWy1OGFZI/7VR0ikZk4RQO67ccdT61SpaXuZyrrm5Lf09jy6CdSwKODjpirMsV1JatdOMwwuIDuYEoWBYDGc44PPTNQafB5k/lKi+c7bQGIXn3J6Vb1Kwu7C8ltLu2lguoTiSORcMueRkfQ1m9HobX0tcfpuktfMoix50hCIB/EScAH05I5qvrmk3Gjaxc2N5HtuYGCOvv1/rWxplzq2n2r3FqfJhchWOxSJOhwc9RkD2rMmnluLyee5YvcSMWYnqTRzWXmRaTfkVlikCsSmMCtDTtLubiaVY4zIUQO23njGcn6VBIxCDGMDmtTTJHhiyhZUfIcoSNw7gkdvaoUr7jd4otxWklzFNFFEjtEm4g8lQO4NUorcRursFYKc4bofatBbiS1ilWCRVWcbDkclaq7gsQUsxfOSPalJ2FC5ANoYBFO4nkDpikvjGTGRGoCk7gvBbirixADzZz5MJ4yBktj0qpbRrMWZvlJzyxzmkrl6XFtkJgwAsik4BY/Mvpj2rY063mvr03gS3uIrMI0kbkRhgMcY7j6dc1QeBYVcbWBIGdx+99KgtxMsoJLKc9FGCa0joxSV1oaaJO9xOlvjMIMhIBzjoSMe1Ohkad7Yp5UhTOYmB6cfnmpZbaaCe4ZUAjl+VlYEcA9j9ayYYXiuATIcKcHIIxWsrxZMUpI2r26kSVAtuNyrgEjJ2jsP8a5+6cB2KjCEnA9K6BgWQHJdgcb1zxkd6orpE8zR+TG8jOQAgXPP+f60TTa0Cm4xWpmIRDOu4MQ4wSe1UtYtWHlymMqW+YHBCsPUVvTW5truWG8ikYHKSIFwyYPBH04rJvbW5YAqHeENsWTB2j29vpWOqNNJD9OdJ0Pmn94Fwv8As1XubSO4udqKIzJlj2AI/wAmnrHcW12glQ5ODkDIIrbayE0fmQhliBw7BDhif4R7cD61dO5lNqL16mLYs6XZaWTfaxkE5Gd5PAHv1z+Fb7ahFBcz2UpnaxtwGiZRkkjGDjtxjpWTPG8cagxEBJMs+O/A6e1V2mkcyPuxLHhNwGNy46/yq7mM4qbPQ/C1/bGff5uNqFsKpDYxz/vYxWVi2nvZ7obXuA3mxrIcBuf8nFZPh2VZZZg88kCRKASpYb8n7px1HFSeVPbsZlTewyibScqc4zjuP8aJu8UzOnDlm7Gvb63f6dExil+fgu5A3cH9cjtXR6V42lS3W3cBcnczRjaDn+L/AOtXMW728mmt8jNe5w4ZMAHr1qnHI1nb7EV5FBJRdoJ3URm11KnQpzTvHUveINaubQXKtcC4huCRukyw65JFee3Vzcvqcd2ygRKT8ij8vw9q78zgFHi0y4nU4MqyglQ2MAjjj/61Ran9huMSLpyW52BWSIkgNnluRx9KlyaNqdopJR/Iy/DUX262nluJJkjVTIiInBf/AAq6lhczqJ5rSVoRjITgEc9+2cH8qjnkWHT/ACwBg4CRxsQc+p/z2qS21nVLaxuNOj8uOG4HzFhk9BwD26fWoTT3NLT1kixaaXptvcGTUgwikVmjjEv3OM845/PFWXh0caclxam3vGaJY1WNisqTPuwGVhgj5eorIeOL7PaSXlk7GWN5CyTKAVzhTgDIIweD1piW9rFbrPGbjAx91QCCKd0tkPkctXJ/odR9m02x0iS5v7X/AEqLy43txKVOC3LY7tgjjpitHQptOuVn02W0ISQEn7RIAyHGQRXLG9vA0M1xbXMrAFc3OHDZGB2BGM981pWFvcw20m2SIBY8MfMyZMggBeM+tVzK+iOerS918z19SHVdLsv7BuWsfNP2c+avHOSwVsnuuc4Of4TWAt1LbKhh2FQhXKjk56k12qQW41KdNP8AlWVVKKfujCk4IPoc1zcliBLN5+43LEjG3GCT6YrOUW1dGlGorcstRl/raXWmR2ssUrzooXzdw5AGOmOfTP0rmlUS55xhuRzk+1bl1Z3MMZu7GGVTbECR0JIU9q6bwT4c0e7hub+e5uYhEEULMmcuw+YMAPukggEcjFOMZTdmaupToQclscroumyJbpqUlmt5abioh8wgyv06LztBwT09M1UsLpYvE+mz3KWqyG6Ectu8RVIxwvPtg561f/tK+tYIdGtoGHk3EihkTDStn5cj29/Ws3UNPmTVkfVVllmlbcwYYz6c+9UlZaFu8m+br+RftdUh8F/EvVbXUbSO6tILthtmTdjg7W5+oOcfSvR9U0+wk8WJ4h1u/srvTvKEJgMxbllwgPqo3d8+teZ+OIl1rxlDu0mHTJFCW9xDBL5iOR0YMOCMEDjpiuh8deGIbTTbg2erxyMkKzR2rp5IbBAdU7PnjjtiuyEknZLQ8urHm5W3aTVv6tscN4c17UvAXinVbJlih8zdZ3UcilgFByCMf/XyDUPhvUNE07xFBqnibT01SORpJzp8GF8l93y+ZuGGXGTtHtn0qbWPBd5JLPqWoahZQ2cSKJZYW3rE5UbYh0LMMgHbnB71i6ppOn2mmWJs7yS4vpC5nVY8JGA2FwTycjnkd601SGuWbfnvY9b0D4n2Vx4w1K7j0+10a1vLYRLIF3NujU7Nx+6v5EcKPeuVvr7StafWb3X9VnubiFvL08xQbGnB3neV6AByCec4zxXD2isAqqrbfpwa0rSyu7uUJa28krkE7VHYcn8K551JPRnRTw9OHvR02/DzNDw/rl54T1uDUdNeC4ZcPkpuVgykFeRlTjIOK2fiJq9n4n1uHxBZBola3VZ4GXHkyKMAAjqDxg1yZM8tr5LFzGDlFPO0+3+FbfhKQPqVvY6mfJsJx5coMed/oCeoBOOe3FSpacpU6ceb2ttV+RHbRmRY5Cf9Fu3W3kk2CRoySCdoPQ8dfwzXX6nYSJcf2jFfiDgQtNuUh/LwMrzlTuUc9awY7W90HVtX0WC6LWkv7qR1jDrNGCGU4PTsfb1qaSKyays7eRLhGHmC5z8yo/8ADIp49sj296wemhTvJpp6foJpGnre6jHYXrEW+otlZwOIpjwrfieD2wfYVlzaI+y5MrPFd2fyvGwJ3tvChU9/b2rpLu2uo1htwwa5tU2KyKQQ+d36dR+lWtYlN9dy68llMxmt/LuVgcq1teBflkI7KSu4evPelcnnafl/X5oz9BlsLmF9J1y6l0HWLBHFvfNHgMOpimXruAyFPpxzwDx7GSW3TzJGWEHCkAgZzz/Ou4t/A994m1hJzfpPFfqZPtEj5kcggEMOobnoccCsi3fXPA2rXNqoaJ1fy5YJoxJDMoPcEYYcDkc+9XJaXew6c1dqDu+39alZZxqlta2s8NlI8shk+1Rxn7QgHVDjAOe2cnnrXq/j7TbPVvAyQ6EJbi4tXW7uZ7uJ1dYgp3BpHAJ5P3ck+nSuI0Txr4gn8QqLy9uXsZ96y28YVI0VgeQOAMfnxVKG1vdRsNZLajezNZqsxikkZlmhBwXyx6jcuBjv7VSnaLtrcxq05TmpN8vLr3WunZFuTXILrQvs9m7WcDxm3YMiksm5TyRwADnhR2965nW7J9NvzbSRSRXMPEqOQcHqCMdtpFPu9JuLextbpopDb3IcxEqRypwf5irmleH5L6ayWOYO9zJtddvzRc8s3tz1rCUuZ+Z0RUaaunoMh0i3n0Nb+HUYDcJIVmtJBtZQfulT/FnvjpVOONtkgijJjIywHb3rqvG1hpUPiB7fw4gFqigOd5cB+Bwf881manaXFsVW7AjlVQqxxLgFccnPvSlFp+g6c1KKffvuZqmQn94ryNtYIvof606I3KOrRgowGASM5p5mlVVjVWyOp7GkjDowJDH061FzVIfHE8ilCpYhc/McAc1reTcJb5aKO1hICBAOG7596pCRp1dbjc5IwrY+6ac0NwhC5O0DKktx+Ga1guxnLUjcvKm4hiucFjnBNEs0juhctkEAn1HbNExlRSm1y4PTniqLmUyA7SPmHGK0SsO1z//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Honey colored crusts are seen on the postauricular skin of this patient with infected atopic dermatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph Morelli, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_9_4246=[""].join("\n");
var outline_f4_9_4246=null;
var title_f4_9_4247="Clinical manifestations and diagnosis of Felty's syndrome";
var content_f4_9_4247=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of Felty's syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/9/4247/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/9/4247/contributors\">",
"     Jonathan Kay, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/9/4247/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/9/4247/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/9/4247/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/9/4247/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/9/4247/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Felty&rsquo;s syndrome (FS) comprise an infrequently occurring but severe subset of seropositive rheumatoid arthritis (RA) complicated by neutropenia and splenomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/1\">",
"     1",
"    </a>",
"    ]. The lifetime risk of developing FS for a patient initially diagnosed with RA had been estimated to be approximately 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, a subsequent study, utilizing a large Veterans Administration database, showed a steady decline in prevalence during the two decades ending in 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/4\">",
"     4",
"    </a>",
"    ]. The clinical manifestations and diagnosis of this disorder are discussed in this review; drug therapy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18695?source=see_link\">",
"     \"Drug therapy in Felty's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, Felty described a syndrome characterized by the triad of rheumatoid arthritis, neutropenia, and splenomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/1\">",
"     1",
"    </a>",
"    ]. However, splenomegaly is sometimes undetectable in RA despite marked neutropenia, spleen size does not correlate with the degree of neutropenia or clinical course, and patients without splenomegaly otherwise resemble patients with the full triad [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Thus, most experts agree that splenomegaly is not an absolute diagnostic requirement, although it is present in most cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Rheumatoid arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid arthritis in patients with Felty&rsquo;s syndrome (FS) almost always appears first and typically has been present for at least 10 years before neutropenia is recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/2\">",
"     2",
"    </a>",
"    ]. Infrequently, however, neutropenia and splenomegaly appear before or simultaneously with the onset of arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    FS is typically associated with severe erosive joint disease and deformity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/2\">",
"     2",
"    </a>",
"    ]. However, one study found that the erosive process was equally advanced both in patients with FS and in matched controls with RA of similar disease duration [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/3\">",
"     3",
"    </a>",
"    ]. Approximately one-third of patients with FS have inactive or &ldquo;burned-out&rdquo; synovitis, but even these individuals almost always have a markedly elevated erythrocyte sedimentation rate (ESR) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/2,9\">",
"     2,9",
"    </a>",
"    ], the mean value for which was 85",
"    <span class=\"nowrap\">",
"     mm/hour",
"    </span>",
"    in one large series [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The demographic features of patients with FS and of RA controls are similar [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/5\">",
"     5",
"    </a>",
"    ]. Women comprise 60 to 80 percent of patients, and the onset of arthritis usually occurs in the patients&rsquo; late 30s or early 40s [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. FS patients are more likely to have a family history of RA, and the histocompatibility complex class II DR4 allele is present in about 95 percent of cases, a frequency that is significantly higher than in RA controls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/3,5,11\">",
"     3,5,11",
"    </a>",
"    ]. FS is rare in patients of African ancestry, who have a low frequency of HLA-DR4 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with FS tend to have more frequent and severe extraarticular manifestations than do other patients with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/2\">",
"     2",
"    </a>",
"    ]. These include vasculitis, which can result in mononeuritis multiplex and necrotizing skin lesions; pleuropericarditis; rheumatoid nodules in subcutaneous and visceral locations; lymphadenopathy; and episcleritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rheumatoid vasculitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=see_link\">",
"     \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some of these extraarticular manifestations may be associated with serious morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. As in other patients with seropositive RA, the extraarticular features are seldom prominent at the onset of arthritis and generally do not play a role in establishing the diagnosis of FS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutropenia (absolute neutrophil count below",
"    <span class=\"nowrap\">",
"     2000/microL)",
"    </span>",
"    in Felty&rsquo;s syndrome (FS) does not cause symptoms unless it leads to infection, to which it predisposes patients with FS. As a result, it may not be detected for a prolonged period unless blood counts are being monitored for some other reason, such as for the detection of possible toxicity to antirheumatic drugs. However, the diagnosis of FS may be masked in patients who present with infection, because active bacterial infection can raise the white blood cell count to a normal or even slightly elevated level; the neutropenia typically reappears within a short time after successful treatment of the infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic cause of neutropenia in FS is an imbalance between granulocyte production and granulocyte removal from the circulating pool. In addition to splenic sequestration (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Splenomegaly'",
"    </a>",
"    below), one or more of the following can contribute to the development of neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/7,12-18\">",
"     7,12-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immune complexes coating granulocytes, thereby leading to sequestration and reduced survival",
"     </li>",
"     <li>",
"      Antigranulocyte antibodies directed against cell surface antigens",
"     </li>",
"     <li>",
"      Increased white blood cell margination",
"     </li>",
"     <li>",
"      Bone marrow abnormalities, including a maturation arrest of the granulocyte cell line (most common), hypoplasia, and, rarely, a lymphocytic infiltration. Overall cellularity either is normal or reveals myeloid hyperplasia.",
"     </li>",
"     <li>",
"      Inhibition of myelopoiesis produced by cytotoxic lymphocytes infiltrating the bone marrow",
"     </li>",
"     <li>",
"      Binding of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      by antibodies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Bacterial infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neutropenia in FS predisposes to recurrent bacterial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Respiratory tract and skin infections due to usual pathogenic bacteria are most common. Risk factors for infection include neutrophil counts below",
"    <span class=\"nowrap\">",
"     1000/microL,",
"    </span>",
"    skin ulcers, glucocorticoid therapy, increases in overall disease severity and in functional impairment, low serum levels of soluble Fc-gamma receptor III (Fc-gamma RIII or CD16, shed from the surface of neutrophils), and elevated levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/12,19,20\">",
"     12,19,20",
"    </a>",
"    ]. However serum Fc-gamma RIII and G-CSF concentrations are seldom measured in clinical practice.",
"   </p>",
"   <p>",
"    Fever in the absence of underlying infection is as unusual in FS as it is in adult-onset RA, with the exception of patients with rheumatoid vasculitis or with fulminant polyarticular synovitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Splenomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenomegaly can be detected in more than 90 percent of patients with FS by carefully palpating the abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/22\">",
"     22",
"    </a>",
"    ]. Ultrasonography or radionuclide scanning can be used to confirm splenic enlargement. The mean splenic weight in FS is about four times normal, but massive splenomegaly can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/22\">",
"     22",
"    </a>",
"    ]. The spleen size does not correlate either with the degree of neutropenia or with the severity of arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Splenomegaly can occur in patients with RA who never develop neutropenia; these individuals should",
"    <strong>",
"     not",
"    </strong>",
"    be considered to have FS [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/2\">",
"     2",
"    </a>",
"    ]. In the absence of splenomegaly, a diagnosis of FS may be appropriate if other causes of granulocytopenia are ruled out.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory data",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only laboratory studies which play a diagnostic role in FS are hematologic tests (white blood cell count and bone marrow aspiration and biopsy) and serologic studies (rheumatoid factor and anticyclic citrullinated peptide [CCP] antibodies). Patients with FS typically have both rheumatoid factor and anti-CCP antibodies, which are both usually in high titer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/10,23\">",
"     10,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Neutrophil count",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absolute neutrophil counts below",
"    <span class=\"nowrap\">",
"     2000/microL",
"    </span>",
"    are required for the diagnosis of FS. The neutropenia should be persistent and should not be explainable by concurrent illnesses or drug therapy. The depression of the neutrophil count in FS varies spontaneously in the individual patient. Those with mild neutropenia may, therefore, transiently achieve counts within the normal range, even without obvious infection. However, a persistently normal count, due to spontaneous remission, is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Blood smear",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood smears must be reviewed to identify the large granular lymphocyte (LGL) leukemia syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5095?source=see_link\">",
"     \"Large granular lymphocyte leukemia in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Bone marrow",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bone marrow usually shows myeloid hyperplasia with a relative excess of immature forms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/2\">",
"     2",
"    </a>",
"    ]. This has been described as &ldquo;maturation arrest,&rdquo; but premature release of granulocytes into the circulation can give the same picture. Less common findings are a hypocellular marrow, suggesting a depression in myeloid activity, and an increase in marrow lymphocytes, which should arouse suspicion of the large granular lymphocyte syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Signs of immune dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoantibody levels are typically more prominent in FS than in RA. The following have been noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antinuclear antibodies, antihistone antibodies, and antineutrophil cytoplasmic antibodies (ANCA), mostly reactive to lactoferrin, are each found in 65 to 83 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/2,25,26\">",
"       2,25,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Circulating autoantibodies in FS preferentially bind peptidylarginine deiminase type 4 (PAD-4)-deiminated histones over non-deiminated histones and bind to activated neutrophils and neutrophil extracellular chromatin traps [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anti-double-stranded DNA (anti-dsDNA) antibody titers are occasionally elevated [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anti-glucose-6-phosphate isomerase antibody titers are elevated in 92 percent of patients with FS [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Circulating immune complexes are seen more commonly in FS than in RA [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, immunoglobulin levels are higher and complement component levels are lower than in other RA patients. However, most values still fall within the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/2,9,10\">",
"     2,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Felty&rsquo;s syndrome is a clinical diagnosis that is suspected in a patient with RA, splenomegaly, and neutropenia. There is no specific diagnostic test. Other causes of neutropenia should be considered and excluded before concluding that FS is present. The diagnostic evaluation should include review of the peripheral smear to exclude LGL leukemia, as well as bone marrow aspiration and biopsy. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Blood smear'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'Bone marrow'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of FS should begin with alternatives to RA in patients presenting with polyarthritis and neutropenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic lupus erythematosus (SLE) and its variants should be excluded first. The neutropenia in SLE typically has a prominent element of lymphopenia, and it is not unusual for these patients to have a normal differential white blood cell count. However, absolute neutropenia can occur. The distinction between RA and SLE is generally made by using both clinical and serologic criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/6,29\">",
"     6,29",
"    </a>",
"    ]. Both are somewhat less useful when FS complicates RA, because these patients often have extraarticular involvement similar to that observed in some patients with SLE and, as noted above, also have a broad spectrum of autoantibodies. However, the following findings may be helpful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of nephritis, central nervous system disease, typical photosensitive rash,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anti-dsDNA antibodies points toward a diagnosis of SLE.",
"     </li>",
"     <li>",
"      Erosive arthritis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      typical rheumatoid nodules are generally indicative of RA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Large granular lymphocyte (LGL) syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The LGL syndrome may be associated with neutropenia with or without splenomegaly. The diagnosis is suggested by an increased proportion of LGL cells on the peripheral smear or in a bone marrow aspirate or biopsy. FS may be difficult to differentiate from the LGL syndrome, particularly when arthritis and splenomegaly are present in the latter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5095?source=see_link\">",
"     \"Large granular lymphocyte leukemia in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Molecular differentiation of the LGL syndrome from FS is based upon the demonstration in the LGL syndrome of a characteristic, expanded (and usually clonal) lymphocyte population. Immunophenotyping in LGL will indicate the presence of a population of cytotoxic T lymphocytes expressing a set of surface markers (eg, CD 2, 3, 8, 16, and 57) that is infrequent in FS. The demonstration of clonal cytogenetic abnormalities or clonal TCR gene recombination in patients with characteristic lymphocyte phenotypes provides additional diagnostic confirmation of the LGL syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other causes of neutropenia and splenomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other conditions superimposed on RA may cause splenomegaly",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neutropenia and must also be excluded with reasonable certainty. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Drug reactions or toxicities",
"     </li>",
"     <li>",
"      Amyloidosis",
"     </li>",
"     <li>",
"      Myeloproliferative disorders",
"     </li>",
"     <li>",
"      Lymphomas",
"     </li>",
"     <li>",
"      HIV infection",
"     </li>",
"     <li>",
"      Sarcoidosis",
"     </li>",
"     <li>",
"      Tuberculosis",
"     </li>",
"     <li>",
"      Cirrhosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With regard to cirrhosis, it should be appreciated that portal hypertension may be directly related to FS and can result in variceal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/2,30,31\">",
"     2,30,31",
"    </a>",
"    ]. The liver is not cirrhotic in this setting but rather exhibits nodular regenerative hyperplasia and compression of the hepatic venous circulation. How this occurs is not well-understood, but immune-mediated injury to the endothelial cells of the portal venules may play a role.",
"   </p>",
"   <p>",
"    Patients with FS have a greater risk than both the general population and other patients with RA for developing non-Hodgkin lymphoma. Similar to other patients with RA, FS patients also have an increased risk of developing lung cancer and other malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4247/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As originally described, Felty&rsquo;s syndrome (FS) refers to patients with RA, otherwise unexplained neutropenia, and splenomegaly. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rheumatoid arthritis (RA) is typically severe, longstanding, erosive, and seropositive (RF and anti-CCP antibody positive). Other extraarticular manifestations of RA are often present. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Rheumatoid arthritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neutropenia (absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &lt;2000/microL)",
"      </span>",
"      may be asymptomatic or may be noted in association with recurrent bacterial infections. Various mechanisms may contribute to the neutropenia of FS. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bacterial infections of the respiratory tract and skin, due to typical pathogens of these sites, are increased in frequency. Lower neutrophil counts and the presence of other clinical and laboratory features are associated with an increased risk of infection. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Bacterial infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Splenomegaly, as determined by physical examination, is present in more than 90 percent of patients with FS. However, a diagnosis of FS may be appropriate in a patient with RA and neutropenia in whom no other cause is apparent. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Splenomegaly'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no diagnostic laboratory test for FS. Elevated markers of the acute phase response (eg, ESR and CRP) and the presence of RF and anti-CCP antibodies in serum are usually noted. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory data'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bone marrow examination is usually necessary to exclude other causes of neutropenia. Adequate or increased myeloid elements with a relative increase in immature granulocyte precursors are the most common finding. Hypocellularity or an excess of lymphocytes is less frequently noted. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Bone marrow'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autoantibodies other than RF (eg, antinuclear antibodies, antihistone antibodies, ANCA, anti-dsDNA antibodies, anti-glucose-6-phosphate isomerase antibodies) are commonly present in sera from those with FS. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Signs of immune dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SLE, the large granular lymphocyte syndrome, and drug reactions are among the other causes of neutropenia and splenomegaly that should be excluded in the differential diagnosis of FS. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Blood smear'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53011417\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editors of UpToDate, Inc. would like to acknowledge Robert S Pinals, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/1\">",
"      Felty AR. Chronic arthritis in the adult associated with splenomegaly and leukopenia. Bull Johns Hopkins Hosp 1924; 35:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/2\">",
"      Goldberg J, Pinals RS. Felty syndrome. Semin Arthritis Rheum 1980; 10:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/3\">",
"      Sibley JT, Haga M, Visram DA, Mitchell DM. The clinical course of Felty's syndrome compared to matched controls. J Rheumatol 1991; 18:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/4\">",
"      Bartels CM, Bell CL, Shinki K, et al. Changing trends in serious extra-articular manifestations of rheumatoid arthritis among United State veterans over 20 years. Rheumatology (Oxford) 2010; 49:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/5\">",
"      Campion G, Maddison PJ, Goulding N, et al. The Felty syndrome: a case-matched study of clinical manifestations and outcome, serologic features, and immunogenetic associations. Medicine (Baltimore) 1990; 69:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/6\">",
"      Starkebaum G. Chronic neutropenia associated with autoimmune disease. Semin Hematol 2002; 39:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/7\">",
"      Burks EJ, Loughran TP Jr. Pathogenesis of neutropenia in large granular lymphocyte leukemia and Felty syndrome. Blood Rev 2006; 20:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/8\">",
"      Bradley JD, Pinals RS. Felty's syndrome presenting without arthritis. Clin Exp Rheumatol 1983; 1:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/9\">",
"      Ruderman M, Miller LM, Pinals RS. Clinical and serologic observations on 27 patients with Felty's syndrome. Arthritis Rheum 1968; 11:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/10\">",
"      Sienknecht CW, Urowitz MB, Pruzanski W, Stein HB. Felty's syndrome. Clinical and serological analysis of 34 cases. Ann Rheum Dis 1977; 36:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/11\">",
"      Turesson C, Schaid DJ, Weyand CM, et al. The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis. Arthritis Res Ther 2005; 7:R1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/12\">",
"      Breedveld FC, Fibbe WE, Cats A. Neutropenia and infections in Felty's syndrome. Br J Rheumatol 1988; 27:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/13\">",
"      Starkebaum G, Arend WP, Nardella FA, Gavin SE. Characterization of immune complexes and immunoglobulin G antibodies reactive with neutrophils in the sera of patients with Felty's syndrome. J Lab Clin Med 1980; 96:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/14\">",
"      Dancey JT, Brubaker LH. Neutrophil marrow profiles in patients with rheumatoid arthritis and neutropenia. Br J Haematol 1979; 43:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/15\">",
"      Abdou NI. Heterogeneity of bone marrow-directed immune mechanisms in the pathogenesis of neutropenia of Felty's syndrome. Arthritis Rheum 1983; 26:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/16\">",
"      Coakley G, Mok CC, Hajeer AH, et al. Interleukin-10 promoter polymorphisms in rheumatoid arthritis and Felty's syndrome. Br J Rheumatol 1998; 37:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/17\">",
"      Meliconi R, Uguccioni M, Chieco-Bianchi F, et al. The role of interleukin-8 and other cytokines in the pathogenesis of Felty's syndrome. Clin Exp Rheumatol 1995; 13:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/18\">",
"      Hellmich B, Csernok E, Schatz H, et al. Autoantibodies against granulocyte colony-stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus. Arthritis Rheum 2002; 46:2384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/19\">",
"      Breedveld FC, Fibbe WE, Hermans J, et al. Factors influencing the incidence of infections in Felty's syndrome. Arch Intern Med 1987; 147:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/20\">",
"      Hellmich B, Csernok E, de Haas M, et al. Low Fcgamma receptor III and high granulocyte colony-stimulating factor serum levels correlate with the risk of infection in neutropenia due to Felty's syndrome or systemic lupus erythematosus. Am J Med 2002; 113:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/21\">",
"      Pinals RS. Polyarthritis and fever. N Engl J Med 1994; 330:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/22\">",
"      Laszlo J, Jones R, Silberman HR, Banks PM. Splenectomy for Felty's syndrome. Clinicopathological study of 27 patients. Arch Intern Med 1978; 138:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/23\">",
"      Turesson C, Jacobsson LT, Sturfelt G, et al. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 2007; 66:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/24\">",
"      Luthra HS, Hunder GG. Spontaneous remission of Felty's syndrome. Arthritis Rheum 1975; 18:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/25\">",
"      Cohen MG, Webb J. Antihistone antibodies in rheumatoid arthritis and Felty's syndrome. Arthritis Rheum 1989; 32:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/26\">",
"      Coremans IE, Hagen EC, van der Voort EA, et al. Autoantibodies to neutrophil cytoplasmic enzymes in Felty's syndrome. Clin Exp Rheumatol 1993; 11:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/27\">",
"      Dwivedi N, Upadhyay J, Neeli I, et al. Felty's syndrome autoantibodies bind to deiminated histones and neutrophil extracellular chromatin traps. Arthritis Rheum 2012; 64:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/28\">",
"      van Gaalen FA, Toes RE, Ditzel HJ, et al. Association of autoantibodies to glucose-6-phosphate isomerase with extraarticular complications in rheumatoid arthritis. Arthritis Rheum 2004; 50:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/29\">",
"      Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/30\">",
"      Thorne C, Urowitz MB, Wanless I, et al. Liver disease in Felty's syndrome. Am J Med 1982; 73:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/31\">",
"      Wanless IR, Godwin TA, Allen F, Feder A. Nodular regenerative hyperplasia of the liver in hematologic disorders: a possible response to obliterative portal venopathy. A morphometric study of nine cases with an hypothesis on the pathogenesis. Medicine (Baltimore) 1980; 59:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4247/abstract/32\">",
"      Gridley G, Klippel JH, Hoover RN, Fraumeni JF Jr. Incidence of cancer among men with the Felty syndrome. Ann Intern Med 1994; 120:35.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7482 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-11D65C23BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_9_4247=[""].join("\n");
var outline_f4_9_4247=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Splenomegaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Neutrophil count",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Blood smear",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Bone marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Signs of immune dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Large granular lymphocyte (LGL) syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other causes of neutropenia and splenomegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H53011417\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=related_link\">",
"      Clinical manifestations and diagnosis of rheumatoid vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18695?source=related_link\">",
"      Drug therapy in Felty's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5095?source=related_link\">",
"      Large granular lymphocyte leukemia in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_9_4248="Magnification endoscopy";
var content_f4_9_4248=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Magnification endoscopy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/9/4248/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/9/4248/contributors\">",
"     Moises Guelrud, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/9/4248/contributors\">",
"     Elissa E Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/9/4248/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/9/4248/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/9/4248/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/9/4248/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/9/4248/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to magnify endoscopic images in real-time (magnification endoscopy) permits visualization of mucosal details that cannot be seen with standard endoscopy. The images can be further enhanced by the topical application of stains or pigments (enhanced magnification endoscopy or magnification chromoscopy).",
"   </p>",
"   <p>",
"    Equipment and experience with these approaches is evolving. A growing number of reports suggest that they offer the ability to improve diagnostic accuracy for a variety of gastrointestinal disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, newer technologies, such as confocal laser endomicroscopy and endocytoscopy, are now allowing for real-time visualization of the gastrointestinal tract at a microscopic level [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Magnification endoscopy will be reviewed here. Other methods for enhanced visualization of the gastrointestinal mucosa are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15370?source=see_link\">",
"     \"Chromoendoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/40/29316?source=see_link\">",
"     \"Narrow band imaging in Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EQUIPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnification endoscopes include an adjustable focusing mechanism that permits standard endoscopic views and the ability to enlarge the image from 1.5X to 150X [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/4\">",
"     4",
"    </a>",
"    ]. Several different models are commercially available. The newest magnification endoscopes permit magnification without loss of resolution.",
"   </p>",
"   <p>",
"    Resolution is related to pixel density. Conventional endoscopes have pixel densities in the range of 100,000 to 200,000. By contrast, the newest magnification endoscopes have pixel densities as high as 850,000, allowing them to discriminate objects that are only 10 to 71 microns in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The technique for performing magnification endoscopy is similar to standard endoscopy. One difference (when performing it in the duodenum) is that we may administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    , which can be helpful for decreasing contractility, thereby aiding in visualization and the application of stains. The magnification and staining portion of the examination adds only five to ten minutes to the procedure.",
"   </p>",
"   <p>",
"    Several topical stains and pigments (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    ) have been used in conjunction with magnification endoscopy. The principles and techniques involved in their application are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15370?source=see_link\">",
"     \"Chromoendoscopy\"",
"    </a>",
"    .) The following sections will focus on the technique involved in the application of acetic acid, for which there is relatively less experience in the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/5\">",
"     5",
"    </a>",
"    ]. We have found application of acetic acid to be particularly helpful when examining Barrett's mucosa.",
"   </p>",
"   <p>",
"    In translucent epithelium, the light beam reaches the subepithelial vascular network. The absorption spectrum of hemoglobin explains the red color in the surface. Instillation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    causes the epithelial surface to opacify, thereby masking the subepithelial vascular network and making the surface appear white. This change has been referred to as the \"acetowhite reaction\" although the exact mechanisms underlying it are unclear. One theory suggests that exposure to acetic acid causes cytokeratins, which are (filaments of proteins within the cells) to organize into large bundles, which increases the index of refraction.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     Acetic acid",
"    </a>",
"    has been used to stain abnormal tissues during examination of the cervix where it whitens immature and dysplastic cervical squamous epithelium. The technique has proven to be inexpensive, safe and clean. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A spray catheter (several manufacturers) is passed through the biopsy channel exposing its tip.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     Acetic acid",
"    </a>",
"    (3 percent) is then sprayed over the surface of the mucosa beginning from the distal extent and then proceeding proximally [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/5\">",
"     5",
"    </a>",
"    ]. The head of the bed should be elevated and the amount of acetic acid used minimized to reduce the risk of aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. As little as 5 to 10 mL is usually sufficient to coat an area of suspected Barrett's mucosa. Excess can be removed by suction.",
"   </p>",
"   <p>",
"    The esophageal and gastric epithelia initially whiten. After two to three minutes of spraying, the esophagus remains white while the gastric epithelium and columnar epithelium of Barrett's mucosa become reddish, thereby accentuating the contrast between normal and metaplastic tissue (",
"    <a class=\"graphic graphic_picture graphicRef62055 \" href=\"UTD.htm?1/40/1665\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef73908 \" href=\"UTD.htm?0/27/433\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ESOPHAGUS AND GASTRIC CARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal metaplasia is frequently translucent when observed with magnification endoscopy alone. Thus, the mucosal surface is not easily examined without staining [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, a variety of tissue stains have been used with standard endoscopy and in conjunction with magnification to improve visualization. Considered together, these studies suggest that enhanced magnification endoscopy improves the detection of intestinal metaplasia (and possibly dysplasia) by permitting better targeting of biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/5,10,11\">",
"     5,10,11",
"    </a>",
"    ]. However, not all studies have reached this conclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/12\">",
"     12",
"    </a>",
"    ]. The best results have been achieved in centers with experience in magnification endoscopy. Thus, training is required to achieve the benefits from this approach.",
"   </p>",
"   <p>",
"    The following illustrates the range of findings.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized prospective, crossover trial that included 31 patients found that magnification endoscopy had 100 percent sensitivity and 66 percent specificity for predicting the presence of Barrett's esophagus [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/13\">",
"       13",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"       Acetic acid",
"      </a>",
"      guided biopsies had a significantly higher yield in detecting Barrett's esophagus compared with random biopsies (78 versus 57 percent).",
"     </li>",
"     <li>",
"      Another study included 80 patients with suspected Barrett's esophagus who underwent magnification endoscopy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"       indigo carmine",
"      </a>",
"      staining, which revealed three distinct mucosal patterns",
"      <span class=\"nowrap\">",
"       (ridged/villous,",
"      </span>",
"      circular, and",
"      <span class=\"nowrap\">",
"       irregular/distorted)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/10\">",
"       10",
"      </a>",
"      ]. The yield on targeted biopsies according to these patterns was 97 percent for the",
"      <span class=\"nowrap\">",
"       ridged/villous",
"      </span>",
"      pattern, compared with 17 percent for the circular pattern. The",
"      <span class=\"nowrap\">",
"       irregular/distorted",
"      </span>",
"      pattern was observed in six patients, all of whom had high-grade dysplasia.",
"     </li>",
"     <li>",
"      A similarly designed study included 247 patients undergoing elective upper endoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/11\">",
"       11",
"      </a>",
"      ]. Patients were included provided that the esophagogastric junction and the squamocolumnar junction were judged to be at the same level. The final study included 195 patients after excluding 52 who had evidence of Barrett's esophagus by standard endoscopy. Enhanced magnification endoscopy was performed with 3 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"       acetic acid",
"      </a>",
"      instillation as described above. Intestinal metaplasia was detected in 44 percent of patients. Four different patterns were recognized on magnified images: round pits, reticular, villous, and ridged. The yield of detection of intestinal metaplasia of the gastric cardia according to this classification was 0, 5, 56, and 96 percent, respectively.",
"     </li>",
"     <li>",
"      A fourth study involved 67 patients who underwent upper endoscopy for upper gastrointestinal symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/14\">",
"       14",
"      </a>",
"      ]. Enhanced magnification endoscopy was performed with 1.5 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"       acetic acid",
"      </a>",
"      during which the mucosal pattern was classified into three types. The overall frequency of intestinal metaplasia in the esophagus or esophagogastric junction was 39 percent. There was good correlation between the type 3 mucosal pattern and the presence of intestinal metaplasia (sensitivity 89 percent, specificity 90 percent, positive predictive value 85 percent, negative predictive value 93 percent).",
"     </li>",
"     <li>",
"      However, discordant data have also been published. One controlled trial, for example, found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"       acetic acid",
"      </a>",
"      enhanced magnification endoscopy was not better than standard endoscopy in detecting intestinal metaplasia in patients with symptoms of GERD [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Magnification endoscopy has also been combined with narrow band imaging (NBI) in the esophagus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study comparing magnification NBI and high-resolution magnification white-light endoscopy in the prediction of histology in Barrett's esophagus found NBI to be superior in the prediction of histology and dysplasia in Barrett's esophagus [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/16\">",
"       16",
"      </a>",
"      ]. However, there was generally poor agreement between endoscopists, although agreement was significantly better with NBI. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/40/29316?source=see_link\">",
"       \"Narrow band imaging in Barrett's esophagus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A second study compared white-light endoscopy, NBI, and NBI plus magnification endoscopy in patients with head and neck cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/17\">",
"       17",
"      </a>",
"      ]. In the 21 patients with esophageal neoplasia, NBI with magnification had the highest combined sensitivity and specificity (100 and 80 percent, respectively) compared with NBI alone (100 and 40 percent, respectively) and white-light endoscopy (63 and 70 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical benefits of improved detection in the screening setting are not entirely clear. Routine application of magnification endoscopy may result in an increasing proportion of patients being diagnosed with intestinal metaplasia, particularly those with short-segment Barrett's esophagus or intestinal metaplasia of the gastric cardia, who may be at relatively less risk for progression compared with those diagnosed with long-segment Barrett's based upon standard endoscopy. As a result, an increasing proportion of patients undergoing screening for Barrett's esophagus would be subjected to the worry, bother, cost, and risk of continued surveillance, even though the majority will not develop adenocarcinoma during their lifetime.",
"   </p>",
"   <p>",
"    Another unsettled issue is the interobserver reliability of the classification systems described above as well as others that continue to be proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/18-23\">",
"     18-23",
"    </a>",
"    ]. The interobserver reliability of two of the classification systems was assessed in a study that focused on 51 patients with reflux-symptoms who underwent enhanced magnification endoscopy using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/20\">",
"     20",
"    </a>",
"    ]. Videotapes of the endoscopic sessions were shown to four experienced endoscopists in a random order. Intestinal metaplasia was detected in 61 percent of the patients overall. However, there was a higher level of interobserver variability (Kappa &lt; 0.4). Overall accuracy was estimated to be only 50 percent, with no differences observed before or after instillation of acetic acid or methylene blue. The authors concluded that these techniques do not significantly improve the detection of intestinal metaplasia.",
"   </p>",
"   <p>",
"    A high level of interobserver variability was also described in other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/12,16,21\">",
"     12,16,21",
"    </a>",
"    ]. In one study, for example, chromoendoscopy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    and narrow band imaging were compared with high resolution magnification endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/12\">",
"     12",
"    </a>",
"    ]. Seven endoscopists with no expertise in Barrett's esophagus or advanced imaging techniques and five international experts evaluated 22 areas for regularity of mucosal and vascular patterns and the presence of abnormal blood vessels. The kappa coefficients range for interobserver agreement for these three features of mucosal morphology with white light images ranged from 0.51 to 0.53 for all observers, from 0.43 to 0.53 for experts, and from 0.51 to 0.64 for non-experts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=see_link&amp;anchor=H15#H15\">",
"     \"Glossary of common biostatistical and epidemiological terms\", section on 'Reliability'",
"    </a>",
"    .) The yield for identifying early neoplasia with white light images was 86 percent for all observers, 90 percent for experts, and 84 percent for nonexperts. The addition of indigo carmine chromoendoscopy, acetic acid chromoendoscopy, or narrow band imaging to white light images did not improve interobserver agreement or the yield in identifying early neoplasia in Barrett's esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast, interobserver variability was somewhat better in another series [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/22\">",
"     22",
"    </a>",
"    ]. In an additional report (published in an abstract), sensitivity for detection of intestinal metaplasia and high-grade intraepithelial neoplasia or early mucosal cancer were 92 and 89 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/23\">",
"     23",
"    </a>",
"    ]. The kappa coefficients for inter- and intraobserver agreement (among six endoscopists) were a remarkable 0.959 and 1.0, respectively. It is likely that some of the variability across studies is due to a learning curve required to be familiar with the classification systems and other morphologic features of Barrett's esophagus.",
"   </p>",
"   <p>",
"    Thus, greater standardization of the methods used to detect and classify esophageal and gastric cardia mucosa is needed before these techniques can be recommended routinely. At present, their greatest role may be for directing targeted biopsies in patients with established intestinal metaplasia who are undergoing surveillance. They may also be helpful for directing biopsies in patients known to have dysplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link\">",
"     \"Management of Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     STOMACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;A role for magnification endoscopy in the stomach has been suggested for the diagnosis of a variety of mucosal conditions. Thus far, most studies have been descriptive but have suggested an improved ability to detect premalignant and malignant lesions and to aid in assessment completeness of excision when endoscopic mucosal resection has been attempted [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=see_link\">",
"     \"Overview of endoscopic resection of gastrointestinal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential to discriminate between benign versus premalignant polypoid lesions has also been suggested, which may aid in assessment of patients found to have multiple gastric polyps in whom complete histologic sampling may not be feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/25,27\">",
"     25,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2361?source=see_link\">",
"     \"Gastric polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pit pattern may also be useful for identifying mucosal changes such as intestinal metaplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/24,28\">",
"     24,28",
"    </a>",
"    ], gastric atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/29\">",
"     29",
"    </a>",
"    ], and early cancers that are potentially amenable to endoscopic mucosal resection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. When a normal tubular pattern cannot be identified, it is called \"non-structural\" pattern. This finding suggests that the cancer involves the submucosal layer and precludes endoscopic mucosal resection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Analysis of the microvascular architecture may also be helpful, especially if combined with narrow band imaging (NBI) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/40/29316?source=see_link&amp;anchor=H2#H2\">",
"     \"Narrow band imaging in Barrett's esophagus\", section on 'Principles'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies that have looked at NBI for the diagnosis of gastric cancer suggest that combining magnification endoscopy with NBI and white-light endoscopy increases diagnostic sensitivity and specificity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 56 patients with small (10 mm or smaller), depressed gastric lesions compared magnification white light endoscopy with magnification endoscopy NBI for diagnosing gastric cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/33\">",
"       33",
"      </a>",
"      ]. Endoscopically, gastric cancer was diagnosed if two criteria were met: (1) there was a definite demarcation line between the lesion and the normal mucosa and (2) an irregular microvascular pattern was present in the lesion. The sensitivity of magnification endoscopy was 33 percent and the specificity was 67 percent. When NBI was added, the sensitivity significantly increased to 70 percent. The specificity was also higher (89 percent), though the difference between the two modalities was not statistically significant.",
"     </li>",
"     <li>",
"      A second study examined 201 lesions in 111 patients using white-light endoscopy without magnification followed by magnification endoscopy with NBI [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/34\">",
"       34",
"      </a>",
"      ]. Diagnostic criteria for gastric cancer using NBI included: disappearance of fine mucosal structure, microvascular dilation, and heterogeneity. Cancer was identified pathologically in 14 of the lesions (7 percent). The sensitivity and specificity of magnification endoscopy with NBI were 93 and 95 percent, respectively. These values were significantly higher than those seen with white light endoscopy (43 and 61 percent, respectively).",
"     </li>",
"     <li>",
"      A trial with 353 patients also compared magnification endoscopy with NBI with conventional endoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/35\">",
"       35",
"      </a>",
"      ]. Patients with small gastric cancers or a history of gastric cancer treated endoscopically were assigned to either magnification endoscopy with NBI or conventional endoscopy for the detection of additional lesions. There was no significant difference in sensitivity between magnification endoscopy with NBI and conventional endoscopy for detecting gastric cancer (60 versus 40 percent, p = 0.34), though magnification endoscopy with NBI had a higher specificity (94 versus 68 percent). When magnification endoscopy with NBI was combined with conventional endoscopy, the sensitivity increased to 95 percent and the specificity increased to 97 percent (p&lt;0.001 compared with conventional endoscopy alone).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SMALL INTESTINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is relatively little experience with magnification endoscopy in the small bowel compared with other regions of the alimentary tract. An area where it shows particular promise is in the evaluation of patients with celiac disease and other disorders associated with malabsorption where biopsies obtained during standard endoscopy may not be diagnostic since the mucosa can be affected in a patchy distribution. Magnification endoscopy has the potential to enhance diagnostic yield by improving targeting of biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/36-40\">",
"     36-40",
"    </a>",
"    ]. In one of the largest studies, the sensitivity and specificity for determining the presence or absence of any villous abnormalities were 95 and 99 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/37\">",
"     37",
"    </a>",
"    ]. The study also demonstrated excellent interobserver reliability.",
"   </p>",
"   <p>",
"    Magnification endoscopy has also been used as a tool for monitoring acute rejection in patients who have undergone small bowel transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1497?source=see_link\">",
"     \"Overview of intestinal and multivisceral transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     COLON",
"    </span>",
"    &nbsp;&mdash;&nbsp;A role for magnification endoscopy in the colon has been suggested for the diagnosis of flat and depressed lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/41-45\">",
"     41-45",
"    </a>",
"    ], identification of dysplasia and disease severity in ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/46-48\">",
"     46-48",
"    </a>",
"    ], discrimination among polyp types [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/49\">",
"     49",
"    </a>",
"    ], and assessing completeness of endoscopic mucosal resection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/44,50\">",
"     44,50",
"    </a>",
"    ]. Classification systems of surface patterns in colonic lesions have been proposed, but have not yet been adopted widely [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Recognition of surface patterns may be enhanced by combining magnification endoscopy with other imaging techniques such as narrow band imaging or chromoendoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/53-62\">",
"     53-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of largest reported series focused on 1850 patients who underwent magnification colonoscopy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"       indigo carmine",
"      </a>",
"      staining by a single endoscopist [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/58\">",
"       58",
"      </a>",
"      ]. A total of 1008 flat lesions were identified all of which were removed or biopsied. The sensitivity and specificity of magnification colonoscopy in distinguishing non-neoplastic from neoplastic lesions were 98 and 92 percent, respectively. However, sensitivity was poor in discriminating between",
"      <span class=\"nowrap\">",
"       neoplastic/non-invasive",
"      </span>",
"      from",
"      <span class=\"nowrap\">",
"       neoplastic/invasive",
"      </span>",
"      lesions. The authors concluded that magnification colonoscopy was useful but does not replace histologic assessment of flat and depressed lesions.",
"     </li>",
"     <li>",
"      Another study included 122 patients with 206 lesions that were 10 mm or smaller [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/54\">",
"       54",
"      </a>",
"      ]. All lesions detected on colonoscopy were first diagnosed using the conventional view, then at chromoendoscopy using 0.2 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"       indigo carmine",
"      </a>",
"      , and finally with chromoendoscopy with magnification. Histologically, 46 lesions (22 percent) were non-neoplastic while 160 (78 percent) were neoplastic. The overall diagnostic accuracies by conventional view, chromoendoscopy, and chromoendoscopy with magnification were 84 percent",
"      <span class=\"nowrap\">",
"       (173/206),",
"      </span>",
"      89 percent",
"      <span class=\"nowrap\">",
"       (184/206),",
"      </span>",
"      and 96 percent",
"      <span class=\"nowrap\">",
"       (197/206),",
"      </span>",
"      respectively. The authors concluded that chromoendoscopy with magnification is the most reliable method for determining whether a colorectal lesion is non-neoplastic or neoplastic during colonoscopy.",
"     </li>",
"     <li>",
"      One of the only controlled trials included a total of 203 patients who were considered at increased risk for colonic neoplasia based upon either a family or personal history or the presence of alarm symptoms after age 60 [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/55\">",
"       55",
"      </a>",
"      ]. Patients were randomly assigned to conventional colonoscopy or colonoscopy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"       indigo carmine",
"      </a>",
"      staining combined with standard resolution and then high-resolution (1.5 fold magnification) inspection. Significantly more hyperplastic polyps and flat adenomas were detected in the high-resolution group but there was no significant difference in the total number of adenomas per patient. The authors concluded that their findings do not support routine use of high resolution colonoscopy in clinical practice.",
"     </li>",
"     <li>",
"      Narrow band imaging (NBI) was used in a series of 495 patients with a total of 617 lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/57\">",
"       57",
"      </a>",
"      ]. NBI uses a high intensity blue light with narrow band filters that emphasize vascular and mucosal patterns. In this study, the sensitivity for differentiation between neoplastic (adenomas and cancers) and non-neoplastic lesions was 91 percent, with a specificity of 97 percent. However, a meta-analysis suggests that adding NBI to standard high-definition white light colonoscopy does not improve the detection rate of colorectal polyps or adenomas [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A pilot study that included 33 polyps smaller than 6 mm compared polyp features assessed with magnification NBI and chromoendoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/60\">",
"       60",
"      </a>",
"      ]. Chromoendoscopic and NBI pit patterns were different for 12 and 20 of 33 polyps. The authors concluded that pit patterns were not always identical with NBI and chromoendoscopy. Thus, the current pit pattern Kudo magnification-chromoendoscopy classification may need to be modified and revalidated before it can be used with confidence with NBI. The vascular pattern intensity, a simple color change, may be as accurate as the pit pattern. The role of NBI in screening colonoscopy needs further evaluation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of enhanced magnification endoscopy is evolving. The available data suggest that it improves the ability to identify mucosal abnormalities throughout the gastrointestinal tract and thus to guide biopsies. However, the technique cannot replace histologic assessment at this time. Furthermore, guidelines on when and what to stain have not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4248/abstract/61\">",
"     61",
"    </a>",
"    ]. Future studies will help determine the validity and reliability of classification systems to permit better standardization of findings.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/1\">",
"      Technology status evaluation report. High resolution and high-magnification endoscopy. Gastrointest Endosc 2000; 52:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/2\">",
"      Inoue H, Kudo SE, Shiokawa A. Technology insight: Laser-scanning confocal microscopy and endocytoscopy for cellular observation of the gastrointestinal tract. Nat Clin Pract Gastroenterol Hepatol 2005; 2:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/3\">",
"      ASGE Technology Committee, Kwon RS, Wong Kee Song LM, et al. Endocytoscopy. Gastrointest Endosc 2009; 70:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/4\">",
"      Kiesslich R, Jung M. Magnification endoscopy: does it improve mucosal surface analysis for the diagnosis of gastrointestinal neoplasias? Endoscopy 2002; 34:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/5\">",
"      Guelrud M, Herrera I. Acetic acid improves identification of remnant islands of Barrett's epithelium after endoscopic therapy. Gastrointest Endosc 1998; 47:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/6\">",
"      Acosta MM, Boyce HW Jr. Chromoendoscopy--where is it useful? J Clin Gastroenterol 1998; 27:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/7\">",
"      Canto MI. Staining in gastrointestinal endoscopy: the basics. Endoscopy 1999; 31:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/8\">",
"      Canto MI, Yoshida T, Gossner L. Chromoscopy of intestinal metaplasia in Barrett's esophagus. Endoscopy 2002; 34:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/9\">",
"      Guelrud M, Herrera I, Essenfeld H, Castro J. Enhanced magnification endoscopy: a new technique to identify specialized intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc 2001; 53:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/10\">",
"      Sharma P, Weston AP, Topalovski M, et al. Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's oesophagus. Gut 2003; 52:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/11\">",
"      Guelrud M, Herrera I, Essenfeld H, et al. Intestinal metaplasia of the gastric cardia: A prospective study with enhanced magnification endoscopy. Am J Gastroenterol 2002; 97:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/12\">",
"      Curvers W, Baak L, Kiesslich R, et al. Chromoendoscopy and narrow-band imaging compared with high-resolution magnification endoscopy in Barrett's esophagus. Gastroenterology 2008; 134:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/13\">",
"      Hoffman A, Kiesslich R, Bender A, et al. Acetic acid-guided biopsies after magnifying endoscopy compared with random biopsies in the detection of Barrett's esophagus: a prospective randomized trial with crossover design. Gastrointest Endosc 2006; 64:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/14\">",
"      Toyoda H, Rubio C, Befrits R, et al. Detection of intestinal metaplasia in distal esophagus and esophagogastric junction by enhanced-magnification endoscopy. Gastrointest Endosc 2004; 59:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/15\">",
"      Ferguson DD, DeVault KR, Krishna M, et al. Enhanced magnification-directed biopsies do not increase the detection of intestinal metaplasia in patients with GERD. Am J Gastroenterol 2006; 101:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/16\">",
"      Singh R, Karageorgiou H, Owen V, et al. Comparison of high-resolution magnification narrow-band imaging and white-light endoscopy in the prediction of histology in Barrett's oesophagus. Scand J Gastroenterol 2009; 44:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/17\">",
"      Lee CT, Chang CY, Lee YC, et al. Narrow-band imaging with magnifying endoscopy for the screening of esophageal cancer in patients with primary head and neck cancers. Endoscopy 2010; 42:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/18\">",
"      Endo T, Awakawa T, Takahashi H, et al. Classification of Barrett's epithelium by magnifying endoscopy. Gastrointest Endosc 2002; 55:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/19\">",
"      Guelrud M, Ehrlich EE. Endoscopic classification of Barrett's esophagus. Gastrointest Endosc 2004; 59:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/20\">",
"      Meining A, R&ouml;sch T, Kiesslich R, et al. Inter- and intra-observer variability of magnification chromoendoscopy for detecting specialized intestinal metaplasia at the gastroesophageal junction. Endoscopy 2004; 36:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/21\">",
"      Mayinger B, Oezturk Y, Stolte M, et al. Evaluation of sensitivity and inter- and intra-observer variability in the detection of intestinal metaplasia and dysplasia in Barrett's esophagus with enhanced magnification endoscopy. Scand J Gastroenterol 2006; 41:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/22\">",
"      Fortun PJ, Anagnostopoulos GK, Kaye P, et al. Acetic acid-enhanced magnification endoscopy in the diagnosis of specialized intestinal metaplasia, dysplasia and early cancer in Barrett's oesophagus. Aliment Pharmacol Ther 2006; 23:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/23\">",
"      Gossner L, Pech O, May A, et al. Inter- and intraobsever variability in high resolution chromoendoscoy with acetic acid for the detection of intestinal metaplasia and early neoplasia in Barrett's esophagus (abstract). Gastrointest Endosc 2005; 61:AB132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/24\">",
"      Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, et al. Magnification chromoendoscopy for the diagnosis of gastric intestinal metaplasia and dysplasia. Gastrointest Endosc 2003; 57:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/25\">",
"      Tajiri H, Doi T, Endo H, et al. Routine endoscopy using a magnifying endoscope for gastric cancer diagnosis. Endoscopy 2002; 34:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/26\">",
"      Sumiyama K, Kaise M, Nakayoshi T, et al. Combined use of a magnifying endoscope with a narrow band imaging system and a multibending endoscope for en bloc EMR of early stage gastric cancer. Gastrointest Endosc 2004; 60:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/27\">",
"      Yang HJ, Wang JT, Wang TH, et al. Diagnosis of gastric polypoid lesions by magnifying endoscopy and dye endoscopy. J Formos Med Assoc 1991; 90:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/28\">",
"      Areia M, Amaro P, Dinis-Ribeiro M, et al. External validation of a classification for methylene blue magnification chromoendoscopy in premalignant gastric lesions. Gastrointest Endosc 2008; 67:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/29\">",
"      Anagnostopoulos GK, Yao K, Kaye P, et al. High-resolution magnification endoscopy can reliably identify normal gastric mucosa, Helicobacter pylori-associated gastritis, and gastric atrophy. Endoscopy 2007; 39:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/30\">",
"      Yoshida T, Kawachi H, Sasajima K, et al. The clinical meaning of a nonstructural pattern in early gastric cancer on magnifying endoscopy. Gastrointest Endosc 2005; 62:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/31\">",
"      Tanaka K, Toyoda H, Kadowaki S, et al. Surface pattern classification by enhanced-magnification endoscopy for identifying early gastric cancers. Gastrointest Endosc 2008; 67:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/32\">",
"      Ohashi A, Niwa Y, Ohmiya N, et al. Quantitative analysis of the microvascular architecture observed on magnification endoscopy in cancerous and benign gastric lesions. Endoscopy 2005; 37:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/33\">",
"      Ezoe Y, Muto M, Horimatsu T, et al. Magnifying narrow-band imaging versus magnifying white-light imaging for the differential diagnosis of gastric small depressive lesions: a prospective study. Gastrointest Endosc 2010; 71:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/34\">",
"      Kato M, Kaise M, Yonezawa J, et al. Magnifying endoscopy with narrow-band imaging achieves superior accuracy in the differential diagnosis of superficial gastric lesions identified with white-light endoscopy: a prospective study. Gastrointest Endosc 2010; 72:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/35\">",
"      Ezoe Y, Muto M, Uedo N, et al. Magnifying narrowband imaging is more accurate than conventional white-light imaging in diagnosis of gastric mucosal cancer. Gastroenterology 2011; 141:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/36\">",
"      Siegel LM, Stevens PD, Lightdale CJ, et al. Combined magnification endoscopy with chromoendoscopy in the evaluation of patients with suspected malabsorption. Gastrointest Endosc 1997; 46:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/37\">",
"      Cammarota G, Martino A, Pirozzi GA, et al. Direct visualization of intestinal villi by high-resolution magnifying upper endoscopy: a validation study. Gastrointest Endosc 2004; 60:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/38\">",
"      Cammarota G, Martino A, Di Caro S, et al. High-resolution magnifying upper endoscopy in a patient with patchy celiac disease. Dig Dis Sci 2005; 50:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/39\">",
"      Badreldin R, Barrett P, Wooff DA, et al. How good is zoom endoscopy for assessment of villous atrophy in coeliac disease? Endoscopy 2005; 37:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/40\">",
"      Lo A, Guelrud M, Essenfeld H, Bonis P. Classification of villous atrophy with enhanced magnification endoscopy in patients with celiac disease and tropical sprue. Gastrointest Endosc 2007; 66:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/41\">",
"      Hurlstone DP, Brown S, Cross SS. The role of flat and depressed colorectal lesions in colorectal carcinogenesis: new insights from clinicopathological findings in high-magnification chromoscopic colonoscopy. Histopathology 2003; 43:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/42\">",
"      Hurlstone DP, Cross SS, Adam I, et al. A prospective clinicopathological and endoscopic evaluation of flat and depressed colorectal lesions in the United Kingdom. Am J Gastroenterol 2003; 98:2543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/43\">",
"      Hurlstone DP, McAlindon ME, Sanders DS, et al. Further validation of high-magnification chromoscopic-colonoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2004; 126:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/44\">",
"      Hurlstone DP, Cross SS, Drew K, et al. An evaluation of colorectal endoscopic mucosal resection using high-magnification chromoscopic colonoscopy: a prospective study of 1000 colonoscopies. Endoscopy 2004; 36:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/45\">",
"      Paggi S, Radaelli F, Amato A, et al. The impact of narrow band imaging in screening colonoscopy: a randomized controlled trial. Clin Gastroenterol Hepatol 2009; 7:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/46\">",
"      Sada M, Igarashi M, Yoshizawa S, et al. Dye spraying and magnifying endoscopy for dysplasia and cancer surveillance in ulcerative colitis. Dis Colon Rectum 2004; 47:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/47\">",
"      Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003; 124:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/48\">",
"      Hurlstone DP, Sanders DS, McAlindon ME, et al. High-magnification chromoscopic colonoscopy in ulcerative colitis: a valid tool for in vivo optical biopsy and assessment of disease extent. Endoscopy 2006; 38:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/49\">",
"      Togashi K, Konishi F, Ishizuka T, et al. Efficacy of magnifying endoscopy in the differential diagnosis of neoplastic and non-neoplastic polyps of the large bowel. Dis Colon Rectum 1999; 42:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/50\">",
"      Hurlstone DP, Cross SS, Brown S, et al. A prospective evaluation of high-magnification chromoscopic colonoscopy in predicting completeness of EMR. Gastrointest Endosc 2004; 59:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/51\">",
"      Kudo S, Tamura S, Nakajima T, et al. Diagnosis of colorectal tumorous lesions by magnifying endoscopy. Gastrointest Endosc 1996; 44:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/52\">",
"      Huang Q, Fukami N, Kashida H, et al. Interobserver and intra-observer consistency in the endoscopic assessment of colonic pit patterns. Gastrointest Endosc 2004; 60:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/53\">",
"      Hirata M, Tanaka S, Oka S, et al. Magnifying endoscopy with narrow band imaging for diagnosis of colorectal tumors. Gastrointest Endosc 2007; 65:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/54\">",
"      Fu KI, Sano Y, Kato S, et al. Chromoendoscopy using indigo carmine dye spraying with magnifying observation is the most reliable method for differential diagnosis between non-neoplastic and neoplastic colorectal lesions: a prospective study. Endoscopy 2004; 36:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/55\">",
"      Le Rhun M, Coron E, Parlier D, et al. High resolution colonoscopy with chromoscopy versus standard colonoscopy for the detection of colonic neoplasia: a randomized study. Clin Gastroenterol Hepatol 2006; 4:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/56\">",
"      Kanao H, Tanaka S, Oka S, et al. Narrow-band imaging magnification predicts the histology and invasion depth of colorectal tumors. Gastrointest Endosc 2009; 69:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/57\">",
"      Wada Y, Kudo SE, Kashida H, et al. Diagnosis of colorectal lesions with the magnifying narrow-band imaging system. Gastrointest Endosc 2009; 70:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/58\">",
"      Hurlstone DP, Cross SS, Adam I, et al. Efficacy of high magnification chromoscopic colonoscopy for the diagnosis of neoplasia in flat and depressed lesions of the colorectum: a prospective analysis. Gut 2004; 53:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/59\">",
"      Chiu HM, Chang CY, Chen CC, et al. A prospective comparative study of narrow-band imaging, chromoendoscopy, and conventional colonoscopy in the diagnosis of colorectal neoplasia. Gut 2007; 56:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/60\">",
"      East JE, Suzuki N, Saunders BP. Comparison of magnified pit pattern interpretation with narrow band imaging versus chromoendoscopy for diminutive colonic polyps: a pilot study. Gastrointest Endosc 2007; 66:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/61\">",
"      Kiesslich R, Jung M, DiSario JA, et al. Perspectives of chromo and magnifying endoscopy: how, how much, when, and whom should we stain? J Clin Gastroenterol 2004; 38:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/62\">",
"      Rastogi A, Keighley J, Singh V, et al. High accuracy of narrow band imaging without magnification for the real-time characterization of polyp histology and its comparison with high-definition white light colonoscopy: a prospective study. Am J Gastroenterol 2009; 104:2422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4248/abstract/63\">",
"      Nagorni A, Bjelakovic G, Petrovic B. Narrow band imaging versus conventional white light colonoscopy for the detection of colorectal polyps. Cochrane Database Syst Rev 2012; 1:CD008361.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2646 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-0D0D3C1A28-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_9_4248=[""].join("\n");
var outline_f4_9_4248=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EQUIPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ESOPHAGUS AND GASTRIC CARDIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      STOMACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SMALL INTESTINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      COLON",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2646\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2646|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/40/1665\" title=\"picture 1\">",
"      Acetic acid mag Endosc1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/27/433\" title=\"picture 2\">",
"      Acetic acid mag Endosc2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=related_link\">",
"      Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15370?source=related_link\">",
"      Chromoendoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2361?source=related_link\">",
"      Gastric polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=related_link\">",
"      Glossary of common biostatistical and epidemiological terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=related_link\">",
"      Management of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/40/29316?source=related_link\">",
"      Narrow band imaging in Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=related_link\">",
"      Overview of endoscopic resection of gastrointestinal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1497?source=related_link\">",
"      Overview of intestinal and multivisceral transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_9_4249="Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type";
var content_f4_9_4249=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/9/4249/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/9/4249/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/9/4249/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/9/4249/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/9/4249/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/9/4249/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/9/4249/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/9/4249/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral T cell lymphomas (PTCL) are a heterogeneous group of generally aggressive neoplasms that constitute less than 15 percent of all non-Hodgkin lymphomas (NHLs) in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among these, in decreasing frequency of occurrence, are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peripheral T cell lymphoma, not otherwise specified (NOS)",
"     </li>",
"     <li>",
"      Anaplastic large cell lymphoma, primary systemic type",
"     </li>",
"     <li>",
"      Angioimmunoblastic T cell lymphoma",
"     </li>",
"     <li>",
"      Extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, nasal type",
"     </li>",
"     <li>",
"      Subcutaneous panniculitis-like T cell lymphoma",
"     </li>",
"     <li>",
"      Enteropathy associated T cell lymphoma",
"     </li>",
"     <li>",
"      Hepatosplenic T cell lymphoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Extranodal natural",
"    <span class=\"nowrap\">",
"     killer/T",
"    </span>",
"    cell lymphoma, nasal type, or nasal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma (formerly called angiocentric lymphoma), is the most common cause of the syndrome known as \"lethal midline granuloma.\" It is an extranodal lymphoma, usually with a natural killer (NK) cell phenotype and positivity for Epstein-Barr virus (EBV), with a broad range of morphologic appearances, frequent necrosis, and angioinvasion. It is designated",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    to reflect ambiguity in its cellular origins. Gene rearrangement studies support a natural killer cell origin in most cases, but a small minority has clonal T cell receptor rearrangements and appears to be derived from cytotoxic T cells.",
"   </p>",
"   <p>",
"    The clinical presentation, pathologic features, and diagnosis of extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type will be discussed here. The treatment of extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12457?source=see_link\">",
"     \"Treatment of extranodal NK/T cell lymphoma, nasal type\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal-type",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma is most common in Asia (eg, China, Japan, Korea, Hong Kong) and in native populations of Central and South America (eg, Peru and Mexico) where it accounts for 5 to 10 percent of all non-Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/6-13\">",
"     6-13",
"    </a>",
"    ]. It is a rare disorder in the United States, Europe, South Asia, the Middle East, and Africa.",
"   </p>",
"   <p>",
"    The median age at presentation is 52 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/11\">",
"     11",
"    </a>",
"    ]; however, rare cases have been reported in childhood. There is a male predominance with an approximately 2:1 male to female ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/8,11,14,15\">",
"     8,11,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma is poorly understood, but is related in part to infection of the tumor cells with Epstein-Barr virus (EBV). Virtually all cases contain monoclonal episomal EBV DNA and detectable EBV encoded small nuclear RNAs (EBERs). Expression of EBV latent membrane protein-1 by immunohistochemistry has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A high percentage of these tumors overexpress the p53 tumor suppressor protein, with about one-quarter showing evidence of p53 mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. Curiously, the cyclin dependent kinase inhibitor p21, which is a downstream target of p53, is overexpressed in these tumors independent of p53 mutational status [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/17\">",
"     17",
"    </a>",
"    ]. In most other tumor types, p21 overexpression is linked to wild-type p53 expression, but in this tumor it has been found even with mutant p53 or low p53 expression; it is hypothesized that p21 overexpression may be related to EBV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The p73 gene, which shares structural and functional homology with p53 and is thought to be a tumor suppressor gene, has been found to be highly methylated in these tumors, with the p15 and p16 genes also methylated but less often [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/20\">",
"     20",
"    </a>",
"    ]. Other tumor suppressor genes that have been implicated in the pathogenesis of extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma include PRDM1 (also known as Blimp-1) and FOXO3. In one study, both PRDM1 and FOXO3 frequently demonstrated nonsense and missense mutations resulting in the down-regulation of these tumor suppressor genes in a majority of clinical samples [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/21\">",
"     21",
"    </a>",
"    ]. Re-expression of PRDM1 and FOXO3 in experimental NK cells inhibited proliferation suggesting that the down-regulation of these genes plays a role in lymphomagenesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The large majority of patients present with localized disease resulting in symptoms of nasal obstruction, epistaxis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a destructive mass involving the nose, sinuses, or palate (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72858 \" href=\"UTD.htm?37/32/38405\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/8,14,22\">",
"     8,14,22",
"    </a>",
"    ]. Other extranodal sites may be involved either primarily (ie, extranasal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma) or as a direct extension of the primary tumor. These sites include the upper airway, Waldeyer's ring, gastrointestinal tract, skin, testis, lung, eye, or soft tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/11,23-31\">",
"     11,23-31",
"    </a>",
"    ]. Lymph nodes may be involved secondarily, but are only rarely the primary site of involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/24\">",
"     24",
"    </a>",
"    ]. Bone marrow involvement and B symptoms (ie, fever, night sweats, weight loss) are seen in approximately 10 and 35 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/11,15\">",
"     11,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a retrospective analysis of 145 patients with nasal-type",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma reported that the majority of patients presented with Ann Arbor stage I (81 percent) or II (17 percent) disease, with nodal involvement being uncommon (17 percent). Systemic B symptoms or an elevated lactate dehydrogenase level were seen in 34 and 46 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 3 percent of cases are associated with the hemophagocytic syndrome, an often fatal complication, which may present with high fevers, maculopapular rash, failure to thrive, central nervous system symptoms, hepatosplenomegaly, lymphadenopathy, cytopenias, coagulopathy, abnormal liver function tests, or extremely high serum ferritin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/11,32,33\">",
"     11,32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link\">",
"     \"Hemophagocytic lymphohistiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some cases of the aggressive variant of NK cell",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    may be related to and seen in conjunction with extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20040?source=see_link\">",
"     \"Natural killer (NK) cell large granular lymphocyte leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Morphologic features",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Growth pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involved tissues demonstrate extensive ulceration and a diffuse, permeative lymphomatous infiltrate. Mucosal glands, if present, are widely spaced and there is usually prominent coagulative necrosis of both tumor cells and normal tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/4\">",
"     4",
"    </a>",
"    ]. An",
"    <span class=\"nowrap\">",
"     angiocentric/angiodestructive",
"    </span>",
"    growth pattern is a characteristic, but not essential, feature that is associated with fibrinoid necrosis of blood vessel walls. Vascular lumina may be occluded by lymphoid cells with varying degrees of cytologic atypia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/35\">",
"     35",
"    </a>",
"    ], sometimes in association with thrombosis. Mitotic figures are variably plentiful, but usually common.",
"   </p>",
"   <p>",
"    The polymorphous infiltrate is composed of a mixture of normal-appearing small lymphocytes and atypical lymphoid cells of varying size [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], along with plasma cells and occasionally eosinophils and histiocytes (",
"    <a class=\"graphic graphic_picture graphicRef59281 \" href=\"UTD.htm?31/58/32678\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cell morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tumor cells can be of any size, but most commonly are either medium-sized or a mixture of small and large cells. They have a moderate amount of",
"    <span class=\"nowrap\">",
"     pale/clear",
"    </span>",
"    cytoplasm with irregularly folded nuclei typically containing granular chromatin and inconspicuous or small nucleoli [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/4\">",
"     4",
"    </a>",
"    ]. Azurophilic granules may be seen on touch preps stained with Giemsa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunophenotype of extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type, is similar to that of a natural killer cell. The atypical cells in most cases express CD2, CD56, and cytoplasmic CD3, but do not express surface CD3. Most cases express cytotoxic granule proteins such as granzyme B, TIA-1, and perforin, and lack surface T cell receptor (TCR) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/16,36\">",
"     16,36",
"    </a>",
"    ]. Uncommon cases may express CD4, CD8,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CD7 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/25,26,37\">",
"     25,26,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Genetic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The T cell receptor (TCR) and immunoglobulin (Ig) genes are usually germline, but a small fraction of cases demonstrate clonal rearrangement of TCR genes, suggesting derivation from a cytotoxic T lymphocyte [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/29\">",
"     29",
"    </a>",
"    ]. Clonal Epstein-Barr virus (EBV) genomes are virtually always present [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/26,27,38\">",
"     26,27,38",
"    </a>",
"    ]. In situ hybridization for EBV encoded small nuclear RNAs (EBERs) is the preferred method of demonstrating the presence of EBV.",
"   </p>",
"   <p>",
"    Many genetic abnormalities have been reported, but there is no single cytogenetic change that is typical or diagnostic. The most common cytogenetic abnormality is deletion of chromosome 6q [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Search for a tumor suppressor gene at this location is ongoing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma is made based upon the evaluation of a biopsy specimen from the site of involvement, usually in midfacial area (",
"    <a class=\"graphic graphic_table graphicRef55385 \" href=\"UTD.htm?5/61/6109\">",
"     table 1",
"    </a>",
"    ). Because the morphology of the tumor cells is so variable, it is important to consider this diagnosis in all cases of aggressive extranodal lymphoma associated with vascular invasion and necrosis, including unusual cases presenting outside of the nasopharynx.",
"   </p>",
"   <p>",
"    The key diagnostic features are the demonstration of",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell markers and Epstein-Barr virus (EBV). Although CD56 is typically expressed, tumors that do not express CD56 may still be classified as extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphomas if both cytotoxic molecules and EBV are positive [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As described above, the histology is typically characterized by a polymorphous lymphoid infiltrate that invades the vascular walls, producing fibrinoid necrosis of vessel walls and coagulative necrosis of surrounding tissues. The tumor cells are highly variable in morphology; sometimes small or large cells predominate, but most often there is a mixture of small and large cells. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Morphologic features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Over 90 percent of cases are of true natural killer (NK) cell origin. These tumors express CD2, cytoplasmic CD3, CD56, and cytotoxic granule proteins, are negative for surface CD3, and have T cell receptor genes in the germline configuration. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Immunophenotype'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type includes other NK and T cell hematologic malignancies and EBV-associated T cell or NK cell lymphoproliferative disorders, certain subsets of which (eg, chronic active EBV infection, systemic EBV positive T cell lymphoproliferative disease of childhood and hydroa vacciniforme-like lymphoma) occur predominately in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=see_link&amp;anchor=H34#H34\">",
"     \"Infectious mononucleosis in adults and adolescents\", section on 'chronic or persistent EBV infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     NK cell leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infrequently, patients with extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma can have involvement of the bone marrow and peripheral blood resembling that seen in aggressive NK cell leukemia. It is unclear whether these are two distinct pathologic entities or if they merely represent two different clinical presentations (ie, leukemia and lymphoma) of a single entity.",
"   </p>",
"   <p>",
"    The immunophenotype of aggressive NK cell leukemia is practically identical to that of extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type. In addition, Epstein-Barr virus (EBV) involvement is common in both entities. However, aggressive NK cell leukemia frequently expresses CD16 (75 percent of cases), while CD16 is typically negative in extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lymphomatoid granulomatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphomatoid granulomatosis is another Epstein-Barr virus (EBV) positive tumor that appears at extranodal sites and can bear a close histologic resemblance to extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type. Cases of pulmonary \"lymphomatoid granulomatosis\" were for a time considered to be part of the spectrum of extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma. However, the EBV positive tumor cells in lymphomatoid granulomatosis are of B cell origin and thus express pan-B cell markers such as CD20, while the EBV positive cells in extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma are of NK or T cell origin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41287?source=see_link&amp;anchor=H10#H10\">",
"     \"Pulmonary lymphomatoid granulomatosis\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     EBV-positive diffuse large B cell lymphoma of the elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma (DLBCL) of the elderly is a variant of DLBCL that often presents at extranodal sites and may exhibit angioinvasion, angiodestruction, and extensive tissue necrosis. However, unlike extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, presentations in the nasopharynx are unusual, the tumor cells are positive for B cell markers (CD20, CD79a), and genotypic studies reveal the presence of clonal immunoglobulin rearrangements. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Peripheral T cell lymphoma, unspecified",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cell lymphomas that cannot be classified into a specific subtype, are labeled peripheral T cell lymphoma, unspecified. Tumors that express CD3 but do not express CD56 and are negative for Epstein-Barr virus (EBV) and cytotoxic molecules should be diagnosed as peripheral T cell lymphoma, unspecified rather than extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35400?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hepatosplenic T cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatosplenic T cell lymphoma is a neoplasm of mature",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    T cells that infiltrate the sinusoids of the spleen, liver, and bone marrow. The immunophenotype may resemble that seen in extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type with expression of CD2, CD7, and variable expression of CD56. However, these tumors also express surface CD3 and surface T cell receptors (usually of the",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    type), findings atypical for extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma. In addition, these tumors do not typically express granzyme B or perforin, which are found in extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma. Isochromosome 7, a genetic aberration that is not seen in extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, is present in most cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4119?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of hepatosplenic T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Squamous cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some cases of extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type may elicit prominent pseudoepitheliomatous hyperplasia of the overlying mucosal epithelium that can resemble squamous cell carcinoma. While exuberant, the epithelial hyperplasia lacks atypia, whereas the underlying lymphoid infiltrate is usually overtly malignant. Detection of Epstein-Barr virus (EBV) in the lymphoid tumor cells is a helpful finding in unusual cases of extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma that are comprised mainly of small lymphoid cells and that lack areas of necrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=see_link\">",
"     \"Pathology of head and neck neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Nonkeratinizing nasopharyngeal carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonkeratinizing nasopharyngeal carcinoma (NPC) is an epithelial neoplasm arising from the epithelial lining of the nasopharynx that has a similar clinical presentation to extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type. In addition, both pathologic entities are associated with Epstein-Barr virus (EBV) infection.",
"   </p>",
"   <p>",
"    Nonkeratinizing NPCs are characterized by a dense lymphoplasmacellular infiltrate containing cohesive nests or scattered tumor cells (",
"    <a class=\"graphic graphic_picture graphicRef73439 \" href=\"UTD.htm?40/21/41304\">",
"     picture 2",
"    </a>",
"    ). The neoplastic cells have large nuclei, prominent eosinophilic nucleoli, and scant cytoplasm. When growing in clusters, the cell borders are indistinct, thus giving a syncytial appearance. The tumor sometimes contains numerous infiltrating lymphocytes, primarily T cells, but these cells are morphologically benign. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathology of head and neck neoplasms\", section on 'Nasopharyngeal carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H185382651\">",
"    <span class=\"h2\">",
"     NK cell enteropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;NK cell enteropathy is a proposed clinicopathologic entity characterized by involvement of the gastrointestinal mucosa by an extensive atypical NK cell lymphoproliferative process with an indolent course [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Gastrointestinal biopsy reveals expansion of the lamina propria by a well-circumscribed but confluent infiltrate. The tumor is comprised of intermediate to large-sized cells with irregular nuclei, inconspicuous nucleoli, finely clumped chromatin, and a moderate amount of pale cytoplasm. There can be sheets of atypical cells with destruction of the mucosal glands, but necrosis is otherwise absent. There is no epitheliotropism, angiocentricity or angiodestructive growth. These atypical cells express CD5, CD7, cytoplasmic CD3, TIA-1",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Granzyme B, but not CD5, CD4, CD8, CD10, CD20, CD30, EBV-latent membrane protein, PAX-5, CD138, or CD68. The",
"    <span class=\"nowrap\">",
"     MIB-1/Ki-67",
"    </span>",
"    proliferation fraction is low. EBV-encoded RNA is not detected. T cell receptor studies are oligoclonal or polyclonal. The peripheral blood and bone marrow are not involved.",
"   </p>",
"   <p>",
"    Tumors involving the GI tract with EBV positivity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a high proliferation fraction are better considered variants of aggressive extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma than NK cell enteropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27785?source=see_link\">",
"     \"Treatment of relapsed or refractory peripheral T cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12457?source=see_link&amp;anchor=H62375632#H62375632\">",
"     \"Treatment of extranodal NK/T cell lymphoma, nasal type\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type is an aggressive lymphoma (",
"    <a class=\"graphic graphic_figure graphicRef78792 \" href=\"UTD.htm?27/34/28205\">",
"     figure 1",
"    </a>",
"    ). As such, without treatment survival is measured in months. The prognosis with treatment is largely related to the location and stage of disease at diagnosis. An overall worse prognosis has been noted in Asian studies, despite a low International Prognostic Index at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/8,14,27,43-45\">",
"     8,14,27,43-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over 60 percent of patients with stage I disease remain in long term remission following treatment with radiation therapy with or without chemotherapy, while patients with stage II to IV disease have a worse prognosis with frequent relapses in other extranodal sites [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/26,43,46-48\">",
"     26,43,46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study of 136 cases of",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma identified through the International Peripheral T cell Lymphoma Project demonstrated that, when compared with patients with nasal presentations, patients with extranasal disease had a significantly shorter median overall survival (4 versus 36 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/11\">",
"     11",
"    </a>",
"    ]. Among those patients with primary nasal disease, other predictors of poor outcome included a Ki-67 proliferation greater than 50 percent, large &ldquo;transformed&rdquo; tumor cells greater than 40 percent, an elevated C-reactive protein, hemoglobin &lt;11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (6.8",
"    <span class=\"nowrap\">",
"     mmol/liter),",
"    </span>",
"    and platelet count",
"    <span class=\"nowrap\">",
"     &lt;150x10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    <span class=\"nowrap\">",
"     (150,000/microL).",
"    </span>",
"   </p>",
"   <p>",
"    Other predictors of a poor outcome in patients with extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type, may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epstein-Barr virus &mdash; Levels of Epstein-Barr virus (EBV) in the plasma or bone marrow appear to correlate with patient outcomes and may serve as an indirect measure of tumor as demonstrated by the following studies:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a report on 18 patients from Hong Kong, those with high plasma levels of EBV-DNA (&ge;600",
"      <span class=\"nowrap\">",
"       copies/mL),",
"      </span>",
"      as measured by real-time quantitative PCR, had a significantly inferior overall survival (OS) rate at 20 months than those with lower levels (21 versus 78 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a Korean study in 91 patients with stage",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      disease, bone marrow positivity for EBER-1 by in situ hybridization was associated with a worse prognosis compared with bone marrow negativity for EBER-1 [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective observational study of 69 patients with stage",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      disease treated with primary radiotherapy with or without chemotherapy, when compared with those with lower levels, patients with high pretreatment plasma EBV-DNA levels (&gt;500",
"      <span class=\"nowrap\">",
"       copies/mL)",
"      </span>",
"      had lower estimated progression-free survival (PFS, 52 versus 79 percent) and OS (66 versus 97 percent) at three years [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/50\">",
"       50",
"      </a>",
"      ]. When compared with patients with detectable EBV-DNA, patients with undetectable EBV-DNA following therapy had significantly higher estimated rates of PFS (78 versus 51 percent) and OS (92 versus 70 percent) at three years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumor invasiveness &mdash; In one report involving 114 patients, local tumor invasiveness (ie, bony invasion or destruction, tumor invasion of the skin) predicted for a low probability of complete remission, as well as reduced disease-free and overall survival in patients with nasal stage IE and IIE disease [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/51\">",
"       51",
"      </a>",
"      ]. This was not confirmed in a larger study of 262 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prognostic models &mdash; The value of the International Prognostic Index used for other non-Hodgkin lymphoma subtypes is unclear for patients with extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, nasal type largely because the vast majority of patients fall into the favorable prognosis subgroup [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/51\">",
"       51",
"      </a>",
"      ]. Other models have been proposed:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A study of 262 patients proposed a new model, the",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma prognostic index (NKPI), based upon four adverse factors (",
"      <a class=\"graphic graphic_table graphicRef67924 \" href=\"UTD.htm?22/12/22732\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/45\">",
"       45",
"      </a>",
"      ]: \"B\" symptoms (fever, night sweats, weight loss), stage &ge;III, increased serum lactate dehydrogenase, and regional lymph node involvement. Subjects with zero, one, two, or three to four adverse factors had five-year overall survival rates of 81, 64, 34, and 7 percent, respectively. A subsequent retrospective study suggested that, without CNS prophylaxis, CNS recurrence will develop in 10 percent of patients with three or four features compared with less than 2 percent of those with one or two features [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study of patients with aggressive NK cell leukemia (22 patients) or extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma (150 patients) proposed four risk factors [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/53\">",
"       53",
"      </a>",
"      ]: non-nasal type, stage III or IV, ECOG performance status &ge;2, and &gt;1 extranodal site. Patients with zero, one, two, and &ge;3 of these factors demonstrated four-year overall survival rates of 55, 33, 15, and 6 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antigen expression &mdash; Several studies have reported on the effect of expression of various antigens on disease outcome. As examples, expression of cutaneous lymphocyte antigen, COX-2 expression, and loss of expression of granzyme B protease inhibitor 9 (PI9) have each been associated with worse outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/44,54,55\">",
"       44,54,55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Absolute lymphocyte count &mdash; A retrospective analysis of 128 patients with newly diagnosed extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma reported rates of overall survival at three and five years of 50 and 42 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4249/abstract/56\">",
"       56",
"      </a>",
"      ]. When compared with patients with a higher absolute lymphocyte count (ALC), patients with an ALC &lt;1.0 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      had a significantly lower rate of survival at five years (13 versus 60 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extranodal natural killer",
"      <span class=\"nowrap\">",
"       (NK)/T",
"      </span>",
"      cell lymphoma, nasal-type is an extranodal lymphoma most common in Asia, Central and South America, which typically presents with localized disease resulting in symptoms of nasal obstruction, epistaxis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a destructive mass involving the nose, sinuses or palate (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72858 \" href=\"UTD.htm?37/32/38405\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is made based upon the evaluation of a biopsy specimen from the site of involvement (",
"      <a class=\"graphic graphic_table graphicRef55385 \" href=\"UTD.htm?5/61/6109\">",
"       table 1",
"      </a>",
"      ). The histology is typically characterized by a polymorphous lymphoid infiltrate with highly variable morphology that invades the vascular walls, often producing extensive necrosis. The key diagnostic features are the demonstration of",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell markers on immunophenotyping (typically CD2+, CD56, cytoplasmic CD3+, surface CD3-,",
"      <span class=\"nowrap\">",
"       CD4+/-,",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       CD8+/-)",
"      </span>",
"      and the presence of Epstein-Barr virus (EBV), usually by in situ hybridization for EBV encoded RNA (EBER). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathologic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, nasal type includes other NK and T cell hematologic malignancies and EBV-associated T cell or NK cell lymphoproliferative disorders. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/1\">",
"      Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/2\">",
"      Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/3\">",
"      Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL (Eds), IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/5\">",
"      Rizvi MA, Evens AM, Tallman MS, et al. T-cell non-Hodgkin lymphoma. Blood 2006; 107:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/6\">",
"      Jaffe ES, Chan JK, Su IJ, et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996; 20:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/7\">",
"      Arber DA, Weiss LM, Alb&uacute;jar PF, et al. Nasal lymphomas in Peru. High incidence of T-cell immunophenotype and Epstein-Barr virus infection. Am J Surg Pathol 1993; 17:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/8\">",
"      Li CC, Tien HF, Tang JL, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer 2004; 100:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/9\">",
"      Barrionuevo C, Zaharia M, Martinez MT, et al. Extranodal NK/T-cell lymphoma, nasal type: study of clinicopathologic and prognosis factors in a series of 78 cases from Peru. Appl Immunohistochem Mol Morphol 2007; 15:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/10\">",
"      Liang R. Advances in the management and monitoring of extranodal NK/T-cell lymphoma, nasal type. Br J Haematol 2009; 147:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/11\">",
"      Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009; 113:3931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/12\">",
"      Au WY, Ma SY, Chim CS, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol 2005; 16:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/13\">",
"      Laurini JA, Perry AM, Boilesen E, et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood 2012; 120:4795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/14\">",
"      Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004; 103:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/15\">",
"      Li YX, Liu QF, Fang H, et al. Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma. Clin Cancer Res 2009; 15:2905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/16\">",
"      Kanavaros P, Lescs MC, Bri&egrave;re J, et al. Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 1993; 81:2688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/17\">",
"      Quintanilla-Martinez L, Kremer M, Keller G, et al. p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease. Am J Pathol 2001; 159:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/18\">",
"      Quintanilla-Martinez L, Franklin JL, Guerrero I, et al. Histological and immunophenotypic profile of nasal NK/T cell lymphomas from Peru: high prevalence of p53 overexpression. Hum Pathol 1999; 30:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/19\">",
"      Li T, Hongyo T, Syaifudin M, et al. Mutations of the p53 gene in nasal NK/T-cell lymphoma. Lab Invest 2000; 80:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/20\">",
"      Siu LL, Chan JK, Wong KF, Kwong YL. Specific patterns of gene methylation in natural killer cell lymphomas : p73 is consistently involved. Am J Pathol 2002; 160:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/21\">",
"      Karube K, Nakagawa M, Tsuzuki S, et al. Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood 2011; 118:3195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/22\">",
"      Proulx GM, Caudra-Garcia I, Ferry J, et al. Lymphoma of the nasal cavity and paranasal sinuses: treatment and outcome of early-stage disease. Am J Clin Oncol 2003; 26:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/23\">",
"      Li YX, Fang H, Liu QF, et al. Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring. Blood 2008; 112:3057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/24\">",
"      Chan JK, Sin VC, Wong KF, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997; 89:4501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/25\">",
"      Chan JK, Ng CS, Lau WH, Lo ST. Most nasal/nasopharyngeal lymphomas are peripheral T-cell neoplasms. Am J Surg Pathol 1987; 11:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/26\">",
"      Ferry JA, Sklar J, Zukerberg LR, Harris NL. Nasal lymphoma. A clinicopathologic study with immunophenotypic and genotypic analysis. Am J Surg Pathol 1991; 15:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/27\">",
"      Lei KI, Chan LY, Chan WY, et al. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma. Clin Cancer Res 2002; 8:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/28\">",
"      Ho FC, Srivastava G, Loke SL, et al. Presence of Epstein-Barr virus DNA in nasal lymphomas of B and 'T' cell type. Hematol Oncol 1990; 8:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/29\">",
"      Lipford EH Jr, Margolick JB, Longo DL, et al. Angiocentric immunoproliferative lesions: a clinicopathologic spectrum of post-thymic T-cell proliferations. Blood 1988; 72:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/30\">",
"      Chim CS, Au WY, Shek TW, et al. Primary CD56 positive lymphomas of the gastrointestinal tract. Cancer 2001; 91:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/31\">",
"      Lan SK, Lin CW, Ho HC, et al. Penile metastasis secondary to nasal NK/T-cell lymphoma. Urology 2008; 72:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/32\">",
"      Falini B, Pileri S, De Solas I, et al. Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood 1990; 75:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/33\">",
"      Okuda T, Sakamoto S, Deguchi T, et al. Hemophagocytic syndrome associated with aggressive natural killer cell leukemia. Am J Hematol 1991; 38:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/34\">",
"      Soler J, Bordes R, Ortno F, et al. Aggressive natural killer cell leukaemia/lymphoma in two patients with lethal midline granuloma. Br J Haematol 1994; 86:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/35\">",
"      Jaffe ES. Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood 1996; 87:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/36\">",
"      Elenitoba-Johnson KS, Zarate-Osorno A, Meneses A, et al. Cytotoxic granular protein expression, Epstein-Barr virus strain type, and latent membrane protein-1 oncogene deletions in nasal T-lymphocyte/natural killer cell lymphomas from Mexico. Mod Pathol 1998; 11:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/37\">",
"      Ho FC, Choy D, Loke SL, et al. Polymorphic reticulosis and conventional lymphomas of the nose and upper aerodigestive tract: a clinicopathologic study of 70 cases, and immunophenotypic studies of 16 cases. Hum Pathol 1990; 21:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/38\">",
"      Chan JK, Yip TT, Tsang WY, et al. Detection of Epstein-Barr viral RNA in malignant lymphomas of the upper aerodigestive tract. Am J Surg Pathol 1994; 18:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/39\">",
"      Siu LL, Chan V, Chan JK, et al. Consistent patterns of allelic loss in natural killer cell lymphoma. Am J Pathol 2000; 157:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/40\">",
"      Sun HS, Su IJ, Lin YC, et al. A 2.6 Mb interval on chromosome 6q25.2-q25.3 is commonly deleted in human nasal natural killer/T-cell lymphoma. Br J Haematol 2003; 122:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/41\">",
"      Mansoor A, Pittaluga S, Beck PL, et al. NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series. Blood 2011; 117:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/42\">",
"      Takeuchi K, Yokoyama M, Ishizawa S, et al. Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. Blood 2010; 116:5631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/43\">",
"      Cuadra-Garcia I, Proulx GM, Wu CL, et al. Sinonasal lymphoma: a clinicopathologic analysis of 58 cases from the Massachusetts General Hospital. Am J Surg Pathol 1999; 23:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/44\">",
"      Yoshino T, Nakamura S, Suzumiya J, et al. Expression of cutaneous lymphocyte antigen is associated with a poor outcome of nasal-type natural killer-cell lymphoma. Br J Haematol 2002; 118:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/45\">",
"      Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/46\">",
"      Isobe K, Uno T, Tamaru J, et al. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer 2006; 106:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/47\">",
"      Lee J, Park YH, Kim WS, et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer 2005; 41:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/48\">",
"      Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006; 24:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/49\">",
"      Lee J, Suh C, Huh J, et al. Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphoma, nasal-type. Clin Cancer Res 2007; 13:3250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/50\">",
"      Wang ZY, Liu QF, Wang H, et al. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood 2012; 120:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/51\">",
"      Kim TM, Park YH, Lee SY, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood 2005; 106:3785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/52\">",
"      Kim SJ, Oh SY, Hong JY, et al. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type? Ann Oncol 2010; 21:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/53\">",
"      Suzuki R, Suzumiya J, Yamaguchi M, et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 2010; 21:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/54\">",
"      Shim SJ, Yang WI, Shin E, et al. Clinical significance of cyclooxygenase-2 expression in extranodal natural killer (NK)/T-cell lymphoma, nasal type. Int J Radiat Oncol Biol Phys 2007; 67:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/55\">",
"      Bossard C, Belhadj K, Reyes F, et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2007; 109:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4249/abstract/56\">",
"      Huang JJ, Jiang WQ, Lin TY, et al. Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol 2011; 22:149.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4712 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-1A66C01F0E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_9_4249=[""].join("\n");
var outline_f4_9_4249=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Morphologic features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Growth pattern",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cell morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Genetic features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NK cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lymphomatoid granulomatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EBV-positive diffuse large B cell lymphoma of the elderly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Peripheral T cell lymphoma, unspecified",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hepatosplenic T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Nonkeratinizing nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H185382651\">",
"      NK cell enteropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4712\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4712|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/32/38405\" title=\"diagnostic image 1\">",
"      MRI extranodal NK-T cell lymphoma nasal type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4712|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/34/28205\" title=\"figure 1\">",
"      Kaplan-Meier analysis extranodal NK-T cell lymphoma nasal type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4712|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/58/32678\" title=\"picture 1\">",
"      Hemophagocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/21/41304\" title=\"picture 2\">",
"      Undiff nasopharyngeal CA Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4712|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/61/6109\" title=\"table 1\">",
"      PTCL path",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/12/22732\" title=\"table 2\">",
"      NKPI for extranodal NK-T cell lymphoma nasal type",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4119?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of hepatosplenic T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35400?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=related_link\">",
"      Infectious mononucleosis in adults and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20040?source=related_link\">",
"      Natural killer (NK) cell large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=related_link\">",
"      Pathology of head and neck neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41287?source=related_link\">",
"      Pulmonary lymphomatoid granulomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12457?source=related_link\">",
"      Treatment of extranodal NK/T cell lymphoma, nasal type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27785?source=related_link\">",
"      Treatment of relapsed or refractory peripheral T cell lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_9_4250="Initial approach to severe traumatic brain injury in children";
var content_f4_9_4250=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial approach to severe traumatic brain injury in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/9/4250/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/9/4250/contributors\">",
"     Monica S Vavilala, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/9/4250/contributors\">",
"     Pichaya Waitayawinyu, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/9/4250/contributors\">",
"     Neil M Dooney, MBBS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/9/4250/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/9/4250/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/9/4250/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/9/4250/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/9/4250/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury is the leading cause of death for children and adolescents in the United States and most developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/1\">",
"     1",
"    </a>",
"    ]. Of these deaths, about 40 percent are the result of traumatic brain injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/2\">",
"     2",
"    </a>",
"    ]. Traumatic brain injury (TBI) is often associated with cervical spine injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rapid identification and stabilization of children with severe traumatic brain injury is essential. Effective initial management of conditions that contribute to secondary brain injury (ie, hypoxia and hypotension) and prompt transfer to a facility that can provide pediatric trauma care are important determinants of outcome.",
"   </p>",
"   <p>",
"    This topic will review the initial evaluation and management of children with severe traumatic brain injury (TBI). The evaluation and management of minor head injury, inflicted head injury, and elevated intracranial pressure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12906?source=see_link\">",
"     \"Minor head trauma in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"     \"Elevated intracranial pressure in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severity of traumatic brain injury (TBI) is typically defined by the initial Glasgow Coma Scale (GCS) score. The GCS score is a widely used assessment of neurological function that has been validated in many studies since it was first introduced in 1976 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/4\">",
"     4",
"    </a>",
"    ]. It has been modified for use in children (",
"    <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Severity of TBI as determined by initial GCS score is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mild (GCS score 13 to 15)",
"     </li>",
"     <li>",
"      Moderate (GCS score 9 to 12)",
"     </li>",
"     <li>",
"      Severe (GCS score &lt;9)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other factors at the initial assessment that have been used to identify patients with severe injury include the Pediatric Trauma Score (as a proxy for other major injuries) and the presence of hypotension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypoxemia (",
"    <a class=\"graphic graphic_table graphicRef52562 \" href=\"UTD.htm?33/37/34397\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7367?source=see_link\">",
"     \"Classification of trauma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head injury occurs commonly in children. Among children 0 to 14 years of age in the United States, traumatic brain injury (TBI) accounted for approximately 475,000 emergency department visits per year between 1995 and 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/2\">",
"     2",
"    </a>",
"    ]. In 2000, about 50,000 children &le;17 years of age were hospitalized for TBI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/5\">",
"     5",
"    </a>",
"    ]. Of these, 29 percent were &le;4 years of age, and 52 percent were between 10 and 17 years of age.",
"   </p>",
"   <p>",
"    Various mechanisms result in TBI severe enough to require hospitalization. Among children less than four years of age, falls accounted for 41 percent of injuries in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/2\">",
"     2",
"    </a>",
"    ]. In comparison, motor vehicle-traffic incidents caused 43 percent of injuries among adolescents. Inflicted head injury is a significant mechanism, particularly for infants less than one year of age. Of children less than one year of age in the United Kingdom who were admitted to intensive care units with head injuries, 52 percent had been assaulted [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link\">",
"     \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among all children presenting to the emergency department in one prospective series, 98 percent had a Glasgow Coma Scale (GCS) score of 15, suggesting that most head injuries are minor [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/7\">",
"     7",
"    </a>",
"    ]. However, approximately 75 percent of children with multiple trauma have TBI and almost 80 percent of all trauma deaths are associated with TBI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Mortality rates between 17 and 33 percent have been reported in retrospective series describing children with severe brain injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. In developed countries, TBI is the most common cause of death and disability in childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. Approximately 3000 children die each year of head injuries in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The highest pediatric morbidity and mortality is reported in children younger than four years of age, and in those with low Glasgow Coma Scale (GCS) scores at initial presentation, coagulopathy, hyperglycemia, and hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/10,14-21\">",
"     10,14-21",
"    </a>",
"    ]. Overall mortality among children with TBI who are treated in emergency departments or require hospital admission is 4.5 percent (compared with 10.4 percent among adults) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the higher survival in children with TBI, disability is significant, and the functional long-term outcome appears to be related to severity of initial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TYPES OF BRAIN INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse brain injury (DBI) is the most common type of severe traumatic brain injury in children and is usually produced by acceleration or deceleration forces [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/24\">",
"     24",
"    </a>",
"    ]. The mildest form of DBI is a concussion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12906?source=see_link&amp;anchor=H7#H7\">",
"     \"Minor head trauma in infants and children\", section on 'Concussion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=see_link&amp;anchor=H5#H5\">",
"     \"Concussion and mild traumatic brain injury\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=see_link&amp;anchor=H14#H14\">",
"     \"Concussion and mild traumatic brain injury\", section on 'Sequelae'",
"    </a>",
"    .) Diffuse axonal injury (DAI) is a more severe form of diffuse brain injury. DAI develops as the result of tissue shearing at the interface of grey and white matter. It can occur in association with focal injuries.",
"   </p>",
"   <p>",
"    Focal injuries include brain contusions and intracranial hemorrhage. An acceleration or deceleration injury can result in a cerebral contusion. Contusions may be in the location of impact (coup), or on the opposite side of the brain (contrecoup), or both. Intracranial hemorrhage may occur from either blunt or penetrating trauma.",
"   </p>",
"   <p>",
"    Epidural hematoma, subdural hematoma, or subarachnoid hemorrhage usually occurs as the result of blunt trauma. In children, an epidural hematoma may arise from the middle meningeal artery, the middle meningeal vein, diploic veins, or venous sinuses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/25\">",
"     25",
"    </a>",
"    ]. A subdural hematoma results from rupture of bridging veins. Subarachnoid hemorrhage develops from tearing of small vessels in the pia mater. Subdural hematoma and subarachnoid hemorrhage usually occur as the result of severe trauma and are frequently associated with other intracranial injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ASSOCIATED INJURIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple trauma is common among children with severe traumatic brain injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/11,26\">",
"     11,26",
"    </a>",
"    ]. In one retrospective series describing severely head injured children, 39 percent had sustained multiple trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/11\">",
"     11",
"    </a>",
"    ]. In these cases, death is typically a result of the head injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/13,27\">",
"     13,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cervical spine injury (CSI) must always be suspected for children with traumatic brain injury or injury above the clavicle. Although CSI in children is uncommon, approximately one-half of patients with CSI have concomitant TBI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/3\">",
"     3",
"    </a>",
"    ]. Cervical spine injury in children is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of severe TBI involves two insults. The primary event is the direct injury to brain parenchyma. A cascade of biochemical, cellular, and metabolic responses causes secondary damage. Secondary injury also occurs as the result of exogenous insults, such as hypoxia and hypotension.",
"   </p>",
"   <p>",
"    Initially following brain injury, cerebral blood flow appears to be decreased in children (rather than increased, as previously thought) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Hypoperfusion in conjunction with increased metabolic demand makes the brain more susceptible to secondary insults, such as hypoxemia and hypotension. Cerebral perfusion may be particularly dependent on maintaining adequate blood pressure because cerebral autoregulation is often impaired following severe pediatric TBI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/12,31\">",
"     12,31",
"    </a>",
"    ]. In addition, release of excitatory neurotransmitters, such as acetylcholine, glutamate, and aspartate causes neuronal damage [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following this initial phase, cerebral swelling develops that generally peaks 24 to 72 hours after the injury. The resulting intracranial hypertension can further compromise cerebral perfusion leading to more ischemia, swelling, herniation, and death.",
"   </p>",
"   <p>",
"    Diffuse cerebral swelling following severe traumatic brain injury is more common among infants and children as compared with adults [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/33\">",
"     33",
"    </a>",
"    ]. Mechanisms that account for this age-related difference are not known. Anatomical and pathophysiological factors likely play a role. As an example, a diffuse pattern of brain injury may develop because the infant skull is more compliant and can tolerate considerable deformation before fracture occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. In addition, brain atrophy that probably begins in young adulthood, allows for more room in the adult skull for the brain to expand. Finally, experimental data from animals suggest that pathophysiological features, such as enhanced diffusion of excitotoxic neurotransmitters, the inflammatory response of the developing brain, and changes in blood-brain-barrier permeability may also be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The volume relationships between brain parenchyma, cerebrospinal fluid, and blood, as well as physiologic mechanisms that maintain pressure homeostasis (including the autoregulation of cerebral blood flow to maintain cerebral perfusion pressure) within the intracranial compartment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link&amp;anchor=H2#H2\">",
"     \"Elevated intracranial pressure in children\", section on 'Physiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with severe traumatic brain injury must be promptly recognized and their conditions emergently stabilized in order to limit secondary brain injury and improve outcomes. Injuries that require immediate neurosurgical intervention and associated injuries that may impact management must also be identified. A systematic primary survey to rapidly identify and treat potentially fatal conditions, such as airway compromise, impaired respiratory mechanics, and hemorrhagic shock should be initially performed. This should be followed by a secondary survey that includes a fully exposed head-to-toe examination of the child, with a neurological assessment.",
"   </p>",
"   <p>",
"    An initial approach to the injured child that includes a detailed description of the primary and secondary surveys, as well as prehospital preparation, is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7367?source=see_link\">",
"     \"Classification of trauma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The assessment of airway, ventilatory, and circulatory function in children is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22327?source=see_link&amp;anchor=H2#H2\">",
"     \"Initial assessment and stabilization of children with respiratory or circulatory compromise\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28948?source=see_link\">",
"     \"Assessment of perfusion in pediatric resuscitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The remainder of this discussion will focus on the evaluation specific to head injured patients, including the recognition of signs and symptoms that may adversely affect outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most children with severe traumatic brain injury (TBI), the history of the injury will be straightforward. A notable exception is for the child who has sustained an inflicted head injury. In this situation, there is often no history of a traumatic event, despite evidence of significant brain injury. The evaluation and diagnosis of inflicted head injury is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Historical features may also identify children who do not appear to have had a significant head injury, but have in fact, sustained a severe TBI and whose condition may deteriorate. In addition to mechanism of injury, other features to consider include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prolonged loss of consciousness",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abnormal mental status",
"     </li>",
"     <li>",
"      Persistent vomiting",
"     </li>",
"     <li>",
"      Severe headache",
"     </li>",
"     <li>",
"      Progression of symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     General assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vital signs must include pulse oximetry and an assessment of ventilation (chest wall movement, breath sounds, or end tidal CO2 measurement). Hypoxia and hypotension should be immediately identified and treated. Respiratory depression, bradycardia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypertension may indicate impending herniation, which must also be promptly treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link&amp;anchor=H12#H12\">",
"     \"Elevated intracranial pressure in children\", section on 'Herniation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Under most circumstances, cervical spine immobilization should be maintained throughout the evaluation, since an adequate examination to exclude cervical spine injury can rarely be performed in children with severe TBI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=see_link\">",
"     \"Pediatric cervical spine immobilization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Open wounds to the head and neck, including penetrating wounds, should be identified during the secondary survey. Management of these injuries may require surgery. In addition, children may lose significant amounts of blood from scalp lacerations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Neurological assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial assessment of the child with severe TBI should include a focused neurological examination and assignment of a Glasgow Coma Scale (GCS) score (",
"    <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A focused neurologic examination should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Level of consciousness",
"     </li>",
"     <li>",
"      Pupillary examination for size, reactivity, and symmetry",
"     </li>",
"     <li>",
"      Extraocular movements",
"     </li>",
"     <li>",
"      Funduscopic examination",
"     </li>",
"     <li>",
"      Brainstem reflexes (corneal and gag reflexes)",
"     </li>",
"     <li>",
"      Deep tendon reflexes",
"     </li>",
"     <li>",
"      Response to pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Any abnormalities in this examination may suggest increased intracranial pressure (ICP) with impending transtentorial herniation that may require immediate intervention. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Management'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28136?source=see_link&amp;anchor=H17#H17\">",
"     \"Evaluation of stupor and coma in children\", section on 'Transtentorial herniation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Signs of herniation that must be recognized include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signs of uncal herniation including a third cranial nerve palsy, followed immediately by hemiplegia.",
"     </li>",
"     <li>",
"      Progressive changes in respiratory pattern, pupil size, vestibuloocular reflexes, and posture that correlate with the anatomic level of brain involvement (",
"      <a class=\"graphic graphic_figure graphicRef76974 \" href=\"UTD.htm?5/13/5335\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Cushing's triad, which includes hypertension, bradycardia, and slow irregular respirations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory evaluation depends upon the type and extent of injuries identified during the primary and secondary surveys. At minimum, most children with multiple injuries require a hematocrit, type and screen, and urinalysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H22#H22\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Laboratory studies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40119?source=see_link\">",
"     \"Approach to the initially stable child with blunt or penetrating injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory tests that may be useful for the management of children with severe TBI include blood glucose (hyperglycemia is a poor prognostic indicator for children with severe TBI) and serum electrolytes with osmolarity. A panel of coagulation studies may be useful in some patients as an indicator of severity of injury. DIC has been associated with poor outcomes in children with severe TBI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=see_link&amp;anchor=H20#H20\">",
"     \"Disseminated intravascular coagulation in infants and children\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) of the head is the preferred initial imaging modality for children with severe traumatic brain injury. Any lesion that requires emergent surgery is reliably identified by CT. There may also be a role for early MRI in the diagnosis and treatment of TBI but this practice is not standard. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=see_link&amp;anchor=H16#H16\">",
"     \"Approach to neuroimaging in children\", section on 'MRI applications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By definition, all children with moderate to severe TBI have an abnormal neurologic evaluation and should receive CT following initial evaluation and stabilization. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The indications for obtaining imaging studies for children with apparent mild head injury are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12906?source=see_link&amp;anchor=H20#H20\">",
"     \"Minor head trauma in infants and children\", section on 'Indications for neuroimaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Focal injuries, such as contusions and hemorrhage, are readily diagnosed by CT. Patients with diffuse axonal injury (DAI) may initially have a normal CT scan but generally have significant neurologic findings on physical examination. Magnetic resonance imaging is more sensitive for DAI but is usually not necessary for initial stabilization and treatment. A repeat CT scan often shows secondary injury due to cerebral edema. The most common finding on CT scan in children with TBI is diffuse cerebral swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial management of children with severe traumatic brain injury (TBI) includes meticulous attention to support of airway, breathing, and circulation in order to prevent secondary injury. Specific therapies may be initiated as indicated to minimize",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treat increased intracranial pressure (ICP). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Airway and breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;General principles of airway management for children (including techniques for opening and maintaining an airway, bag-mask ventilation, and tracheal intubation) are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"     \"Basic airway management in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific considerations for the management of airway and breathing for children with severe TBI are discussed here.",
"   </p>",
"   <p>",
"    The child who is lucid and has a normal blood pressure can be managed with supplemental oxygen alone. Advanced airway management, including tracheal intubation, may be required to maximize oxygenation and ventilation and protect against aspiration of gastric contents in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decreasing level of consciousness (GCS &lt;9)",
"     </li>",
"     <li>",
"      Marked respiratory distress",
"     </li>",
"     <li>",
"      Hemodynamic instability",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cervical spine immobilization must be maintained while airway procedures are being performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=see_link&amp;anchor=H9#H9\">",
"     \"Pediatric cervical spine immobilization\", section on 'Airway management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Considerations for tracheal intubation for children with traumatic brain injury include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nasotracheal intubation should not be performed in patients with midface trauma or signs of a basilar skull fracture (raccoon's eyes, mastoid hematoma, or CSF drainage from the nose or ear canals). Children with these injuries may have fractures of the cribriform plate.",
"     </li>",
"     <li>",
"      We generally use cuffed tracheal tubes for all major pediatric trauma to protect the airway from aspiration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link&amp;anchor=H1618840#H1618840\">",
"       \"Emergent endotracheal intubation in children\", section on 'Cuffed versus uncuffed'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Rapid sequence intubation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unless consciousness is severely depressed, endotracheal intubation is accomplished by using a rapid-sequence technique with application of cricoid pressure and preoxygenation (",
"    <a class=\"graphic graphic_table graphicRef51456 \" href=\"UTD.htm?17/26/17837\">",
"     table 3",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link\">",
"     \"Rapid sequence intubation (RSI) in children\"",
"    </a>",
"    ) as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pretreatment &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"       Lidocaine",
"      </a>",
"      may minimize any increase in intracranial pressure that can be associated with airway manipulation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link&amp;anchor=H13#H13\">",
"       \"Rapid sequence intubation (RSI) in children\", section on 'Lidocaine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sedative agents &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       Etomidate",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/13/11478?source=see_link\">",
"       thiopental",
"      </a>",
"      have neuroprotective properties. Thiopental causes vasodilatation and myocardial depression, resulting in a decrease in systolic blood pressure and should not be used in patients who are hemodynamically unstable. Etomidate is frequently used during RSI in children with severe traumatic brain injury; although etomidate can cause transient adrenal suppression, the benefits appear to outweigh the risks in most patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link&amp;anchor=H17#H17\">",
"       \"Rapid sequence intubation (RSI) in children\", section on 'Sedative and induction agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Paralytic agents &ndash; Although increased ICP with the use of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"       succinylcholine",
"      </a>",
"      has been reported in patients with brain tumors, there is no definitive evidence that succinylcholine causes a rise in ICP in humans with brain injury [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. Factors that must be considered in choosing between succinylcholine and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/37/12886?source=see_link\">",
"       rocuronium",
"      </a>",
"      include the risk of succinylcholine for children with undiagnosed neuromuscular conditions and the longer duration of paralysis with rocuronium for those who may have a difficult airway. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link&amp;anchor=H24#H24\">",
"       \"Rapid sequence intubation (RSI) in children\", section on 'Paralysis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperventilation (PaCO2 &lt;35 mmHg) may cause cerebral ischemia as the result of decreased cerebral blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/30,40\">",
"     30,40",
"    </a>",
"    ]. Consequently, PaCO2 should be maintained between 35 and 38 mmHg unless there are signs of pending herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Neurological assessment'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14\">",
"     'Management'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Fluid management",
"    </span>",
"    &nbsp;&mdash;&nbsp;General principles of the management of hypovolemic and hemorrhagic shock in children, as well as techniques for vascular access, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8057?source=see_link\">",
"     \"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=see_link&amp;anchor=H13#H13\">",
"     \"Hypovolemic shock in children: Initial evaluation and management\", section on 'Fluid resuscitation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, isotonic fluids are preferred to hypotonic fluids. Adult data suggest that albumin may be harmful after TBI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific considerations for fluid management for children with severe TBI are discussed here.",
"   </p>",
"   <p>",
"    Outcomes for children with severe TBI who are hypotensive at the initial evaluation are typically poor [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/10,12,14,20,43-45\">",
"     10,12,14,20,43-45",
"    </a>",
"    ]. Volume should be restored. Isotonic solutions should be used for fluid resuscitation. Blood products should be administered as indicated. For example, in one observational study of 118 children with moderate to severe traumatic brain injury and documented hypotension, fluid therapy during early resuscitation was associated with significantly lower mortality (30 percent [17 of 57 patients] versus 56 percent [34 of 61 patients]) and significantly better functional neurologic outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The target blood pressure required to maintain the minimum cerebral perfusion pressure necessary to meet cerebral metabolic demands in infants and children has not been established and may be an age dependent continuum. Systolic blood pressures should be maintained above the fifth percentile for age and gender at the very least [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/46\">",
"     46",
"    </a>",
"    ]. However, improved outcomes have been reported for patients with substantially higher initial blood pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/10,12\">",
"     10,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other initial management considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interventions that are typically used to treat children with severe traumatic brain injury improve intermediate outcomes, such as intracranial pressure, cerebral oxygen consumption, and cerebral blood flow. Evidence that these treatments improve long-term clinical outcomes is therefore largely indirect.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Head positioning &ndash; The head should be maintained in a neutral position to avoid jugular venous obstruction. In prospective observational studies, elevating the head to 30 degrees appears to optimize cerebral perfusion pressure and decrease ICP for adult patients, provided that mean arterial pressure is maintained [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. There are no data regarding the efficacy of this intervention for children.",
"     </li>",
"     <li>",
"      Sedation and neuromuscular blockade &ndash; Adequate sedation and pharmacologic paralysis facilitate the safe transportation of intubated children with severe TBI. Oxygenation, ventilation, and blood pressure must be vigilantly monitored for patients who are sedated, with or without paralysis. Limited evidence suggests that cerebral oxygen consumption may be decreased in patients receiving neuromuscular blockade [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antiseizure prophylaxis &ndash; Prophylactic treatment with anticonvulsants reduces the incidence of early posttraumatic seizures among children with severe TBI [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. Seizures immediately following severe traumatic brain injury may increase brain metabolic demands and increase ICP, leading to secondary brain injury [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/41\">",
"       41",
"      </a>",
"      ]. In addition, retrospective studies have demonstrated improved outcomes among children with TBI who were treated with anticonvulsants [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]. Experts suggest that children receive anticonvulsant therapy during the first week following severe TBI [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hyperthermia should be aggressively prevented and treated [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypothermia decreases cerebral metabolism and may reduce CBF and ICP. Its use in children with severe traumatic brain injury is controversial, and in one multicenter trial was shown to be harmful. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link&amp;anchor=H30#H30\">",
"       \"Elevated intracranial pressure in children\", section on 'Hypothermia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperosmolar therapy &ndash; Randomized trials, observational reports, and extensive clinical experience have demonstrated that hyperosmolar therapy effectively decreases increased intracranial pressure in children with TBI [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/56-62\">",
"       56-62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The effectiveness of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/60/43975?source=see_link\">",
"       mannitol",
"      </a>",
"      for decreasing intracranial pressure among patients with traumatic brain injury has been demonstrated by extensive clinical experience and in several small series describing adult and pediatric patients [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. Nephrotoxicity can occur with mannitol therapy, particularly if patients become hypovolemic [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Evidence from small randomized trials and observational reports suggests that hypertonic saline, administered either as a bolus or a constant infusion, is effective for reducing intracranial pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/58-62\">",
"       58-62",
"      </a>",
"      ]. Adverse effects related to therapy with hypertonic saline include rebound intracranial hypertension, central pontine myelinolysis, and subarachnoid hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/64\">",
"       64",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link&amp;anchor=H23#H23\">",
"       \"Elevated intracranial pressure in children\", section on 'Mannitol'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperventilation &ndash; Although hyperventilation reduces intracranial pressure, indirect evidence suggests that routine hyperventilation may be harmful for patients with TBI. Hyperventilation produces hypocapnia which causes vasoconstriction and decreased cerebral blood flow (CBF) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/65,66\">",
"       65,66",
"      </a>",
"      ]. Decreased CBF has been associated with poor outcomes among children with TBI [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/30\">",
"       30",
"      </a>",
"      ], and severe hypocapnia (PaCO2 &lt;30 mmHg) has been associated with increased mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/67\">",
"       67",
"      </a>",
"      ]. Patients should only receive temporary hyperventilation (to reduce PaCO2 to less than 35 mmHg) with signs and symptoms of impending herniation [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link&amp;anchor=H25#H25\">",
"       \"Elevated intracranial pressure in children\", section on 'Hyperventilation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glucose &ndash; Hyperglycemia has been associated with poor outcomes for children and adults with TBI [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/11,15,68,69\">",
"       11,15,68,69",
"      </a>",
"      ]. This may be because hyperglycemia (as the result of a stress response) is a marker for severity of injury",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      elevated blood sugar contributes to poor outcome by worsening brain tissue lactic acidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/70-73\">",
"       70-73",
"      </a>",
"      ]. In an observational study of 101 children under 14 years of age who underwent emergent craniotomy for TBI, perioperative hyperglycemia (serum glucose &ge;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [11.1",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      was found in 45 percent of children and was significantly associated with age &lt;4 years, GCS &le;8, and the presence of multiple traumatic lesions, including subdural hematoma [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/74\">",
"       74",
"      </a>",
"      ]. We typically maintain glucose levels &le;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      for head injured children.",
"     </li>",
"     <li>",
"      Corticosteroids &ndash; Limited evidence does not support a benefit for treatment with corticosteroids for head injured patients. In addition, a large, prospective, multicenter trial described increased mortality among patients with acute traumatic brain injury who received corticosteroids [",
"      <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/75\">",
"       75",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link&amp;anchor=H28#H28\">",
"       \"Elevated intracranial pressure in children\", section on 'Corticosteroids'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rarely, a patient with an epidural hematoma may require emergent drainage through a burr hole. This procedure should be done by a neurosurgeon whenever possible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial monitoring of the child with severe TBI includes measurement of heart rate, blood pressure, and pulse oximetry. Capnography should be used (when available) to monitor end-tidal CO2 to avoid excessive hyperventilation for patients who require controlled ventilation. If end-tidal CO2 is to be used as the primary monitor for ventilation, an initial determination of arterial pCO2 should also be performed to ensure that end tidal and arterial CO2 are correlating well [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intracranial pressure monitoring is generally recommended for children who have an abnormal initial head CT and an initial GCS score between 3 and 8 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/77\">",
"     77",
"    </a>",
"    ]. Interventions that have been effective for decreasing ICP (ie, hyperosmolar therapy, decompressive craniotomy, and hyperventilation) require accurate and continuous monitoring of intracranial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/61,78,79\">",
"     61,78,79",
"    </a>",
"    ]. ICP monitoring is usually not initiated in the emergency department. However, children who may need ICP monitoring should be admitted to a pediatric intensive care unit at a trauma center.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Initial management decisions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immediate management of a child with severe traumatic brain injury (GCS score &le;8) (",
"    <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"     table 1",
"    </a>",
"    ), or with moderate injury (GCS score between 9 and 12) (",
"    <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"     table 1",
"    </a>",
"    ) whose condition is deteriorating or has associated injuries should include the following :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Focal injuries that may require neurosurgical intervention (ie, penetrating injuries, epidural hematomas, or subdural hematoma) must be quickly identified. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immediate neurosurgical consultation should be requested for children with focal injuries who have signs of increased intracranial pressure on physical examination or imaging studies. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Neurological assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with GCS scores &le;8 or with GCS scores between 9 and 12 whose conditions are deteriorating should undergo endotracheal intubation. Intubation should also be considered for those with GCS scores between 9 and 12 who cannot protect their airways or are being transported out of the emergency department. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Rapid sequence intubation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with signs of herniation should be treated as follows (",
"      <a class=\"graphic graphic_figure graphicRef76974 \" href=\"UTD.htm?5/13/5335\">",
"       figure 1",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"local\" href=\"#H19\">",
"       'Other initial management considerations'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Assure adequate oxygenation, breathing, and blood pressure.",
"     </li>",
"     <li>",
"      Give hyperosmolar therapy. We typically use",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/60/43975?source=see_link\">",
"       mannitol",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Provide mild hyperventilation (PaCO2 30 to 35 mmHg) for children who do not respond to hyperosmolar therapy.",
"     </li>",
"     <li>",
"      Request immediate neurosurgical evaluation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcomes appear to be improved for children with severe pediatric traumatic brain injury (TBI) who are treated at trauma centers with expertise in caring for children [",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Experts recommend that patients in the field with a GCS &le;12 or Pediatric Trauma Score &le;8 be transported directly to a pediatric trauma center whenever possible (",
"    <a class=\"graphic graphic_table graphicRef52562 \" href=\"UTD.htm?33/37/34397\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/9/4250/abstract/82-85\">",
"     82-85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children who are initially treated at a community hospital who should be transferred to a pediatric trauma center once their conditions are stabilized include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      GCS &le;8",
"     </li>",
"     <li>",
"      GCS &le;12 with associated major injuries",
"     </li>",
"     <li>",
"      Deterioration in clinical condition, including decrease in GCS",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/47/8947?source=see_link\">",
"       \"Patient information: Closed head injury (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rapid identification and stabilization of children with severe traumatic brain injury is essential for the effective initial management of focal injuries and conditions that contribute to secondary brain injury (ie, hypoxia and hypotension). Prompt transfer to a facility that can provide pediatric trauma care is an important determinant of outcome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe traumatic brain injury (TBI) is defined by an initial Glasgow coma scale (GCS) score &lt;9. Patients with moderate TBI have GCS scores between 9 and 12. Associated injuries also contribute to poor outcomes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Causes of severe TBI in children include falls, motor vehicle-traffic incidents, and inflicted head injury. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Types of brain injury include diffuse brain injury (including diffuse axonal injury) and focal injuries, such as contusions or hemorrhage. Children with severe TBIs often have associated injuries. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Types of brain injury'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Associated injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Brain injury occurs as a result of the primary injury and secondary events including the brain's response to the injury and exogenous insults, such as hypoxia and hypotension. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation includes a primary assessment to identify life-threatening injuries, followed by a thorough physical examination. A GCS score and focused neurological examination should be performed. Initial imaging for head injury should be with computed tomography. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Evaluation'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Management of severe TBI includes aggressively maintaining oxygenation, ventilation, and blood pressure. Other management considerations include the following (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Management'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The head should be elevated to 30 degrees, provided that means arterial pressure can be maintained.",
"     </li>",
"     <li>",
"      We suggest that children with severe TBI receive anticonvulsants to prevent early posttraumatic seizures (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Immediate management decisions include indications for intubation and emergent neurosurgical consultation. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Initial management decisions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Impending herniation is an emergency. We suggest that patients with signs of impending herniation be treated initially with hyperosmolar therapy rather than hyperventilation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We prefer",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/60/43975?source=see_link\">",
"       mannitol",
"      </a>",
"      to hypertonic saline for initial management. We suggest that patients who do not respond to hyperosmolar therapy be treated with hyperventilation (PaCO2 30 to 35) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Initial management decisions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with severe TBI or those with moderate TBI who have associated injuries or whose clinical condition is deteriorating should be treated at a trauma center with pediatric capability whenever possible.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/1\">",
"      Krug EG, Sharma GK, Lozano R. The global burden of injuries. Am J Public Health 2000; 90:523.",
"     </a>",
"    </li>",
"    <li>",
"     Langlois, JA, Rutland-Brown, W, Thomas, KE. Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Atlanta 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/3\">",
"      Brown RL, Brunn MA, Garcia VF. Cervical spine injuries in children: a review of 103 patients treated consecutively at a level 1 pediatric trauma center. J Pediatr Surg 2001; 36:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/4\">",
"      Marcin JP, Pollack MM. Triage scoring systems, severity of illness measures, and mortality prediction models in pediatric trauma. Crit Care Med 2002; 30:S457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/5\">",
"      Schneier AJ, Shields BJ, Hostetler SG, et al. Incidence of pediatric traumatic brain injury and associated hospital resource utilization in the United States. Pediatrics 2006; 118:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/6\">",
"      Parslow RC, Morris KP, Tasker RC, et al. Epidemiology of traumatic brain injury in children receiving intensive care in the UK. Arch Dis Child 2005; 90:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/7\">",
"      Dunning J, Daly JP, Malhotra R, et al. The implications of NICE guidelines on the management of children presenting with head injury. Arch Dis Child 2004; 89:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/8\">",
"      Mayer T, Walker ML, Johnson DG, Matlak ME. Causes of morbidity and mortality in severe pediatric trauma. JAMA 1981; 245:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/9\">",
"      Mayer T, Matlak ME, Johnson DG, Walker ML. The modified injury severity scale in pediatric multiple trauma patients. J Pediatr Surg 1980; 15:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/10\">",
"      White JR, Farukhi Z, Bull C, et al. Predictors of outcome in severely head-injured children. Crit Care Med 2001; 29:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/11\">",
"      Chiaretti A, Piastra M, Pulitan&ograve; S, et al. Prognostic factors and outcome of children with severe head injury: an 8-year experience. Childs Nerv Syst 2002; 18:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/12\">",
"      Vavilala MS, Bowen A, Lam AM, et al. Blood pressure and outcome after severe pediatric traumatic brain injury. J Trauma 2003; 55:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/13\">",
"      Michaud LJ, Rivara FP, Grady MS, Reay DT. Predictors of survival and severity of disability after severe brain injury in children. Neurosurgery 1992; 31:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/14\">",
"      Luerssen TG, Klauber MR, Marshall LF. Outcome from head injury related to patient's age. A longitudinal prospective study of adult and pediatric head injury. J Neurosurg 1988; 68:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/15\">",
"      Michaud LJ, Rivara FP, Longstreth WT Jr, Grady MS. Elevated initial blood glucose levels and poor outcome following severe brain injuries in children. J Trauma 1991; 31:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/16\">",
"      Nakayama DK, Copes WS, Sacco WJ. The effect of patient age upon survival in pediatric trauma. J Trauma 1991; 31:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/17\">",
"      Vavilala MS, Dunbar PJ, Rivara FP, Lam AM. Coagulopathy predicts poor outcome following head injury in children less than 16 years of age. J Neurosurg Anesthesiol 2001; 13:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/18\">",
"      Jennett B, Teasdale G, Braakman R, et al. Prognosis of patients with severe head injury. Neurosurgery 1979; 4:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/19\">",
"      Kokoska ER, Smith GS, Pittman T, Weber TR. Early hypotension worsens neurological outcome in pediatric patients with moderately severe head trauma. J Pediatr Surg 1998; 33:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/20\">",
"      Pigula FA, Wald SL, Shackford SR, Vane DW. The effect of hypotension and hypoxia on children with severe head injuries. J Pediatr Surg 1993; 28:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/21\">",
"      Keenan HT, Hooper SR, Wetherington CE, et al. Neurodevelopmental consequences of early traumatic brain injury in 3-year-old children. Pediatrics 2007; 119:e616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/22\">",
"      Langlois JA, Rutland-Brown W, Thomas KE. The incidence of traumatic brain injury among children in the United States: differences by race. J Head Trauma Rehabil 2005; 20:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/23\">",
"      Massagli TL, Michaud LJ, Rivara FP. Association between injury indices and outcome after severe traumatic brain injury in children. Arch Phys Med Rehabil 1996; 77:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/24\">",
"      Bruce DA, Alavi A, Bilaniuk L, et al. Diffuse cerebral swelling following head injuries in children: the syndrome of \"malignant brain edema\". J Neurosurg 1981; 54:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/25\">",
"      Mohanty A, Kolluri VR, Subbakrishna DK, et al. Prognosis of extradural haematomas in children. Pediatr Neurosurg 1995; 23:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/26\">",
"      Levi L, Guilburd JN, Linn S, Feinsod M. The association between skull fracture, intracranial pathology and outcome in pediatric head injury. Br J Neurosurg 1991; 5:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/27\">",
"      Walker ML, Storrs BB, Mayer T. Factors affecting outcome in the pediatric patient with multiple trauma. Further experience with the modified injury severity scale. Childs Brain 1984; 11:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/28\">",
"      Zwienenberg M, Muizelaar JP. Severe pediatric head injury: the role of hyperemia revisited. J Neurotrauma 1999; 16:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/29\">",
"      Sharples PM, Stuart AG, Matthews DS, et al. Cerebral blood flow and metabolism in children with severe head injury. Part 1: Relation to age, Glasgow coma score, outcome, intracranial pressure, and time after injury. J Neurol Neurosurg Psychiatry 1995; 58:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/30\">",
"      Adelson PD, Clyde B, Kochanek PM, et al. Cerebrovascular response in infants and young children following severe traumatic brain injury: a preliminary report. Pediatr Neurosurg 1997; 26:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/31\">",
"      Vavilala MS, Muangman S, Tontisirin N, et al. Impaired cerebral autoregulation and 6-month outcome in children with severe traumatic brain injury: preliminary findings. Dev Neurosci 2006; 28:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/32\">",
"      Ruppel RA, Kochanek PM, Adelson PD, et al. Excitatory amino acid concentrations in ventricular cerebrospinal fluid after severe traumatic brain injury in infants and children: the role of child abuse. J Pediatr 2001; 138:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/33\">",
"      Lang DA, Teasdale GM, Macpherson P, Lawrence A. Diffuse brain swelling after head injury: more often malignant in adults than children? J Neurosurg 1994; 80:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/34\">",
"      Margulies SS, Thibault KL. Infant skull and suture properties: measurements and implications for mechanisms of pediatric brain injury. J Biomech Eng 2000; 122:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/35\">",
"      Coats B, Margulies SS. Material properties of human infant skull and suture at high rates. J Neurotrauma 2006; 23:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/36\">",
"      Kochanek PM. Pediatric traumatic brain injury: quo vadis? Dev Neurosci 2006; 28:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/37\">",
"      Palchak MJ, Holmes JF, Vance CW, et al. A decision rule for identifying children at low risk for brain injuries after blunt head trauma. Ann Emerg Med 2003; 42:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/38\">",
"      Kovarik WD, Mayberg TS, Lam AM, et al. Succinylcholine does not change intracranial pressure, cerebral blood flow velocity, or the electroencephalogram in patients with neurologic injury. Anesth Analg 1994; 78:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/39\">",
"      Clancy M, Halford S, Walls R, Murphy M. In patients with head injuries who undergo rapid sequence intubation using succinylcholine, does pretreatment with a competitive neuromuscular blocking agent improve outcome? A literature review. Emerg Med J 2001; 18:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/40\">",
"      Stocchetti N, Maas AI, Chieregato A, van der Plas AA. Hyperventilation in head injury: a review. Chest 2005; 127:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/41\">",
"      Mazzola CA, Adelson PD. Critical care management of head trauma in children. Crit Care Med 2002; 30:S393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/42\">",
"      Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/43\">",
"      Zebrack M, Dandoy C, Hansen K, et al. Early resuscitation of children with moderate-to-severe traumatic brain injury. Pediatrics 2009; 124:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/44\">",
"      Samant UB 4th, Mack CD, Koepsell T, et al. Time of hypotension and discharge outcome in children with severe traumatic brain injury. J Neurotrauma 2008; 25:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/45\">",
"      Chaiwat O, Sharma D, Udomphorn Y, et al. Cerebral hemodynamic predictors of poor 6-month Glasgow Outcome Score in severe pediatric traumatic brain injury. J Neurotrauma 2009; 26:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/46\">",
"      Adelson, PD, Bratton, SL, Carney, NA, et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 4. Resuscitation of blood pressure and oxygenation and prehospital brain-specific therapies for the severe pediatric traumatic brain injury patient. Pediatr Crit Care Med 2003; 4:S428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/47\">",
"      Feldman Z, Kanter MJ, Robertson CS, et al. Effect of head elevation on intracranial pressure, cerebral perfusion pressure, and cerebral blood flow in head-injured patients. J Neurosurg 1992; 76:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/48\">",
"      Ng I, Lim J, Wong HB. Effects of head posture on cerebral hemodynamics: its influences on intracranial pressure, cerebral perfusion pressure, and cerebral oxygenation. Neurosurgery 2004; 54:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/49\">",
"      Vernon DD, Witte MK. Effect of neuromuscular blockade on oxygen consumption and energy expenditure in sedated, mechanically ventilated children. Crit Care Med 2000; 28:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/50\">",
"      Lewis RJ, Yee L, Inkelis SH, Gilmore D. Clinical predictors of post-traumatic seizures in children with head trauma. Ann Emerg Med 1993; 22:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/51\">",
"      Schierhout G, Roberts I. Anti-epileptic drugs for preventing seizures following acute traumatic brain injury. Cochrane Database Syst Rev 2001; :CD000173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/52\">",
"      Chiaretti A, De Benedictis R, Polidori G, et al. Early post-traumatic seizures in children with head injury. Childs Nerv Syst 2000; 16:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/53\">",
"      Tilford JM, Simpson PM, Yeh TS, et al. Variation in therapy and outcome for pediatric head trauma patients. Crit Care Med 2001; 29:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/54\">",
"      Adelson PD, Bratton SL, Carney NA, et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 19. The role of anti-seizure prophylaxis following severe pediatric traumatic brain injury. Pediatr Crit Care Med 2003; 4:S72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/55\">",
"      Natale JE, Joseph JG, Helfaer MA, Shaffner DH. Early hyperthermia after traumatic brain injury in children: risk factors, influence on length of stay, and effect on short-term neurologic status. Crit Care Med 2000; 28:2608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/56\">",
"      James HE. Methodology for the control of intracranial pressure with hypertonic mannitol. Acta Neurochir (Wien) 1980; 51:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/57\">",
"      Miller JD, Piper IR, Dearden NM. Management of intracranial hypertension in head injury: matching treatment with cause. Acta Neurochir Suppl (Wien) 1993; 57:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/58\">",
"      Huang SJ, Chang L, Han YY, et al. Efficacy and safety of hypertonic saline solutions in the treatment of severe head injury. Surg Neurol 2006; 65:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/59\">",
"      Fisher B, Thomas D, Peterson B. Hypertonic saline lowers raised intracranial pressure in children after head trauma. J Neurosurg Anesthesiol 1992; 4:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/60\">",
"      Simma B, Burger R, Falk M, et al. A prospective, randomized, and controlled study of fluid management in children with severe head injury: lactated Ringer's solution versus hypertonic saline. Crit Care Med 1998; 26:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/61\">",
"      Peterson B, Khanna S, Fisher B, Marshall L. Prolonged hypernatremia controls elevated intracranial pressure in head-injured pediatric patients. Crit Care Med 2000; 28:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/62\">",
"      Khanna S, Davis D, Peterson B, et al. Use of hypertonic saline in the treatment of severe refractory posttraumatic intracranial hypertension in pediatric traumatic brain injury. Crit Care Med 2000; 28:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/63\">",
"      Adelson, PD, Bratton, SL, Carney, NA, et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 11. Use of hyperosmolar therapy in the managment of severe traumatic brain injury. Pediatr Crit Care Med 2003; 4:S456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/64\">",
"      Qureshi AI, Suarez JI. Use of hypertonic saline solutions in treatment of cerebral edema and intracranial hypertension. Crit Care Med 2000; 28:3301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/65\">",
"      Skippen P, Seear M, Poskitt K, et al. Effect of hyperventilation on regional cerebral blood flow in head-injured children. Crit Care Med 1997; 25:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/66\">",
"      Stringer WA, Hasso AN, Thompson JR, et al. Hyperventilation-induced cerebral ischemia in patients with acute brain lesions: demonstration by xenon-enhanced CT. AJNR Am J Neuroradiol 1993; 14:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/67\">",
"      Curry R, Hollingworth W, Ellenbogen RG, Vavilala MS. Incidence of hypo- and hypercarbia in severe traumatic brain injury before and after 2003 pediatric guidelines. Pediatr Crit Care Med 2008; 9:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/68\">",
"      Kushner M, Nencini P, Reivich M, et al. Relation of hyperglycemia early in ischemic brain infarction to cerebral anatomy, metabolism, and clinical outcome. Ann Neurol 1990; 28:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/69\">",
"      Lam AM, Winn HR, Cullen BF, Sundling N. Hyperglycemia and neurological outcome in patients with head injury. J Neurosurg 1991; 75:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/70\">",
"      Hamill RW, Woolf PD, McDonald JV, et al. Catecholamines predict outcome in traumatic brain injury. Ann Neurol 1987; 21:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/71\">",
"      McClain C, Cohen D, Phillips R, et al. Increased plasma and ventricular fluid interleukin-6 levels in patients with head injury. J Lab Clin Med 1991; 118:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/72\">",
"      Shimazu T, Fukuda A, Ban T. Reciprocal influences of the ventromedial and lateral hypothalamic nuclei on blood glucose level and liver glycogen content. Nature 1966; 210:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/73\">",
"      Zygun DA, Steiner LA, Johnston AJ, et al. Hyperglycemia and brain tissue pH after traumatic brain injury. Neurosurgery 2004; 55:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/74\">",
"      Sharma D, Jelacic J, Chennuri R, et al. Incidence and risk factors for perioperative hyperglycemia in children with traumatic brain injury. Anesth Analg 2009; 108:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/75\">",
"      Alderson P, Roberts I. Corticosteroids for acute traumatic brain injury. Cochrane Database Syst Rev 2005; :CD000196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/76\">",
"      Warner KJ, Cuschieri J, Garland B, et al. The utility of early end-tidal capnography in monitoring ventilation status after severe injury. J Trauma 2009; 66:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/77\">",
"      Adelson, PD, Bratton, SL, Carney, NA, et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 5. Indications for intracranial pressure monitoring in pediatric patients with severe traumatic brain injury. Pediatr Crit Care Med 2003; 4:S435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/78\">",
"      Taylor A, Butt W, Rosenfeld J, et al. A randomized trial of very early decompressive craniectomy in children with traumatic brain injury and sustained intracranial hypertension. Childs Nerv Syst 2001; 17:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/79\">",
"      Bruce DA, Raphaely RC, Goldberg AI, et al. Pathophysiology, treatment and outcome following severe head injury in children. Childs Brain 1979; 5:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/80\">",
"      Potoka DA, Schall LC, Gardner MJ, et al. Impact of pediatric trauma centers on mortality in a statewide system. J Trauma 2000; 49:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/81\">",
"      Johnson DL, Krishnamurthy S. Send severely head-injured children to a pediatric trauma center. Pediatr Neurosurg 1996; 25:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/82\">",
"      Ramenofsky ML, Ramenofsky MB, Jurkovich GJ, et al. The predictive validity of the Pediatric Trauma Score. J Trauma 1988; 28:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/83\">",
"      Eichelberger MR, Gotschall CS, Sacco WJ, et al. A comparison of the trauma score, the revised trauma score, and the pediatric trauma score. Ann Emerg Med 1989; 18:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/84\">",
"      Phillips S, Rond PC 3rd, Kelly SM, Swartz PD. The need for pediatric-specific triage criteria: results from the Florida Trauma Triage Study. Pediatr Emerg Care 1996; 12:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/9/4250/abstract/85\">",
"      Engum SA, Mitchell MK, Scherer LR, et al. Prehospital triage in the injured pediatric patient. J Pediatr Surg 2000; 35:82.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6566 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-BC6E475435-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_9_4250=[""].join("\n");
var outline_f4_9_4250=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TYPES OF BRAIN INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ASSOCIATED INJURIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - General assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Neurological assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Airway and breathing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Rapid sequence intubation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Fluid management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other initial management considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Initial management decisions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6566\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6566|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/13/5335\" title=\"figure 1\">",
"      Transtentorial herniation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6566|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/58/2989\" title=\"table 1\">",
"      Glasgow and pediatric coma scales",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/37/34397\" title=\"table 2\">",
"      Trauma scoring children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/26/17837\" title=\"table 3\">",
"      Rapid overview of rapid sequence intubation in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=related_link\">",
"      Approach to neuroimaging in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40119?source=related_link\">",
"      Approach to the initially stable child with blunt or penetrating injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28948?source=related_link\">",
"      Assessment of perfusion in pediatric resuscitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=related_link\">",
"      Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=related_link\">",
"      Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7367?source=related_link\">",
"      Classification of trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=related_link\">",
"      Concussion and mild traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=related_link\">",
"      Disseminated intravascular coagulation in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=related_link\">",
"      Evaluation of cervical spine injuries in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28136?source=related_link\">",
"      Evaluation of stupor and coma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=related_link\">",
"      Hypovolemic shock in children: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22327?source=related_link\">",
"      Initial assessment and stabilization of children with respiratory or circulatory compromise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12906?source=related_link\">",
"      Minor head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/47/8947?source=related_link\">",
"      Patient information: Closed head injury (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=related_link\">",
"      Pediatric cervical spine immobilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8057?source=related_link\">",
"      Vascular (venous) access for pediatric resuscitation and other pediatric emergencies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_9_4251="Broadband or narrowband UVB MED";
var content_f4_9_4251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Determination of the minimal erythema dose (MED) with broadband or narrowband UVB sources",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <colgroup span=\"6\" width=\"10%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Exposure doses (mJ/cm",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Broadband UVB",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        120",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Narrowband UVB",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        600",
"       </td>",
"       <td>",
"        800",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        1200",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_9_4251=[""].join("\n");
var outline_f4_9_4251=null;
var title_f4_9_4252="Chronic weakness child";
var content_f4_9_4252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of chronic muscle weakness in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Anatomic region",
"       </td>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Cerebral cortex",
"       </td>",
"       <td>",
"        Brain tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral palsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Juvenile amyotrophic lateral sclerosis and other neurodegenerative disorders*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Spinal cord",
"       </td>",
"       <td>",
"        Myelomeningocele",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tethered spinal cord",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chiari malformations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amyotrophic lateral sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Anterior horn cell",
"       </td>",
"       <td>",
"        Spinal muscular atrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postasthmatic amyotrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amyotrophic lateral sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Peripheral nerve",
"       </td>",
"       <td>",
"        Erb palsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heavy metal poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital peripheral neuropathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuromuscular junction",
"       </td>",
"       <td>",
"        Myasthenia gravis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Muscle",
"       </td>",
"       <td>",
"        Congenital myopathies/muscular dystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myotonic dystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatomyositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Steroid myopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Other",
"       </td>",
"       <td>",
"        Congenital hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cushing syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Conversion disorder",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For example, metachromatic leukodystrophy, Alexander disease, Krabbe disease.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_9_4252=[""].join("\n");
var outline_f4_9_4252=null;
var title_f4_9_4253="Blood lactate during exercise";
var content_f4_9_4253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lactate threshold during exercise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 310px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the normal blood lactate-VO2 relationship during incremental exercise. The lactate threshold (LT) denotes the onset of a sustained rise in blood lactate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_9_4253=[""].join("\n");
var outline_f4_9_4253=null;
var title_f4_9_4254="Clopidogrel in CREDO 28 days";
var content_f4_9_4254=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clopidogrel pretreatment before PCI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 262px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data from the CREDO trial of more than 2100 patients undergoing elective percutaneous coronary intervention (PCI), almost all with stenting, who were treated with a 300 mg loading dose of clopidogrel or placebo before the procedure and then clopidogrel (75 mg/day) for 28 days. In a subset analysis, the combined end point of death, myocardial infarction, or urgent target vessel revascularization at 28 days occurred less often in those treated for at least six hours before the procedure compared to a shorter duration of pretreatment or no pretreatment (relative risk reduction 38.6 percent, 95 percent CI -1.6 to +62.9 percent).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Steinhubl SR, Berger PB, Mann JT 3rd, et al. JAMA 2002; 288:2411.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_9_4254=[""].join("\n");
var outline_f4_9_4254=null;
var title_f4_9_4255="3D ultrasound of normal fetal face";
var content_f4_9_4255=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal face and lip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rendered 3-dimensional image of a second trimester fetal face. The image demonstrates normal nose and lips.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_9_4255=[""].join("\n");
var outline_f4_9_4255=null;
        